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The concept of anaemia due to excessive red cell 
destruction was first advanced at the end of last century. 
Since then the development of methods for measuring the red 
cell survival time, sophistication of serological techniques 
for detection of erythrocyte antibodies and discoveries 
regarding the nature of inborn red cell defects have clearly 
shown that many causes for haemolysis exist. Increased red 
cell destruction is now known to be an accompaniement of 
many diseases, often in the absence of the classical signs 
of anaemia, reticulocytosis and acholuric jaundice. 
Moreover, it has been found that in only a few conditions 
are therapeutic measures available which will ameliorate or 
arrest the haemolytic process. 
The thesis describes studies on the pathogenesis, 
natural history and management of haemolytic disease and has 
been divided into five chapters. The first chapter outline 
briefly the evolution of knowledge leading to a definition 
of haemolysis and to a classification of the important 
haemolytic disorders. In the second chapter the methods of 
investigation have been discussed and particular emphasis 
has been given to the technique of red cell survival 
measurement, to the possibility of evaluating the role of 
the spleen in the haemolytic process and to the interpreta- 
tion/ 
interpretation of results. It was decided to restrict the 
main considerations of the thesis to observations in the 
three groups of haemolytic disease that are seen most 
frequently in Great Britain, namely autoimmune haemolytic 
anaemia, symptomatic non - immune haemolytic anaemia (as 
encountered in leukaemia, reticulosis and myeloid metaplasia 
and congenital spherocytosis; accordingly the third, fourth 
and fifth chapters deal respectively with these subjects 
and data from seventy -six patients have been used. 
In each series, the modes of presentation of disease, 
the clinical features and the diagnostic indicators have 
been reviewed. The principal contributions are concerned 
with the assessment of different forms of treatment in 
autoimmune haemolytic anaemia, leading to the use of anti - 
neoplastic drugs in fulminating disease, the effect of 
splenic irradiation in the symptomatic non - immune group and 
observations on the mode of inheritance of disease and on 
the action of the spleen in congenital spherocytosis. 
Other studies have dealt with the utilisation of haemo- 
poietic factors in haemolytic anaemia, the uptake of 
chromium -51 labelled red cells by different body tissues 
obtained at autopsy and the incidental finding of hypo - 
cholesterolaemia in untreated congenital spherocytosis. 
The present methods for quantitating the splenic sequestra- 
tion of radioactive labelled red cells are considered to be 
unsatisfactory and the use of a new index, termed the 
"Spleen/ 
"Spleen Number ", has been proposed. 
My interest in haemolytic disease began in 1955, when 
in collaborative studies with Dr. J. J. R. Duthie at the 
Rheumatic Diseases Unit, Northern General Hospital, 
Edinburgh, it was found that shortened red cell survival was 
one factor in the anaemia complicating rheumatoid arthritis. 
On return'to the Department of Medicine, University of 
Edinburgh, in 1956, the interest widened under the guidance 
of Sir Stanley Davidson, particularly after learning the 
procedure for labelling red corpuscles with radioactive 
chromium. Then in 1958 -59, I spent twelve months at the 
Memorial Center for Cancer and Allied Diseases, New York; 
this afforded a unique opportunity for studying the haemo- 
lytic process that accompanies leukaemia and lymphoma, and 
during this period I received much helpful criticism and 
advice from Dr. Lloyd F. Craver, Head of the Lymphoma 
Service and Dr. Allyn B. Ley, Head of the Hematology Service 
Subsequently I have been indebted to Professor K. W. Donald 
for encouraging me to continue clinical and experimental 
studies in this field. 
I wish to thank the many Physicians in Edinburgh and 
New York who, during the past eight years, have allowed me 
to investigate patients under their care. I also 
acknowledge the important contribution to diagnosis and to 
the assessment of each patient's progress that has been made 
by the routine haematological and biochemical departments in 
the/ 
the two centres. Two colleagues require particular 
mention. First, Professor R. H. Girdwood from whom I have 
learned a great deal about haematology, many of whose cases 
are featured in the thesis and who has kindly undertaken 
serum assays for folic acid and vitamin B12. Second, 
Dr. R. A. Cumming who has supplied all the information 
regarding serological studies in the Edinburgh cases and 
whose efficient Blood Transfusion Service has contributed in 
large measure to the survival of a number of the patients. 
CHAPTER ONE 
THE LANDMARKS OF PROGRESS 
1. 1. Historical 
The develoZiment of the microscope in the seventeenth 
century led to the first accounts of red corpuscles in blood 
Swammerdam (1658) may have discovered them but the best of 
the early descriptions is attributed to a little Dutch groce 
(Leuwonhoeck 1674) who made the practice of examining his o 
blood every day and regulating his habits from what he found 
It was probably not until the time of Hewson, 100 years 
later, that the erythrocytes were known to be biconcave 
discs, not "ruddy globules" as Leuwonhoeck had believed; in 
dissertations to the Royal Society Hewson reported their 
behaviour in water and in hypertonic saline. 
Boyle (1661), through his own observations, rejected th 
earlier view that the function of breathing was to cool the 
blood. He showed that if a burning candle and a mouse or 
sparrow were placed in a chamber from which air were gradu- 
ally exhausted, then the animal would die almost at the same 
time as the candle went out. Lavoisier prior to his execu- 
tion seems to have been near to interpreting the respiratory 
process, but it is generally believed that the role of the 
red corpuscle in oxygen transport was first propounded 
correctly in an important paper to the British Association 
by von Liebig in 1852. Fifteen years later, Hoppe -Selyer 
confirmed that haemoglobin had the capacity for reversible 
combination with oxygen and carbon dioxide as had been 
uggested/ 
2. 
suggested in von Liebig's theory. 
During this time search was being made for the source 
erythrocytes. Hewson believed they originated from 
leucocytes, Hayem from platelets, Addison the adrenals, 
eichert the liver and Kölliker the spleen. It was Neumann 
ho in 1868 demonstrated that mammalian red corpuscles arise 
from colourless nucleated elements in the bone marrow. 
lthough laborious techniques were introduced for counting 
lood cells and for measuring the colouring matter of blood 
in the middle of the nineteenth century (Vierordt 1852, 
elcker 1854), marrow biopsy was not performed during life 
ntil the beginning of the present century Oanese 1903) and 
arrow aspiration, as is now practised, not until after the 
ork of Arinkin in 1929. 
Lieutaud, a physician of Versailles, popularised the 
term anaemia, "an exhaustion of the blood vessels ", in a 
textbook published in 1759. In the previous century, long 
efore iron was known to be present in blood Sydenham had 
owever been using chalybdeates in the treatment of chlorosìd; 
the modern views on the correction of iron deficiency date 
from the introduction of the "veritable pills" of Dr. Blaud 
in 1832. The clinical features of pernicious anaemia were 
first fully described by Addison in 1855 although others 
(Combe 1823, Andral 1823) probably reported this condition 
uch earlier. The concept of "aplastic anaemia" was 
introduced by Ehrlich in 1888. 
Two/ 
3. 
Two Belgian physicians (Vanlair and Masius 1871) in 
their description of a patient with "microcythaemia" were 
vidently the first to propose that anamia might be due to 
he abnormally rapid destruction of red blood cells (Crosby 
1952). They suggested that their patient's jaundice was 
.ue to the excess of bile pigment formed when haemoglobin 
as released from the "senile" red cells. 
According to Crosby (1952) it was Hunter (1901) who 
introducedthe term "haemolytic ". From the studies of 
others and from his own experiments on chemically induced 
anaemia in dogs he concluded that small spherical micro - 
cytes, as had been seen and illustrated by Vanlair and 
Masius, "mark the anaemia as due to excessive destruction 
of blood and not to deficient formation (and) that they 
denote the anaemia to be haemolytic, not haemogenic in its 
origin" (Dacie 1960). 
2. The recognition of acquired haemolytic anaemias 
A familial form of jaundice was reported by several 
authors towards the end of last century and the account of 
Wilson and Stanley (1893) undoubtedly referred to, and 
described in some detail, congenital spherocytosis. 
Minkowski (1900) then clearly separated haemolytic icterus 
from that due to biliary obstruction. Hayem (1898) and 
later Widal, Abrami and Brule (1907) drew attention to 
another disorder that seemed to be distinct from congenital 
spherocytosis,/ 
4. 
spherocytosis, in which autohaemagglutination was frequently 
noted and in which anaemia could be severe and illness 
profound. Furthermore Chauffard and Troisier (1908) 
described cases in which haemolysins were present in the 
patients' serum. Numerous studies were reported by 
Chauffard and by Widal and his colleagues but were over- 
looked and when Lederer in 1925 described three cases of 
acute and severe haemolytic anaemia associated with the 
presence of serum haemolysins this was hailed as a new 
discovery. However it was not until the report of 
Dameshek and Schwartz (1940) that the existence of an 
acquired type of haemolytic anaemia as distinct from con- 
genital disease was finally accepted. These authors 
undertook extensive studies in four patients in whom acute 
anaemia appeared to be due to abnormal haemolysins, a 
phenomenon they were able to repeat in experimental animals, 
and just as Lederer's patients had responded dramatically 
to blood transfusion, theirs responded dramatically to 
splenectomy. Dameshek and Schwartz are also responsible 
for emphasising that spherocytosis and increased fragility 
of spherocytes in hypotonic solutions of saline may occur in 
both the congenital and acquired varieties of haemolytic 
anaemia and that these findings are not, as Naegeli (1931) 
taught, pathognomonic of the former. 
The next advance followed two apparently unrelated 
findings. One of these concerned haemolytic disease of 
the/ 
5. 
the newborn, for which many theories had been proposed; it 
fell to Levine, Katzin and Burnham (1941) to make the 
significant observation that there was a haemagglutinin in 
the serum of mothers with affected children which agglutinatéd 
the red cells of the fathers as well as those of the children. 
he other, which had been slightly earlier, was the dis- 
overy by Landsteiner and Wiener (1937, 1941) of the Rh 
-ystem of blood group agglutinogens. Soon afterwards it 
as shown that anti -Rh was a potent cause of haemolytic 
ransfusion reactions (Wiener and Peters 1940, 1941) and 
hat Rh incompatibility between mother and child was the 
ost frequent cause of erythroblastosis foetalis. 
Experience with Rh sensitisation revealed that Rh 
: ntibodies might not behave in the same way as the naturally 
ccurring red cell antibodies (anti -A, anti -B). They were 
termed "incomplete" antibodies because they appeared to 
combine specifically with Rh- positive erythrocytes, "coating' 
the surface of the cell without producing in vitro agglutina- 
tion and "blocking" agglutination of these cells, when 
axposed to appropriate anti -sera, in saline suspensions. 
It is now known that this form of sensitisation can occur 
with antibodies against a variety of blood group substances 
other than the Rh system and in addition to its implication 
in erythroblastosis foetalis and blood transfusion it 
appears to be the cause of a large proportion of cases of 
acquired haemolytic anaemia. 
One/ 
6. 
One of the greatest difficulties, initially, was the 
recognition and characterisation of these "coating anti- 
bodies" until Coombs, Mourant and Race (1945) using the 
fact that the antibodies were globulins were able to induce 
their in vitro detection by the exposure of sensitised cells 
to anti -human globulin serum (prepared by immunising a 
rabbit). Although other tests have been introduced Coombs' 
test remains a major contribution to the study of haemolytic 
disorders and is still the most generally useful procedure 
when a haemolytic process is believed to be due to red cell 
antibodies. 
Despite intensive study the precise mechanism of action 
of red cell antibodies in shortening red cell survival is 
not certain and as Wintrobe (1961) suggests a number of 
activities are probably involved. One reason for this 
that was known fifty years ago (Muir and McNee 1911) and 
which has more recently been confirmed (Wasastjerna 1948) is 
the discrepancy between the in vitro and vivo behaviour of 
anti -erythrocytic serum. Not only are there great differ- 
ences in the rate of reaction in the two situations but anti- 
bodies that appear to cause haemolysis in the intact animal 
may only cause agglutination in the test tube. Erythro- 
phagocytosis of sensitised cells certainly occurs (Zinkham 
and Diamond 1952) but seems unlikely to be quantitatively 
important. Although agglutination of coated cells is 
difficult/ 
7. 
difficult to secure in vitro, agglutination is considered to 
be a fundamental factor and has been seen to occur intra- 
vascularly in animals and in man (Wasastjerna, Pisciotta and 
Dameshek 1954a, 1954b). Agglutination is the fate of 
sensitised cells injected experimentally and this is prob- 
ably a first step leading to their sequestration in the 
spleen and elsewhere (Jandl, Jones and Castle, 1957). 
There is much conflicting data regarding the spleen which 
will be referred to again (p.80 ). An important feature 
of experimental immune haemolytic anaemias is that blood 
destruction is much less in animals after splenectomy than 
in normal animals (Wasastjerna 1948). In man studies using 
radioactive labelled red corpuscles also indicate that the 
spleen may play a major role in certain antibody -induced 
haemolytic anaemias (Jandl, Greenberg, Yonemoto and Castle 
1956, Schoesser, Korst, Clatanoff and Schilling 1957); 
other work suggests, however, that coarsely agglutinated 
cells may be removed from the circulation chiefly by the 
liver and lung (Jandl 1955). 
It may yet be shown that the most important sequel of 
red cell sensitisation is critical interference with red 
cell metabolism which renders the corpuscle more susceptible 
to destruction by other mechanisms. Allusions to the 
results of early experiments which support this hypothesis 
have been made by Prankerd (1959). One visible result 
that has been mentioned is spherocytosis and convincing 
evidence of red cell damage is obtained in the work of 
Sharpsteen/ 
s. 
Sharpsteen (1955) who showed that coating by antibody 
significantly reduced the tensile strength of the red cell 
membrane. 
1. 3. Enlargement of knowledge of intrinsic red 
cell defects 
That spherocytosis might not be the only inherited 
red cell defect which could give rise to anaemia was 
suggested by the report of Herrick (1910) who found sickle - 
shaped red corpuscles in a patient with severe anaemia; the 
development of sickling in vitro was demonstrated by Emmel 
(1917); the inheritance of the corpuscular defect was 
established by Huck in 1923 and in Sydenstricker's paper in 
1924 it was realised that "sickle cell anaemia" was a 
familial disease which affected the negro race. Hahn (1928) 
and later Sherman (1940) showed clearly that the phenomenon 
was enhanced in atmospheres of low oxygen tension and was 
favoured by lowering pH and by increasing the temperature 
to that of the body, while exposure to oxygen or carbon 
monoxide restored the circular form of sickled erythrocytes. 
During the period of these discoveries Cooley and Lee 
(1925) described an anaemia characterised by "target" cells 
in the blood, splenomegaly and skeletal changes. They 
considered the anaemia to be of haemolytic type (Cooley, 
Witwer and Lee 1927) but were also concerned with the 
obvious defects in haemopoiesis (Cooley and Lee 1932) 
which is now regarded as the more important factor. The 
familial/ 
9. 
familial nature of the disease was established, serious and 
benign forms were observed and the incidence appeared to be 
in people of Mediterranean origin and in the Far East. 
The first indication of specific biochemical red cell 
abnormalities in some of the haemolytic disorders came in 
1949 when Pauling, Itano, Singer and Wells showed that 
haemoglobin from sickle cells had a different electro- 
phoretic mobility from that of normal adult haemoglobin. 
Numerous reports of other variants of haemoglobin followed 
(known by different letters of the alphabet and by various 
eponyms) and since the haem moiety was the same in each, 
alteration in the globin part of haemoglobin came to be 
regarded as the abnormality. The validity of this concept 
of "molecular disease" was proved by Ingram in 1956 who, in 
a series of ingenious experiments using chromatography of 
tryptic digests of haemoglobin, showed that the difference 
between normal haemoglobin and sickle cell haemoglobin lay 
in the amino acid sequence in one of the polypeptide chains 
of globin. Further work has established that similar 
defects occur in several haemoglobinopathies while in others 
there is absence of one or both normal adult polypeptide 
chains; in haemoglobin -H for example only ß chains are 
present but these appear to be normal (Jones, Schroeder, 
Balog and Vinograd 1959). 
A notable advance followed investigation into the 
pathogenesis /. 
10. 
pathogenesis of the haemolytic anaemia which accompanies 
the giving of the anti -malarial drugs, pamaquine and prima - 
quine, to susceptible subjects (Earle, Bigelow, Zubrod and 
Kane 1948, Dern, Weinstein, Le Roy, Talmage and Alving 1954). 
Negroes were found to be the most frequently affected 
(although it is now known that susceptibility is also found 
in Sephardic Jews, certain Arab groups and Caucasians of 
Italian and Greek extraction), the abnormality clearly 
resided in the erythrocytes of sensitive subjects and 
haemolysis was self limiting because only the older cells 
in the patients' circulation appeared to be destroyed. 
These findings led to the belief that sensitivity to these 
drugs might be related to deficiency in an enzyme system 
which decreases in activity as the red cell ages. Beutler, 
Dern, Larkin, Flanagan and Alving (1955) demonstrated that 
primaquine sensitive erythrocytes were uniformly deficient 
in reduced glutathione. Shortly afterwards Carson, 
Flanagan, Ickes and Alving (1956) presented evidence that 
this abnormality was associated with a deficiency of glucose 
6-phosphate dehydrogenase activity; one action of this 
enzyme is known to be the maintenance of substrates necessary 
to reduce oxidised glutathione. Lately it has been demon- 
strated that this red cell enzyme defect is present in 
iatients who show haemolysis when exposed to a wide range of 
rugs and chemicals, particularly aniline derivatives, as 
ell as in those who are sensitive to the bean or the 
ollen/ 
11. 
pollen of the fava plant. It has still to be determined 
whether depletion of reduced glutathione plays a primary 
role in the destruction of sensitive cells or whether this 
is only a convenient indicator of more important deficiencie 
(Wintrobe 1961). 
Reports of various other metabolic abnormalities in the 
cells of patients with congenital haemolytic anaemia are now 
numerous. A most exhaustive study by Erickson and her 
colleagues ( IErickson, Williams, Hummel, Lee and Macey 1937; 
Erickson, Williams, Hummel and Macey) and later by Harris, 
Prankerd and Westerman (1958, demonstrated an increase in 
all groups of lipids in the red corpuscles in sickle cell 
anaemia; thalassaemic cells on the other hand show a 
marked deficit of lipid,especially of cerebroside, with 
some increase in phospholipid. Others have demonstrated 
that in the erythrocytes in congenital spherocytosis there 
is a significantly higher proportion of lysophosphatidyl 
ethanolamine and lower proportion of phosphatidyl ethanol - 
amine than in normal cells (Allison, Kates and James 1960). 
In paroxysmal nocturnal haemoglobinuria (PNH) the haemolytic 
process is undoubtedly complex. Experimental evidence 
suggests that the fault in this condition is also in the 
red corpuscles (Dacie 1949). Differing abnormalities in 
the lipoprotein of the cells have been reported by Harris, 
Prankerd and Westerman 1957)and by Munn and Crosby 195'7,. 
The former group found a marked specific deficit of 
phosphatidyl/ 
12. 
phosphatidyl -choline. Reduction in acetylcholinesterase 
activity has also been observed (Hartmann and Auditore 
1959); this appears to be a consistent finding in severe 
and moderately severe cases (Metz, Bradlow, Lewis and Dacie 
1960). 
The nature of the corpuscular defect in congenital 
spherocytosis is a study of particular interest. Using 
radioactive phosphorus it is found that there is a smaller 
flux of 32P into adenosine triphosphate and 2,3- diphospho- 
glyceric acid than in normal cells (Prankerd, Altman and 
Young 1955, 1960) indicating a disturbance in phosphoryla- 
tion. A number of enzyme deficiences have been suggested 
but are still to be proved. 
The impression is gained that while the pathogenesis 
of none of the congenital haemolytic disorders has yet been 
explained, the evidence accumulating strongly suggests that 
these conditions will ultimately be shown to be true inborn 
errors of metabolism due to defects of enzymes or other 
vital substances. Moreover, the present enquiries into red 
cell metabolism suggest that red cell ageing may well be the 
sequel of utilisation of non -replicating enzymes, particu- 
larly those concerned in glycolysis (Hirschberg and Banks 
1958, Bernstein 1959). 
1. 4. The contribution of red cell survival measurement 
It is uncertain when it was first appreciated that red 
corpuscles/ 
13. 
corpuscles had a finite survival time. The first studies 
into the life span of erythrocytes that are known were made 
100 years ago when various investigators (Marfels and 
Moleschott 1856, Brown -Sequard 1867) examined the question 
by injecting nucleated red corpuscles from birds and frogs 
into animals having non -nucleated corpuscles and measuring 
the rate of disappearance of transfused nucleated corpuscles 
from the recipient's circulation. We now know that because 
of species' difference these experiments cannot have yielded 
valuable information. 
The first technically good estimates of red cell 
survival in man are believed to have been made by Ashby 
(1919) who developed a method used a few years earlier in 
bulls (Todd and White 1911). The method depended on the 
transfusion to the subject under study, of blood that was 
compatible but immunologically identifiable (e.g. Group 
'O' blood to a Group 'A' recipient). Subsequently the 
rate of disappearance of donor red cells could be followed 
by agglutinating the recipient's red cells in serial samples 
of peripheral blood using appropriate antisera and enumerat- 
ing the free donor cells that remained. While the techniqu 
is tedious and subject to certain criticisms, it has 
contributed much to the understanding of haemolytic 
disorders; improvements made it possible to utilise the 
MN and Rh blood group systems and it was widely employed 
until about ten years ago, since which time it has been 
largely/ 
14. 
largely superseded by methods using radioactive isotopes 
(P.l ). 
Although investigators (Callender, Powell and Witts 
1947, Berlin 1951, Iiurley and Weisman 1953, Eadie, Brown 
and Curtis 1955) have shown a slight deviation from a 
straight line in a small number of patients, when the graph 
of percentage survival is plotted against time, it has been 
found that in health the disappearance of normal red cells 
from the circulation of a normal individual is usually a 
linear function and that the red corpuscles have a life 
span in the region of 110 to 120 days. Approximately 
0.8 per cent of the total number of corpuscles are destroyed 
each day and this form of elimination has been taken to 
indicate that the age of the red cells is the main factor 
in determining survival. 
This orderly pattern of destruction does not however 
obtain in haemolytic disorders. In various types of 
acquired haemolytic anaemia,Loutit and Mollison (1946) and 
Mollison (1947) showed that the rate of elimination of 
transfused normal corpuscles was greatly accelerated. 
When the results of their observations were plotted the 
curve was exponential and not straight; the loss of 
transfused cells was at first very rapid and then slow. 
The implication was that red cell destruction was being 
determined by at least two factors, age and extrinsic 
injury/ 
15. 
injury to the normal donor cells. The rapid initial 
disappearance of transfused erythrocytes was due to the 
"random" elimination of young cells as well as old, and as 
the transfused cells became fewer their chance of survival 
improved. 
In paroxysmal nocturnal haemoglobinuria, in which 
condition the main abnormality is believed to reside in the 
red cells, transfusion of the patient's cells to a normal 
subject also produces an exponential type of elimination 
of cells (Dacie and Mollison 1949). The red cells differ 
widely in their ability to survive suggesting that in this 
type of disease the important factor affecting life span, 
other than age, is individual variation of the red cells in 
their susceptibility to destruction. Dacie and Mollison 
(1943) had earlier obtained similar results for congenital 
spherocytosis cells; furthermore they had found that when 
cells from healthy subjects were transfused to patients 
with congenital spherocytosis their survival time was normal 
The accuracy of these early transfusion experiments has 
been confirmed, studies have been expanded and two important 
concepts have resulted. Firstly, it has been realised that 
there are two main groups of haemolytic disorder; there 
are on the one hand conditions in which the primary defect 
is in the red corpuscle; on the other hand are conditions 
in which the patient's erythrocytes are normal, there is no 
congenital abnormality and the haemolytic process is due to 
factors/ 
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factors outwith the red corpuscle. Secondly, the use of 
measurements of red cell survival has led to our present 
definition of a haemolytic disorder as one in which the 
life span of the red cells is shortened; whatever else is 
clinically evident, this is the essential feature. The 
patient may not show splenomegaly or icterus or reticulo- 
cytosis and because of the marrow's ability to increase its 
productive capacity six to eight fold to compensate for 
increased blood destruction (Crosby and Akeroyd 1952, 
Crosby 1955), the patient may not be anaemic. It was this 
last observation that led Crosby (1955) to suggest that 
"haemolytic disease was a more appropriate term than 
"haemolytic anaemia} or "haemolytic jaundice" for the 
group of disorders in which the main abnormality in the 
blood was excessively rapid destruction of red corpuscles. 
Studies of red cell survival have also shown that shorten- 
ing of red cell life is found in a very wide range of 
conditions that had not formerly been regarded as causing 
haemolysis; these include infection, chronic inflammation 
(notably rheumatoid arthritis), hepatic cirrhosis, uraemia 
and malignant disease (Berlin, Waldmann and Weissman 1959, 
Dameshek and Schwarz 1959). In these disorders the normal 
indicators of overthaemolysis, namely acholuric jaundice 
and signs of increased activity of the bone marrow, are 
usually absent and it is probable that in these conditions 
reduced/ 
17. 
reduced red cell survival is only one factor and not the 
main factor in the genesis of anaemia. 
1. 5. Classification of the haemolytic disorders 
The landmarks of progress into the understanding of 
haemolytic disorders in the last twenty years have been 
discussed; the chief among these have been the development 
of serological techniques for the study of red cell anti- 
bodies, the extensive use of red cell survival measurements 
and the accelerating knowledge regarding metabolic defects 
in red corpuscles. A number of classifications for 
haemolytic disease have been suggested, based either on the 
severity of illness, e.g. into acute and chronic, or on 
inherited aspects of the illness (Dameshek and Schwartz 1940 
into congenital and acquired. The best classification, 
utilising the present views on pathogenesis, recognises two 
main groups; an outline of this aetiological division is 
given in Table 1. 
In the first group (Group A) the red cells are held to 
e inherently normal, biochemically and morphologically. 
The cause for red cell injury and premature destruction is 
some extracorpuscular factor. This may be infection, eithe 
.acterial (e.g. staphylococcal septicaemia) or parasitic 
(e.g. malaria). A number of chemicals (e.g. lead) or 
herapeutic agents (e.g. sulphones) may be implicated and 
evere thermal burns undoubtedly cause significant red cell 
amage (Moore, Peacock, Blakely and Cope 1946, James, 
rnell/ 
TABLE 1 
CLASSIFICATION OF HAEMOLYTIC DISORDERS 
A. Due to mechanisms extrinsic to the red cell. 
Infections 
Chemical and physical agents 
Red cell antibodies - 
Symptomatic 
Idiopathic 
Cause undetermined - 
With underlying disease 
Without underlying disease 
B. Due to defects within the red cell. 
1. No other factor known to be implicated. 
Congenital spherocytosis 
Congenital elliptocytosis 
Congenital non -spherocytic haemolytic anaemia 
Thalassaemia 
Haemoglobinopathies other than haemoglobin -S 
2. An extracorpuscular factor required for 
full expression. 
Sickle cell disease 
Paroxysmal nocturnal haemoglobinuria 
Glucose -6- phosphate dehydrogenase deficiency 
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Purnell and Evans 1954). In a large and important group 
haemolysis appears to be due to antibodies produced by the 
patient against his own red cells. This may be associated 
with reticuloendothelial disease, particularly when lymphoid 
proliferation is predominant, (e.g. lymphosarcoma), or with 
connective tissue diseàse (e.g. lupus erythematosus). In 
approximately 50 per cent of patients no cause can be found 
for the spontaneous generation by a patient of antibodies 
against his own red cells, and the condition is described 
as "idiopathic autoimmune acquired haemolytic anaemia ". 
There remain in Group A acquired haemolytic anaemias that 
have still to be explained; these are the ones that 
complicate chronic diseases (p.í33 ) and those that are 
found in patients with splenomegaly of miscellaneous causes 
and others without any guiding clue as to their aetiology. 
Group B includes all the conditions in which the main 
abnormality is an intrinsic red cell defect. In some of 
these no other important factor has been found, e.g. con- 
genital spherocytosis, while in others an extrinsic 
challenge appears to be necessary for the red corpuscle to 
become fully susceptible to destruction; in sickle cell 
disease this environmental factor is lowered oxygen tension, 
in PNH it is the metabolic changes associated with sleep 
and in glucose -6- phosphate dehydrogenase deficiency it is 
certain drugs, particularly aniline derivatives, and 
derivatives of the fava plant. 
In/ 
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In the chapters that follow the concept of two 
fundamental groups of haemolytic disease has been accepted 
and examples of most haemolytic diseases will be used to 
illustrate methods of investigation, such as tests of 
fragility and red cell survival measurement. The main 
considerations will, however, be restricted to three 
conditions in which the greatest experience has been gained. 
20. 
CHAPTER TWO 
CLINICAL MATERIAL AND METHODS OF INVESTIGATION 
2. 1. The patients. 
Two varieties of haemolytic disorder are most commonly 
encountered in Northern Europe; these are congenital 
spherocytosis and autoimmune acquired haemolytic anaemia. 
For reasons of their racial incidence the haemoglobino- 
pathies and thalassaemia are seldom seen and the other 
specific entities are rare. Experience has shown, however, 
that reduction of red cell survival accompanies many 
systemic diseases; this is not due to identifiable red cell 
antibodies and the pathogenesis is ill understood. Refer- 
ence has already been made to this occurrence in a number 
of chronic infections and inflammations (p. It ). Studies 
in rheumatoid arthritis (Alexander, Richmond, Roy and Duthie 
1956, Richmond, Alexander, Potter and Duthie 1961) are 
typical of others and while a haemolytic process is present 
in this condition and will contribute to anaemia, it is 
unlikely to be an important clinical factor. There is, 
however, a different picture in patients with leukaemia, 
reticulosis and primary myeloid metaplasia; in this hetero- 
geneous group there may be more striking reduction of red 
cell survival, particularly in those with splenomegaly, 
while the classical diagnostic indicators of haemolysis are 
absent. Excessive red cell destruction is frequently a 
major/ 
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ajor cause for morbidity in these patients; the incidence 
is unknown because it seems to depend on the frequency with 
hich the possibility of haemolysis is considered. For the 
urpose of this thesis, this last group will be referred to 
s suffering from "symptomatic non - immune haemolytic anaemia' 
A special study has been made of the following: - 
(i) Autoimmune acquired haemolytic anaemia; 
twenty -three patients, 
(ii) Symptomatic non - immune haemolytic anaemia; 
twenty -seven patients, 
(iii) Congenital spherocytosis; twenty -six 
patients. 
All the cases in Groups (i) and (iii) and nine of the 
atients in Group (ii) have been investigated as in- patients 
r while attending hospitals in Edinburgh during the past 
ight years. Eighteen patients in Group (ii) were studied 
n the Memorial Hospital, New York, U.S.A., in the period 
958 -59. The details regarding age, sex, clinical features 
nd mode of presentation for each disease group will be 
iven in the appropriate chapters. 
While consideration of the natural history of the 
isease, pathogenesis of haemolysis and management of these 
eventy -six patients is the main substance of the thesis, 
eference will also be made to normal subjects, patients 
ith miscellaneous conditions and patients with the rarer 
aemolytic/ 
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haemolytic disorders in evaluation of osmotic fragility 
tests and measurements of red cell survival. 
2. Methods of investigation. Introduction. 
Clinical suspicion of haemolytic disease usually arise 
from the presence of anaemia, acholuric jaundice and spleno- 
megaly. Recurrent cholelithiasis, particularly when only 
pigment stones are found at operation, may also indicate 
excessive blood destruction while considerations of family 
history and race are obviously important. It will be 
apparent, however, from later discussion that the modes of 
presentation of haemolytic disease are several and that 
diagnosis depends to some extent on the clinical setting 
but more so on the analysis of a number of investigations, 
each of which gives particular information and has a 
distinct purpose. There are first, routine and simple 
tests which show the indirect results of haemolysis, 
namely changes in bile pigment metabolism due to increased 
bilirubin production from excessive red cell destruction, 
and the changes in peripheral blood and bone marrow which 
reflect compensatory erythropoiesis. If these tests when 
considered together do not permit a confident diagnosis of 
haemolytic disease, then it is likely that the rate of blood 
destruction is not greatly increased and direct measurement 
f red cell survival will be necessary for full evaluation 
f the case. 
Having/ 
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Having determined that a haemolytic process is present, 
it must then be established whether the condition is due to 
an intrinsic red cell defect or to some extracorpuscular 
mechanism and to determine precisely which condition is 
present. Some information may have been gained regarding 
defects in the red cell from the routine examination of 
their morphological characteristics in films of the peri- 
pheral blood. This will be so when the defect is 
pronounced and applies particularly to spherocytes, ellipto- 
cytes, target cells and sickle cells. In general, more 
sophisticated examination of the erythrocytes is required. 
This involves tests of fragility or susceptibility to 
destruction; electrophoresis of haemoglobin; measurements 
of glucose -6- phosphate dehydrogenase deficiency, either 
through the production of Heinz bodies on exposure of the 
corpuscles to aromatic nitrogen compounds (Fertman and 
Fertman 1955), or through the glutathione stability test, 
a measurement of reduced glutathione levels in red cells 
before and after incubation with acetylphenylhydrazine 
(Beutler 1957). Finally the acid serum test of Ham (Ham 
1939) may be required; this with suitable control (Dacie 
1949) is diagnostic of paroxysmal nocturnal haemoglobinuria. 
Search for extracorpuscular factors entails in practice 
examination and investigation of the patient for diseases 
that are known to be associated with excessive blood 
destruction and examination of the patient's blood for red 
cell/ 
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cell antibodies; recognition of the former since they are 
mainly diseases of the reticulo -endothelial system and 
connective tissue can usually be achieved by study of the 
blood and bone marrow, biopsy of certain tissues (e.g. 
marrow, lymph node and liver) and screening for disseminated 
lupus erythematosus particularly using LE cell preparations. 
Serological studies begin with Coombs' test but then follow 
complex procedures for characterisation of red cell anti- 
body to which reference will be made. 
Not all the methods of investigation of haemolytic 
disease have been required in this thesis. The techniques 
employed will be described in five sections: - 
(i) Routine tests of blood, urine and bone 
marrow; procedures to exclude underlying 
disease, 
(ii) Red cell fragility tests, 
(iii) Serological studies, 
(iv) Red cell survival measurements using 
chromium -51. Since these have a major 
role in the thesis they will be discussed 
in detail. 
(v) Ancillary investigations that are more 
concerned with the effects of haemolytic 
disease than with diagnosis. 
2. 3./ 
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2. 3. Routine tests. 
The tests used in the initial assessment of patients 
that are referred to in this section have been undertaken 
in the routine haematological, biochemical and pathological 
departments of the Edinburgh hospitals and the Memorial 
Hospital, New York. 
Peripheral blood 
Haemoglobin estimation and reticulocyte counts have 
always been undertaken since these have been found to be the 
most useful single measurements, both for diagnostic purpose 
and for the assessment of a patient's progress. Haemo- 
globin levels will be referred to as a percentage; 
100% = 14.8 g. Hb. /100 ml. Reticulocyte counts will be 
expressed as a percentage of the red cell count; the normal 
value has been accepted as less than 2% (Dacie 1956). 
Films of peripheral blood have been made in all patients; 
frequently spherocytosis accompanying reticulocytosis has 
been the basis for suspecting a haemolytic disorder; 
examination of blood films has also been essential to the 
exclusion of leukaemia. Since the absolute indices (mean 
corpuscular volume, M.C.V.; mean haemoglobin concentration, 
M.C.H.C.) and the white cell count have not been found to 
contribute to the diagnosis or to the management of a 
patient, these values are not available for every patient. 
The common occurrence of macrocytosis that was known many 
years ago (Dameshek and Schwartz 1940) has been confirmed. 
he/ 
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The reason for a raised mean corpuscular volume is 
uncertain; it may be partly due to the presence of reticulo 
cytes but this cannot be the whole explanation ( Dacie 1960), 
and it seems possible that the macronormoblasts found in the 
marrow in haemolytic disease (Dacie and White 1949) might 
well be the source of abnormally large corpuscles. 
Bone marrow 
The marrow has been examined in most patients; aspira- 
tion of the medullary cavity in the sternum or ilium has 
always been attempted first and if unsuccessful (e.g. in 
the patients with myelofibrosis) marrow trephine has been 
undertaken. Study of the marrow has not been used to 
confirm the presence of a haemolytic process but rather to 
exclude leukaemia, reticulosis and myelofibrosis. More 
recently, since the reports of Crosby and Sacks (1949), 
Chanarin, Dacie and Mollin (1959) and Delamore, Richmond and 
Davies (1961), there has been interest to exclude megalo- 
blastic erythropoiesis. 
3ile pigments 
The work of Lathe and his colleagues (Cole and Lathe 
1954, Billing and Lathe 1958) has led to an understanding of 
the changes in bile pigment metabolism that occur in haemo- 
lytic disease. Their chief observátion is that bilirubin 
from haemoglobin catabolism (prehepatic bilirubin, haemo- 
bilirubin, unconjugated bilirubin) is converted into water 
soluble forms in the liver by conjugation with hydrophilic 
compounds/ 
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compounds of which glucuronic acid is the most important. 
This difference between prehepatic bilirubin, which is bound 
to protein and cholesterol in the plasma, and post hepatic 
bilirubin (hepatobilirubin, conjugated bilirubin), as is 
regurgitated into the plasma in obstructive jaundice, has 
explained the direct and indirect Van den Bergh reactions 
and also the mechanism of production of "acholuric jaundice. 
There are three measurements by which bile pigment 
metabolism may be sampled easily; the bilirubin level in 
the plasma and the level of urobilinogen in the urine and in 
the faeces. There are, however, a number of factors that 
govern the quantity of bilirubin produced; the chief of 
these are the rate of red cell destruction leading to 
catabolism of haemoglobin and the red cell mass. Other 
factors govern the actual level of bilirubin in the plasma 
and the amount of urobilinogen that is excreted; the chief 
of these, other than the amount of bilirubin that is 
produced, is the capacity of the liver to deal with it. 
Quantitative measurements of urobilinogen were formerly 
considered to be useful indices of haemoglobin breakdown 
and the "haemolytic index" (Miller, Singer and Dameshek 1942, 
was an attempt to relate the daily output of urobilinogen 
in the faeces to the total mass of circulating haemoglobin. 
However, in addition to the influences on bile pigments 
already mentioned there are a number of other reasons why 
such/ 
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such techniques are not of value and why no attempt has been 
made to employ them in the present study. First, there is 
the uncertainty regarding the degree of reabsorption of 
urobilinogen from the bowel. Second, it has been shown 
from studies with nitrogen -15 labelled glycine that a signi- 
ficant proportion of urobilinogen, probably in the region of 
15% in normal individuals, and more in haemolytic disorders, 
is derived from sources other than haemoglobin within mature 
circulating erythrocytes (London, West, Shemin and 
Pittenberg 1950); a number of porphyrins of endogenous 
origin, such as myoglobin, probably contribute to the total 
urobilinogen (Lemberg and Legge 1949, Schmid 1959); it is 
also suggested (Bingold 1949) that there may be oxidation 
products of haem, such as dipyrrholes, which are not included 
in the measurement of urobilinogen. These different find- 
ings undoubtedly help to explain why a number of investigator 
(Hagen and MacDonald 1954, Crosby 1955, Baldini and di 
Pietrantoni 1957) have failed to recover the expected amount 
of urobilinogen from patients with various haemolytic 
disorders. 
On the few occasions that the direct and indirect 
reacting bilirubin of the Van den Bergh reaction has been 
measured it has not been found to make a significant diag- 
nostic contribution. 
Taking liver function into account it has been found 
sufficient/ 
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sufficient, both for diagnosis and for following the 
progress of most patients, to estimate the serum level of 
bilirubin and qualitatively, using Ehrlich's aldehyde 
reagent, to assess the degree of urobilinogenuria. 
Presumably because of the large capacity of the liver to 
excrete bile (Billing and Lathe consider that the healthy 
liver could excrete all the bilirubin normally contained in 
the plasma in ten to twelve hours), the serum bilirubin is 
seldom high in haemolytic disease; Dacie (1960) states 
that the level may be normal, is usually in the range 
1 - 3 mg. and rarely exceeds 5 mg. 
Haemoglobin breakdown products in severe haemolysis 
When haemolysis is very severe and because much of the 
red cell destruction is intra -vascular, free haemoglobin 
accumulates in the plasma. It is now known that the 
haptoglobins have the capacity for combining with haemo- 
globin and are probably the main pathway by which it is 
cleared from the blood (Jayle and Boussier 1955). Smithies 
(1955a, 1955b) showed that the haptoglobins were saturated 
by haemoglobin in a concentration of the order of 125 mg./ 
100 ml.; Laurell and Nyman (1957) found that the level of 
saturation varied in normal subjects in the range 50 - 140 
mg. /100 ml., and when saturation occurred excess of haemo- 
globin that had been given intravenously caused haemoglobin - 
uria. Haemoglobinaemia, methaemalbuminaemia and 
haemoglobinuria, the various results of rapid haemoglobin 
degradation/ 
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degradation have not been looked for routinely but will be 
discussed in the two-patients with autoimmune haemolytic 
anaemia in whom their estimation was relevant. 
Exclusion of underlying disease 
In addition to the routine examination of blood, bone 
marrow and urine that was undertaken for signs of increased 
erythropoiesis and of increased haemoglobin catabolism, it 
was in some patients necessary to exclude underlying disease 
by lymph gland biopsy, liver biopsy and examination of the 
peripheral blood for the LE cell phenomenon. Reference will 
be made to these procedures where applicable. For the 
demonstration of LE cells the methods described by Hargraves 
(1954) and Snapper and Nathan (1955) have been used. 
2. 4. Red cell fragility tests 
There is no single satisfactory test which correlates 
susceptibility of red cells to destruction in the circula- 
tion with a measurable abnormality in the laboratory. 
This would be expected from the different mechanisms of red 
cell destruction in each disease; for example, when the 
patient has a high titre of cold antibodies (p. ('5 ), it is 
believed that agglutination of the patient's corpuscles 
occurs in the extremities, particularly in a cold environ- 
ment, and that the agglomerates of red cells are trapped 
and traumatised in their further passage through the 
circulation; in sickle cell disease it is likely to be the 
shape/ 
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shape of the cell that will cause damage from mechanical 
factors; in glucose -6- phosphate dehydrogenase deficiency it 
is the age of the cell that is important and then only if 
a particular aromatic compound is in the surrounding medium. 
Mechanical fragility 
Although not the first to be devised, the most rational 
type of in vitro test offers some form of mechanical trauma 
to mimic the effect of the circulation. Meltzer and Welch 
(1884) drew attention to the destruction of erythrocytes by 
physical factors but it was not until the work of Dameshek 
and Miller (1943) and Shen, Castle and Fleming (1944) that 
mechanical fragility tests suitable for clinical application 
were devised. The early investigations showed that mechan- 
ical fragility paralleled osmotic fragility (see below) and 
that agglutinated erythrocytes and sickled erythrocytes were 
also susceptible to mechanical destruction. Schaub and 
Maier (1956) have reported the widest experience and found 
mechanical fragility tests to be of value in doubtful cases 
of hereditary spherocytosis, showing a positive result when 
the osmotic fragility test was in the normal range. 
Most methods have depended on the agitation of uncoagu- 
lated blood with glass beads. The results obtained in a 
small series of patients, using a modification of the method 
described by Dacie (1956) are given in Table 2. 
The/ 
TABLE 2. 
COMPARISON OF FRAGILITY OF RED CORPUSCLES IN 
DIFFERENT DISEASES TO MECHANICAL TRAUMA 


















2.8 - 5.6 
5.1 - 11.3 
5.2 
3.6 
4.6 - 6.0 
1.8 - 5.1 
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The patients with autoimmune haemolytic anaemia and 
symptomatic non - immune haemolytic anaemia had a severe 
haemolytic process; these results were not felt to contri- 
bute to the present study and mechanical fragility tests 
were abandoned. 
Osmotic fragility 
According to Wintrobe (1961), it was Hamburger (1883) 
who first proposed a fragility test which measured haemo- 
lysis of red cells in hypotonie salt solutions. Chauffard 
(1907) introduced the present type of test and considered 
that the wide "resistance span" in haemolytic jaundice was 
an expression of heterogeneity of cell population in respect 
of diameter. Following the work of Haden (1934), who 
correlated increased susceptibility to haemolysis with a 
falling diameter -thickness ratio, Castle and Daland (1937) 
in extensive studies concluded that differences in the 
susceptibility of erythrocytes to haemolysis with hypotonie 
sodium chloride were due to differences in form and not to 
differences in osmotic behaviour. Direct microscopic 
observations convinced them that the erythrocytes assumed a 
spherical shape before haemolysis and the more susceptible 
the erythrocyte to "hypotonie haemolysis" the less hypotonie 
the plasma necessary to cause the production of a spherical 
form. The paper of Hunter (1940) probably introduced the 
present quantitative methods for determining "osmotic 
fragility " / 
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fragility" of erythrocytes by increasing haemolysis photo - 
colorimetrically. Despite the general acceptance of these 
pioneer observations, Sharpsteen (1955) showed convincingly 
that the intracellular protein osmotic pressure and the 
tensile strength of corpuscular membranes was more important 
in determining red cell fragility than the conformation of 
the cell. 
Numerous reports now indicate that increases of fragil- 
ity are seen in all haemolytic disorders that are associated 
with spheroidicity of the corpuscles. Hence ( Dacie 1960) 
it is found in almost all patients with congenital sphero- 
cytosis, in most patients with autoimmune haemolytic anaemi- 
in some patients with chemically induced haemolysis and 
after extensive burns. Dacie (1943) pointed out the 
"tailed" type of curve that is characteristic of congenital 
spherocytosis, and Bolton (1949) and Emerson, Shen, Ham, 
Fleming and Castle (1956) demonstrated the disappearance of 
the population of very sensitive cells, which account for 
the "tail ", after splenectomy in this condition. Increased 
fragility in autoimmune haemolytic anaemia has been known 
since the work of Dameshek and Schwartz (1938). In 
elliptocytosis, when haemolysis is present, osmotic fragil- 
ity may or may not be increased (Dacie 1960). In condition 
where the red corpuscles have an increased diameter- thicknes 
ratio, as seen in the target cells (Barrett 1938) of 
thalassaemia and chronic liver disease, there is seen to be 
resistance/ 
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resistance to osmotic haemolysis. In many anaemias, 
notably iron deficiency and pernicious anaemia (Cassells 
1938), the red cells are less fragile than in health, the 
fragility improving as the cells become normal. Simon and 
Topper (1957) and Prankerd (1958) have found, using radio- 
active iron as a red cell label, that young red cells are 
less fragile than old red cells. 
Method used for measuring osmotic fragility. 
The method used for determining osmotic fragility in 
the present studies was modified from that described by 
Wintrobe (1956). A stock solution with the osmotic activi- 
ty of 10% sodium chloride was prepared by dissolving 18 g. 
sodium chloride, 2.731 g. dibasic sodium phosphate and 
0.486 g. monobasic sodium phosphate (2H20) in 200 ml. of 
distilled water. This was kept in a stoppered flask at 
40 C. and was replaced at the first hint of bacterial con- 
tamination. Using a 1% working solution, 10 ml. of the 
following dilutions of sodium chloride (expressed as per- 
centage) was prepared in matched test tubes:- 0.9, 0.85, 
0.8, 0.75, 0.70, 0.65, 0.60, 0.55, 0.52, 0.50, 0.48, 0.46, 
0.44, 0.42, 0.40, 0.38, 0.35, 0.30, 0.25, 0.20, 0.10. 
Ten ml. of distilled water was added to a final tube and 
this tube was used to indicate 100% haemolysis. 
To each tube was added 0.05 ml. blood which had been 
anticoagulated by sequestrene and previously oxygenated by 
frequent rotation in the tube (Creed 1938) under test; 
each/ 
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each test was done in duplicate and on each occasion that 
osmotic fragility tests were undertaken the blood of a 
normal individual was tested' as a control. 
The test,tubes, after thorough mixing, were incubated 
for thirty minutes at 37° C. They were then centrifuged 
and the amount of haemoglobin in the supernatant fluid in 
each tube was determined in an EEL (Evans Electroselenium 
Limited) colorimeter, previously calibrated for different 
dilutions of haemoglobin. The data were then plotted 
graphically with the percentage haemolysis as ordinate and 
the percentage concentration of saline as abscissa. 
Results of osmotic fragility tests in normal subjects 
and an illustration of abnormal results. 
Fig. i shows the results obtained in twenty -six 
normal subjects, in various haemolytic disorders and in 
other disorders of the blood. The observations are typical 
of those obtained by others. The "tail" of very fragile 
cells seen in some patients with congenital spherocytosis is 
illustrated, as is the normal fragility of cells from a 
patient with symptomatic non - immune haemolytic anaemia and 
the comparative resistance of macrocytic cells, iron 
deficient cells and cells from a patient with thalassaemia 
minor. Charting the increments of haemolysis between 
successive concentrations of sodium chloride as suggested by 
Momigliano, Levi and Bairati (1935) and practised by others, 













Range in 26 normal subjects 
Congenital spherocytosis 
Idiopathic autoimmune haemolytic 
anaemia 
Symptomatic autoimmune haemolytic 
anaemia (lymphosarcoma) 
Ovalocytosis 
Iron deficiency anaemia 
Addisonian pernicious anaemia 
Thalassemia minor 
Symptomatic non -immune haemolytic 
anaemia. 
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Fig. 1 
The lysis of red blood cells in hypotonic solutions 
of saline (osmotic fragility) in normal subjects and 
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Acquired 
spherocytosis 














0.20 0.40 0.60 0.80 
Thalassemia 
minor 
020 0.40 0.60 0.80 
The increments of haemolysis between successive dilutions 
of saline in the osmotic fragility test. This method of 
recording the data illustrates cell populations of differing 
fragility and emphasises "shifts" to the left or the right 
of the normal range. 
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normal as is illustrated in Fig. 2. This procedure helps 
to indicate populations of cells of different susceptibili- 
ties to osmotic haemolysis but does not otherwise add to the 
interpretation of the data. 
Various workers, notably Emerson, Shen and Castle 
(1944), Young (1947) and Dacie, Mollison, Richardson, Selwyn 
and Shapiro (1953), have used the observation that the red 
cells of congenital spherocytosis undergo greater increase 
of osmotic fragility than do normal cells after the blood of 
the patient has been incubated under sterile conditions for 
twenty -four hours at 37° C. before undertaking the test. 
Young, Izzo and Platzer (1951) in studies of seventeen 
patients with congenital spherocytosis showed how this 
procedure increased the chance of diagnosis in patients 
with mild degree of red cell abnormality. Results in three 
patients with congenital spherocytosis, in two of whom 
osmotic fragility was not markedly abnormal and in whom the 
presence of spherocytes in blood films was doubtful, is 
shown in Fig.3. 
In referring to results of osmotic fragility tests, 
two measurements will be described; first the concentration 
of saline where haemolysis begins and haemolysis is complete 
and second the concentration of saline (calculated from a 
graph of the data) at which 50% of the patient's erythro- 
cytes have been haemolysed. 



























Range in 10 
normal subjects 
AFTER INCUBATION 
0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 010 020 0.30 0.40 0.50 0.60 0.70 0.80 0.90 
°h CONCENTRATION OF SALINE °b CONCENTRATION OF SALINE 
6-6 Patient I. 
D- 0 Patient 2 
0-0 Patient 3 
Fig. 3 
The effect of incubation of blood for 24 hours on 
the osmotic fragility of red cells. This technique is 
useful in distinguishing patients with mild spherocytosis 
(Patients 1 and 2), since the deviation from normal after 
incubation is increased, compared with that obtained in the 
standard test. 
TABLE 3 
RESULTS OF OSMOTIC FRAGILITY TESTS IN NORMAL SUBJECTS 
A. Standard procedure 
(26 individuals) % concentration of sodium 
chloride 
Range Mean 
Onset of haemolysis 0.52 - 0.45 0.490 
Completion of haemolysis 0.38 - 0.25 0.305 
50% haemolysis 0.440 - 0.345 0.395 
B. Incubation procedure 
- see text 
(10 individuals) 
Onset of haemolysis 0.90 - 0.75 0.835 
Completion of haemolysis 0.48 - 0.35 0.405 
50% haemolysis 0.585 - 0.520 0.560 
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2. 5. Serological tests. 
Tests for the detection of red cell antibody have been 
used in the evaluation of all but five of the patients that 
have been studied. They have been undertaken for the 
Edinburgh patients by the staff of the Blood Transfusion 
Service for the South -Eastern Region of Scotland by courtesy 
of Dr. R. A. Cummings, and for the American patients by the 
staff of the Haematology Department, Memorial Center for 
Cancer and Allied Diseases, New York, by courtesy of Dr. 
Allyn B. Ley. 
To make for clarity in later discussion of investiga- 
tions, a brief outline of the serological procedures that 
have been employed follows. (Since each laboratory uses 
its own modification of the various techniques, only the 
originator of a test will be referred to where relevant.) 
(i) On receipt of a sample of clotted blood from the 
patient, the cells have been separated from the serum. 
(ii) The cells were typed for ABO and Rhesus D blood 
groups; genotyping followed where indicated. 
(iii) The patient's cells were then incubated at 37° C. 
with Coombs' antiserum (Coombs, Mourant and Race 1945) 
/ antihuman globulin serum prepared by immunising a rabbit -4 
usually at two specified dilutions of serum, one of which i 
likely to detect antibodies of theY globulin type (in the 
region of 1/40), and the other likely to detect antibodies 
of/ 
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of the non -Y globulin type (in the region of 1 /10). This i 
the "Direct Coombs' test" which should recognise that the 
P atient's red cells are coated with globulin. 
(iv) A series of tests were applied to the patient's 
erum. Dilutions of serum were mixed with red cells in 
aline suspension and albumen suspension (Diamond and Denton 
945); serum was added to cells previously treated with a 
roteolytic enzyme, e.g. papain (Morton and Pickles 1947, 
951); it was incubated with compatible cells in an attempt 
o sensitise them, after which these cells were incubated 
ith Coombs' antiglobulin serum (Indirect Coombs' test). 
11 these tests for free antibody in the patient's serum 
tilised a panel of red cells selected to include the common 
lood group systems (ABO, Rh, HIT'S, P, Lewis, IKell, Duffy and 
n occasions Lutheran and I {idd). The tests were done at t 
evels of temperature, 40 C. and at 370 C. 
If the screening tests in (iii) and (iv) were negative 
was considered to be virtually certain that no red cell 
ntibody was present. If positive, it was possible to 
tate whether there appeared to be one antibody or a multi- 
plicity of antibodies, whether complete or incomplete, 
whether warm or cold (indicating the in vitro temperature 
at which they held greatest activity) i.e. the thermal 
range, and whether the antibody had shown any specificity 
for the panel of blood cells used. 
(v)/ 
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(v) More specialised tests followed. The first was 
usually the " Y globulin neutralisation test" (Coombs and 
Mourant 1947, Dacie 1951), in which the Direct Coombs' test 
was repeated in the presence of dilutions of)( globulin. 
If complete neutralisation occurred the antibody was bel- 
ieved to be ay globulin and therefore also almost certainly 
of the warm type; if no neutralisation was seen the anti- 
body was referred to as a non -Y globulin (and was almost 
always of the cold type); partial neutralisation usually 
indicated that a mixture of antibodies was present. 
Then followed an attempt to elute the coating antibody 
from sensitised cells, usually by heating them for ten 
minutes at 560 C. (Kidd 1949, Weiner 1957). The eluate 
was treated in the same way as the patient's serum (see 
(iv) above) to decide if the coating antibody was of the 
same nature as any free serum antibody that may have been 
found. 
Specificity was decided by incubating the patient's 
antibody in serum or in red cell eluate with a narrowing 
panel of cells, using homozygous cells in respect of blood 
groups where necessary. Where several antibodies are 
present, the character of each can only be determined by 
laborious absorption tests in which each antibody is 
removed from the serum or red cell eluate in turn, and this 
was seldom considered to be necessary. 
(vi)/ 
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(vi) Finally it was of value, not in determining the 
severity of a haemolytic process, but in following the 
progress of an individual patient to perform a quantitative 
Coombs' test titration (Wiener and Gordon 1953). This was 
achieved by setting up the Direct Coombs' test using serial 
dilutions of antiglobulin serum, e.g. from 1 /10 to 1/1250. 
The result for each dilution was charted depending on the 
strength of agglutination: -ve, ±, +, + +, + + +, 
2. 6. Studies using radioactive chromium -51 
as a red cell label. 
Other techniques for red cell survival measurement 
The introduction of the differential agglutination 
technique of Ashby (1919) for the measurement of red cell 
survival has been discussed on page 13. The method was 
improved over the years, particularly when MN blood groups 
(Landsteiner, Levine and Janes 1928) and the Rh blood 
groups and antisera (Monism and Young 1942, Wiener 1942) 
were utilised; Hurley and Weisman (1954) added a further 
refinement by developing the use of potent haemolytic anti - 
sera to obviate errors due to the trapping of cells in 
agglutinates (e.g. transfused O cells might be trapped in 
agglutinates of the recipients' A or B cells). 
The Ashby technique has always had the limitations 
that study of an individual was governed by considerations 
of/ 
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of blood group, that it was necessary to begin the measure- 
ment with the transfusion of two to three pints of blood, 
but most important, by the nature of the technique it was 
never possible to study the survival of a patient's own 
cells in his own circulation. 
Because of the obvious advantage of using isotopes as 
red cell labels, a number have been tried. Nitrogen -15 
and carbon -14 have been administered in aminoacids, partic- 
ularly glycine, for incorporation in haemoglobin (Shemin an 
Rittenburg 1946, Bale, Yuile, Delavergne, Miller and Whippl 
1949, Berlin, Lawrence and Lee 1951), but both of these 
isotopes are difficult to use for routine purposes; the 
first is a stable isotope and the second emits only low 
energy ß radiation. Radioactive iron has been employed 
extensively but the conservation of iron derived from the 
catabolism of haemoglobin of senescent red cells for re- 
utilisation in haemoglobin synthesis makes difficult the 
interpretation of changes in the specific activity of red 
cells (i.e. the concentration of radioactivity per unit 
volume of red cells) as a measure of red cell survival. 
One or other of the two isotopes of iron, 55Fe and 59Fe, 
may be used either to label the cells of an individual who 
is later going to donate blood to the patient under study 
(Ross and Chapin 1943, Gibson, Aub, Evans, Peacock, Irvine 
and Sack 1947), or the patient's plasma may be tagged with 
radioactive iron which reappears in newly formed red cells 
increasingly/ 
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increasing over the next ten days. In normal subjects 
and some patients with haemolytic disease, where compensat- 
ory erythropoiesis is not active, the approximate survival 
time pf the labelled red cells is seen as a small dip in 
the graph of radioactivity in the patient's circulation 
against time (Huff and Judd 1956, Berlin, Beeckmans, 
Elmlinger and Lawrence 1957). Radioactive phosphorus in 
the form of sodium orthophosphate is taken up by red cor- 
puscles very readily and it is useful in measurements of 
red cell mass; it escapes, however, from the cells at the 
rate of 10-12% per hour thereafter and is valueless in 
studies of red cell life. Phosphorus -32 has, however, been 
used in diisopropyl fluorophosphonate (DF32P); this compoun 
inhibits cholinesterase activity in the red cell with the 
result that the phosphorus label is fixed; using this effec 
measurements of red cell survival have been achieved (Cohen 
and Warringa 1954). 
The introduction of chromium -51 as a red cell label 
When Gray and Sterling (1950) discovered that trace 
amounts of chromium were normally present in red blood cells 
and that sodium chromate containing radioactive chromium -51 
became fixed to the corpuscles of dogs, a new and valuable 
technique for measuring red cell life span became available. 
Chromium -51 has a radioactive half life of 27.8 days and a 
biological half life of 110 days. It decays by K electron 
capture, 8% of disintegrations being associated with the 
emission of X -rays of energy 0.32 MeV. In principle, for 
studies/ 
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for studies of cell survival the red cells (either the 
patient's own cells or donor cells) are labelled in vitro 
with radioactive sodium chromate (Na251CrO4), injected into 
the circulation of the recipient, and the rate of change of 
51Cr concentration per unit volume of red cells is deter- 
mined. Experiments have shown that red cells mixed with 
acid citrate dextrose mixture take up chromium -51 more 
readily than do cells from heparinised blood (Necheles, 
Weinstein and Le Roy 1953, Mollison and Veall 1955); the 
uptake of chromium on incubation of red cells with radio- 
active sodium chromate at room temperature is almost 
complete after thirty minutes and chromium remaining in the 
supernatant at this stage can be almost completely removed 
by washing the cells twice or three times and re- suspending 
them in saline. The washing of chromium- labelled cells 
up to twenty -five times does not affect their subsequent 
survival (Necheles, Weinstein and Le Roy 1953, Hughes -Jones 
and Mollison 1956, O'Brien 1958). Examination of the 
effect of concentrations of chromium certainly up to 10 µg. 
per ml. of red cells also does not affect the survival data; 
according to Hughes -Jones and Mollison (1956) concentrations 
of the order of 30-40 µg. per ml. of red cells induce 
methaemoglobin production. 
Hexavalent chromium -51 (as in sodium chromate) has the 
unique advantage over all other red cell labels which have 
been used to date in that there is no evidence of re- 
utilisation/ 
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utilisation of chromium released from labelled cells; 
there is no transfer of the isotopic label to red cells 
from circulating 51Cr- tagged haemoglobin, haemolysed red 
cells or from incompatible cells (Jandl, Greenberg, 
Yonemoto and Castle 1956), and it seems likely that this 
property results from the conversion of anionic hexavalent 
chromium to the cationic trivalent form once the chromium 
has entered the red cell; the latter is known to bind 
firmly with protein but will not penetrate the corpuscular 
membrane. 
The use of chromium -51 for measurements of red cell 
survival was largely developed by the studies of Ebaugh, 
Emerson and Ross (1953), Necheles, Weinstein and Le Roy 
(1953), Read, Wilson and Gardner (1954) and Mollison and 
Veall (1955). Two factors emerged from the early work that 
greatly influence the interpretation of red cell survival 
data obtained by this method and which have not yet been 
fully explained. Firstly, the graph of the 51Cr content 
of red blood cells injected into a normal subject as a 
function of time is curvilinear and not straight; in 
comparative studies using the 51Cr method and the Ashby 
method of differential agglutination, chromium disappears 
from the circulation more rapidly than the red cells, and 
this is presumed to be due to the elution of the metal from 
the cells. Secondly, it is clear that the rate of elution 
of radioactive chromium is not the same throughout the 
period/ 
45. 
period of a survival measurement; there are at least two 
components (Mollison and Veall 1955), a rapid component in 
the first few hours when 5 -10% of the chromium label is 
eliminated with a half period of approximately 1.5 days, 
and a slower component affecting the remainder which is 
calculated to be 54.2 days. 
The interpretation of red cell survival data obtained 
with chromium -51. 
Problems of elution of chromium -51, limitations as to 
the dose and specific activity of chromium that can be used 
and the half life of the isotope have led to a number of 
methods of analysis of the data. All the methods yield 
only comparative information; perhaps the most acceptable 
is to follow the disappearance of radioactivity from a 
patient's circulation to the point of extinction, but this 
might mean continuing the survival measurement for more than 
100 days and such duration of study is seldom practicable 
in clinical investigation. 
A common method in current use is to plot the specific 
activity of the red cells as a function of time and calcula 
the time required for the injected radioactivity to decrease 
in the circulation by 50%. This time has been referred to 
as the TlCr. 
Table 4- gives a summary of the results of red cell 
survival measurements using chromium -51 in normal subjects 
compiled by Berlin, Waldmann and Weissman (1959). 
It/ 
TABLE !f- 
ANALYSIS OF PUBLISHED RESULTS OF RED CELL SURVIVAL 
MEASUREMENTS IN NORMAL SUBJECTS USING CHROMIUM -51. 
(from Berlin, Waldmann and Weissman 1959) 
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It will be seen that there is considerable variation 
in the TiCr obtained by different investigators; this is 
discussed by Mollison (1961) who presents evidence that the 
scatter of data is due to different rates of elution of 
chromium consequent on differences in technical procedure. 
The question of the practical interpretation of the 
51Cr method has been discussed by Hughes -Jones and Mollison 
(1956). It has first to be decided if any correction for 
elution of chromium should be applied. There is no 
problem when the Tier falls within the range of values 
obtained by a particular investigator for his series of 
control subjects, since such results can be taken as being 
normal. Similarly, there is no problem when red cell 
destruction is considerably increased because the question 
of a rapid component of chromium elution and the exact 
method of correction for chromium elution becomes unimportan 
The difficulty arises in patients where red cell life span 
is reduced, but not grossly so, because whether the chromium 
51 results are corrected for chromium elution or not, their 
interpretation depends on the assumption that the rate of 
elution is the same in the disease that is being studied as 
in normal subjects. Cline and Berlin (1963) have recently 
presented evidence to suggest that the rate of elution may 
indeed by slightly more rapid in haematological disorders 
than in health. In thirty -eight patients with a wide 
range/ 
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range of conditions, they obtained an average elution rate 
of 51Cr of 1.29 per cent per day. 
It is for these reasons that several methods have been 
recommended for deducing true red cell survival from data 
obtained using chromium -51. For example, it is suggested 
by Hughes -Jones and Mollison (1956) thattrue survival can 
be derived from the expression:- 
Nt 51Cr observed 
Nt 51Cr normal 
(110 - t) 
x 
( 110 ) 
where Nt 51Cr = percentage injected 51Cr remaining in the 
circulation on day t. This assumes a mean cell life in 
the normal of 110 days, that the range of elution rates in 
normals is small and that the elution rate in disease states 
is the same as in the normal. Subsequently the corrected 
estimates are plotted and the mean cell life is calculated 
as described by Dornhorst (1951). There is evidence that 
this method over -corrects when applied to abnormal cells, 
(Mollison 1959), and a more widely used treatment of data 
(Ebaugh, Emerson and Ross 1953) in haemolytic disorders is 
to assume a steady rate of elution of chromium with a half 
period of approximately seventy days. 
The use of body surface measurements of radioactivity. 
Although the radiation from chromium -51 is of low 
energy and is highly absorbed by tissues, it has been 
possible, by making measurements over the surface of the 
body, to follow the distribution of chromium -51 labelled 
erythrocytes/ 
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rythrocytes during the course of red cell survival measure- 
ments. Hughes -Jones and Szur (1957) showed that in normal 
subjects the only significant collections of radioactivity 
ere found over the heart, over the liver and over the 
spleen, presumably in consequence of the blood flow through 
these areas. Korst, Clatanoff and Schilling (1955), 
ppreciating the possible role of this in the management of 
aemolytic disease, found that the relative accumulation of 
adioactivity in the liver and spleen was very variable, and 
was only in two patients out of three who showed a higher 
ptake of radioactivity in the spleen compared with the 
iver that splenectomy was beneficial. Jandl, Greenberg, 
onemoto and Castle (1956) in observations in various haemo- 
ytic disorders tried to quantitate their data by using the 
'spleen sequestration index" which was the percentage 
ncrement in the spleen/praecordium ratio of radioactivity 
etween the start of the survival study and the TzCr. 
These authors offered a tentative grading of intensity of 
splenic sequestration on the basis of this index and 
suggested that less than 30 was subnormal, 30-60 normal, 
0-100 mild to moderate and more than 100 moderate to severe. 
n the work of Hughes -Jones and Szur (1957), an attempt was 
ade to correct the surface measurements for radioactivity 
ue to perfusing blood and they also showed that when there 
as a high uptake of 51Cr in spleen tissue this was an 
ndication of the likely value of splenectomy. Goldberg 
(1960)/ 
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(1960), using the spleen/liver ratio of radioactivity at 
TZCr as originally suggested by Korst, Clatanoff and 
Schilling (1955), found that in acquired haemolytic anaemia 
when this ratio exceeded 2.4 remission followed removal of 
the spleen. . 
These measurements of surface radioactivity have great 
value in helping to understand the pathogenesis of different 
forms of haemolytic disease; they also have a possible 
place in evaluating the role of the spleen and in trying to 
establish which patients are likely to benefit from splen- 
ectomy. The number of methods advanced for analysing the 
data is an indication of the difficulties of interpretation 
that have been encountered. 
Methods used in the present study. 
Chromium -51 was obtained in 2 millicurie amounts from 
The Radiochemical Centre, Amersham. In the Memorial 
Hospital, New York, supplies were obtained from Abbot Labor- 
atories Ltd. The specific activity was always in the 
range 50-100 µc. /µg. On receipt, the consignment was 
diluted to 10 ml. with normal saline to facilitate dispens- 
ing as the radioactivity decayed. 
The method of labelling erythrocytes was modified from 
that described by Mollison and Veall (1955). Ten to 20 ml. 
of blood (either the patient's own blood or, where applic- 
able, donor blood that was less than forty -eight hours old) 
were added to a bottle of 25 ml. capacity and mixed with 
-5/ 
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3 -5 ml. acid citrate dextrose solution or with six drops of 
heparin (5,000 units /mi.). Fifty to 100 µc. of chromium - 
51 were then mixed with the blood, and the bottle was 
incubated at room temperature for at least forty -five 
minutes. After incubation, the cells were washed twice 
with normal saline and reconstituted to a volume of 15 ml. 
A precise amount, usually 12 ml., was injected intravenous) 
into the patient and 1 ml. retained as a standard, if blood 
volume measurements were desired; otherwise and in most 
cases, the whole of the red cell suspension was given. 
Samples of blood were then withdrawn from the patient 
after one hour, twice in the next four days, and thereafter 
every three to seven days. The study was always continued 
for twenty days unless the amount of radioactivity in the 
blood had fallen to levels of 30-40% of that injected 
earlier than this. 
Blood was collected in tubes containing approximately 
0.5 g. sodium oxalate and 0.5 g. saponin. The radio- 
activity in these serial samples was then measured with 
orthodox equipment which combined á well type scintillation 
counter and a scaler (Ecko, Panax or Nuclear- Chicago), 
appropriate correction being made for background radiation. 
To avoid the need for correction for radioactive decay the 




One hour after the radioactive labelled blood had been 
injected and thereafter, at intervals similar to that used 
for venous sampling, measurements of radioactivity over the 
surface of the body were made in selected patients using a 
directional .scintillation counter (Ecko, Panax or Nuclear - 
Chicago) and a scaler. After preliminary studies the 
patient was always examined in the supine posture and the 
following positions at contact with the skin were used for 
the directional counter; for the heart, the fourth inter- 
costal space, one inch from the left sternal edge, for the 
liver, the right midclavicular line, one inch above the 
costal margin, and for the spleen, the left mid axillary 
line at the tenth rib, the counter being in a horizontal 
plane. For analysis of some of these body surface data, 
the radioactivity in a 51Cr standard, prepared as described 
by Hughes -Jones and Mollison (1956), was measured at con- 
tact with the counter. 
Measurements of red cell survival in normal subjects 
with illustrations from different disease states. 
The data for survival of the individual's own red cells 
obtained in nine normal subjects are illustrated in Fig.1f -, 
The radioactivity in 102 samples of blood are plotted and 
the study in each individual has been followed for thirty 
or more days. As has been reported for all other normal 
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Fig. 4 
Red cell survival measurements in 9 normal subjects 
using chromium -51 as a red cell label. The data are 
uncorrected for chromium elution. The bold interrupted 
line represents the regression of the log. percentage 
chromium -51 remaining in the circulation on time and will 
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Fig. 5 
Red cell survival data obtained by the chromium -51 
method in one normal subject plotted on an arithmetical 
scale (left) and logarithmic scale (right). 
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function of time, is curvilinear. The results for each 
individual, when plotted on a semilogarithmic graph, approx- 
imated to a straight line and this is illustrated for one 
control subject in Fig. S. 
For these nine control subjects the linear correlation 
coefficient between the logarithm of the percentage of 
injected chromium -51 remaining in the circulation and time 
is - 0.9887 (p < 0.001); the regression coefficient of the 
log. percentage 51Cr remaining in the circulation on days 
is - 0.0107. The calculated average normal curve illus- 
trated by the bold interrupted line in Fig.4, is that of 
the equation : - 
Log. y = 1.9851 - 0.0107x 
This line will appear on subsequent illustrations for 
reference. 
The TiCr in these nine control subjects ranged from 
24.5 to 31 days (mean 28 days). 
The results given by Mollison and Veall (1955), whose 
method was being followed, were examined in the same way. 
It was found, using the data for the average percentage of 
51Cr remaining in the circulation in ten of their normal 
subjects for the first twenty days, that the regression 
coefficient was - 0.01159. The average percentage of 
injected 51Cr at twenty -five days was 50.3. 
It was realised at an early stage that results for 
blood/ 
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blood radioactivity in patients with haemolytic disease whe 
plotted on a semilogarithmic graph, seldom produced a strai ht 
line and hence comparison of data with that obtained in 
normal subjects could not be on the basis of regression 
coefficients. The results obtained using chromium -51 in 
various chronic diseases are illustrated in Fig.(o. 
Reduction of red cell survival appears to vary from slight 
to moderate. The results obtained in various known 
haemolytic disorders are illustrated in Fig. 7. In view 
of the generally marked deviation of these curves from the 
normal, it was felt reasonable not to undertake elaborate 
analyses of the curves or to undertake correction for 
chromium elution but to use the T2Cr as the basis for 
comparison. 
Comparison of Ashby technique and chromium -51 technique 
in disease states. 
Although, as has already been stated, the precise rate 
of elution of chromium is not important in the interpretation 
of measurements using chromium -51 labelled red cells when 
haemolysis is marked, it was felt that in order to have 
confidence in the use of the T2Cr the assumption that the 
rate of elution was approximately the same in disease state . 
as in health should be tested. Accordingly, simultaneous 
measurements were made of red cell survival using the Ashby 
technique and chromium -51 in three patients with symptomati 










0 Cirrhosis of liver 
x -x Carcinomatosis - 0Addisonian pernicious anaemia 
Rheumatoid arthritis +- +Primary polycythaemia f aUraemia 
I 1 1 I 1 
10 15 20 25 30 
DAYS 
51Cr labelled patient's red cells i.v. 
Fig. 6 
Red cell survival measurements in various chronic 







80 0-3 Congenital spherocytosis \ x-x Ovalocytosis 
70 " D-o Paroxysmal nocturnal haemoglobinuria 








I_ i i i 1 I 
5 10 15 20 25 30 
DAYS 
51Cr labelled patient's red cells 01. 
Fig. 7 
Red cell survival measurements in various haemolytic 
disorders. 
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corrected, assuming that the elution of 51Cr from the cells 
had a half period of seventy days. The results are 
illustrated in Fig. 8. 
The close "fit" of the corrected chromium data with 
that obtained by the Ashby method was taken to support the 
validity of the use of the TiCr for comparison of results 
that are discussed in this thesis. 
Reproducibility of chromium -51 method. 
Little information is available regarding the reproduc- 
ibility of the chromium -51 survival measurements. Results 
in four subjects are illustrated in Fig.9. The first 
graph shows the curve obtained in one normal individual (A), 
in whom the survival of his own red cells was compared with 
that of forty -eight hour old compatible donor red cells. 
Subject B, a patient with a mild haemolytic process due to 
rheumatoid arthritis, showed more rapid elimination of cells 
from a healthy donor than of his own red cells; this is a 
well known phenomenon (Mollison 1959) in acquired haemolytic 
disorders and is believed to be due to the wide distribution 
of red cells in terms of age and susceptibility to destruc- 
tion in the donor compared with the patient; the latter's 
red cells probably comprise more young erythrocytes and 
cells that have resisted destruction. Subject C and Subjec 
D both had symptomatic non - immune haemolytic anaemia; the 
red cell survival measurement was made on two occasions 
during/ 
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Fig. 8 
Comparison of simultaneous red cell survival measurements 
by the Ashby technique and by the chromium -51 method in 
three patients with symptomatic non - immune haemolytic 
anaemia. The 51Cr data have been corrected for chromium 
elution assuming an elution rate of half period 70 days. 
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Two measurements of red cell survival in four subjects. 
The reproducibility in terms of TLCr in Subjects A, C and D 
is good. Subject B, a patient with rheumatoid arthritis, 
illustrates the more rapid destruction of erythrocytes from 
a healthy donor compared with his own as is usually seen in 
acquired haemolytic disease. 
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during a period when the haemoglobin level and haematocrit 
were stable. The high reproducibility of results in these 
circumstances, as in the normal individual, is well seen. 
Interpretation of body surface measurements. 
At an early stage in the collection of data on body 
surface radioactivity, an attempt was made to dissociate 
the radioactivity due to tissue uptake from that due to 
perfusing blood using the following formula:- 
B 
Organ radioactivity on day t = St - So x 
t 
Bo 
where S = radioactivity over surface of organ, B = blood 
radioactivity, t = day t, and O is the measurement made one 
hour after injection of 51Cr. 
The effect of this procedure on the graphical presenta- 
tion of data is illustrated in a typical case of symptomatic 
non - immune haemolytic anaemia in Fig. lo. This handling 
of the data did not contribute anything to the understanding 
of results and was not pursued. All the body surface 
measurements will be described using the spleen /praecordium 
and the liver /praecordium ratios, as originally suggested by 
Jandl, Greenberg, Yonemoto and Castle (1956), and the 
analysis of these data will be by the "spleen sequestration 
index" at TiCr and the spleen /liver ratio at TiCr (Fig.(o ). 
2. 7. Ancillary investigations. 
tilisation/ 
BLOOD, SPLEEN AND LIVER RADIOACTIVITY AFTER iv. INJECTION OF 
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Data obtained using chromium -51 in one patient regarding 
red cell survival and body surface measurements of radio- 
activity. The derivation of the spleen sequestration index 
and the spleen /liver ratio at TiCr is illustrated. The 
absolute tissue radioactivity for liver and spleen have 
been estimated in this patient (see text) by subtracting 
that calculated to be due to perfusing blood; it is seen 
that these data do not add to the information that can be 
derived from the spleen /praecordium and liver /praecordium 
ratio. 
56. 
Utilisation of haemopoietic factors. 
Since the introduction of radioactive iron into routine 
haematological practice, a number of investigators have 
shown that, with the greatly increased marrow activity which 
accompanies haemolytic disease, there is a very rapid turn- 
over of iron (Wetherley -Mein, Hutt, Langmead and Hill 1956, 
Giblett, Coleman, Pirzio -Biroli, Donohue, Motulsky and 
Finch 1956, Bothwell, Hurtado, Donohue and Finch 1957). 
Because of the body's ability to conserve and re- utilise 
iron, iron deficiency does not arise and haemoglobin syn- 
thesis is unimpaired. As in all anaemias not due to iron 
deficiency, there is evidence of accumulation of iron in the 
tissues; there is also in haemolytic disease, as in 
aplastic anaemia, elevation of the level of iron in the 
plasma. One measure of the change in ferrokinetics is to 
observe the rate of clearance of intravenously injected 
iron -59 labelled patient's plasma. This has been under- 
taken in six patients with haemolytic disease using the 
method of Veall and Vetter (1958) and the results are 
illustrated in Fig. R. Whereas in normal subjects 5O% of 
the injected radioactive iron is removed from the circula- 
tion in 70-120 minutes (Ledlie and Baxter 1954), in 
haemolytic disease the rate of elimination is greatly 
accelerated; in the six test subjects the half period of 
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The clearance of intravenously injected 59Fe labelled 
plasma in G patients with haemolytic disease. 
57. 
More interest attaches to the metabolism of folic acid 
and vitamin B12- Clinical experience of these B vitamins 
does not suggest that they are readily conserved by the 
body or that they are re- utilised like iron, and although 
the body stores of vitamin B12 may last for many months, it 
has been suggested that our supplies of folic acid may be 
depleted very rapidly (Vinke and Van der Sar 1956). 
Reference has already been made to the occasional complica- 
tion of haemolytic disease by megaloblastic erythropoiesis. 
The first account of this is believed to be that of Crosby 
and Sacks (1949) who described megaloblastic anaemia in a 
young man with thalassaemia. Additional examples of the 
association have been seen in acquired haemolytic anaemia 
(Baikie and Pirrie 1956), hereditary spherocytosis (Davidson 
1952, Drury and Geoghegan 1957, Delamore, Richmond and 
Davies 1961), thalassaemia (Goldberg and Schwartz 1954, 
Jandl and Greenberg 1958), sickle cell anaemia (Jonsson 
1958) and paroxysmal nocturnal haemoglobinuria (Heffernan 
and Jaswon 1955). 
In a detailed study of three patients with megalo- 
blastic erythropoiesis and a haemolytic disorder, Chanarin, 
Dacie and Mollin (1959) were able to show that the serum 
vitamin B12 level was normal but in each case there was an 
abnormally rapid clearance of intravenously injected folic 
acid and the administration of folic acid caused conversion 
of the marrow picture to normoblastic erythropoiesis and 
orreetion/ 
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correction of the reticulocytopenia which had developed. 
In the present investigations the following measure- 
ments have been made:- 
Serum Vitamin B12 (L. Leichmannii method with added 
cyanide as described by Girdwood 1960). 
17 patients; 
Serum folic acid, by courtesy of Professor R. H. Girdwood 
and Dr. P. W. Kershaw (L. casei method 
as described by Waters and Mollin 1961) 
12 patients; 
Plasma clearance of injected folic acid, by courtesy of 
Professor R. H. Girdwood (Method of 
Chanarin, Mollin and Anderson 1958). 
9 patients. 
The results of these tests are illustrated in I*igs.I24-r3 
It will be seen that the rate of clearance of injected 
folic acid from the plasma is increased in all but one 
patient. However, in only three patients (all of whom 
showed megaloblastic erythropoiesis) is the serum folic 
acid level outwith the normal range, and likewise in only 
three patients (one of whom showed megaloblastic erythro- 
poiesis) is the serum vitamin B12 level subnormal. The 
implications of these changes in vitamin B12 and folic acid 
metabolism will be discussed in relation to the patients 
marked with an asterisk on pages (ot and IS1. 
Plasma cholesterol 
The chance finding of low levels of cholesterol in the 
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59. 
study of the incidence of this abnormality and of the 
-ffect of arresting the haemolytic process by splenectomy. 
The results are discussed on page 203 The estimations 
were undertaken in the Biochemistry Department, Royal 
Infirmary of Edinburgh, by courtesy of Dr. C. P. Stewart and 
Dr. J. A. Owen, using the methods of Sackett (1925) and 
Searcy and Berquist (1960). 
60. 
CHAPTER THREE 
AUTOIMMUNE ACQUIRED HAEMOLYTIC ANAEMIA 
3. 1. Introduction 
There is an extensive literature referring to the 
incidence of overt haemolytic anaemia with reticulocytosis 
and acholuric jaundice, complicating various haemopoietic 
disorders, diseases of connective tissue and miscellaneous 
conditions such as infections and ovarian tumours. There 
is particular emphasis on this occurrence in malignant 
lymphocytic disease (Rosenthal, Pisciotta, Komninos, 
Goldenberg and Dameshek 1955) and Hodgkin's disease 
(Wasserman, Stats, Schwartz and Fudenberg 1955), and atten- 
tion has been drawn to the fact that it may be the first 
evidence of disseminated lupus erythematosus (Sarles and 
Levin 1959). In these diseases a clinically significant 
symptomatic haemolytic anaemia may be much more common than 
is generally realised; Wasserman and his colleagues (1955) 
estimate, for example, that it dominates the clinical 
picture in 15 per cent of patients with chronic lymphatic 
leukaemia. Many haematologists are also aware of the 
frequency of haemolytic disease in myeloid metaplasia and 
the problems of management which this creates (Cartwright, 
Finch, Loeb, Moore, Singer and Dameshek 1955). It seems on 
the other hand that while severe haemolysis may present in 
various other reticuloses and leukaemias, in other connect- 
ive tissue/ 
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tissue diseases, in virus pneumonia and infectious mono- 
nucleosis and in dermoid cysts and ovarian tumours, this is 
much less common than in the conditions referred to. The 
aetiological relationship of the underlying disorder can not 
always be proved but is strongly suggested by remission of 
all signs of excessive blood destruction following success- 
ful treatment of the primary disease, e.g. after the giving 
of nitrogen mustard in Hodgkin's disease (Sievers and 
Harwerth 1953) or after the surgical removal of an ovarian 
tumour (Allibone and Collins 1951). 
Many of the studies of symptomatic haemolytic anaemia 
were undertaken before serological studies were widely 
applied. The more recent reports indicate that the direct 
antiglobulin test is frequently positive Caller and 
Schubothe 1958) and the basis for the haemolytic process is 
an "autoimmune" reaction, but experience of large numbers of 
patients (Dacie 1959, 1962) indicates that a positive Direct 
Coombs' test is only common in diseases of lymphoid tissue, 
virus infections and lupus erythematosus,being rare in the 
other conditions of the symptomatic group. In the present 
state of knowledge, this type of haemolysis in which red 
cell antibodies cannot be demonstrated has to be regarded 
as "non- immune" and it is the basis for the considerations 
in the next chapter. 
Despite these several diseases which are associated 
with the development of auto -erythrocyte antibodies, there 
is/ 
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is still a majority of patients with autoimmune haemolytic 
anaemia in whom there is no demonstrable underlying disease; 
it is to them that the unsatisfactory term "idiopathic" is 
applied. Idiopathic autoimmune haemolytic anaemia may be 
a cumbersome term but it is probably retained for the want 
of something more descriptive and also because it emphasises 
the fact that the reason why some individuals spontaneously 
generate antibodies against constituents of their own red 
corpuscles is still unknown. 
Information is accumulating on the relative incidence 
of symptomatic autoimmune haemolytic anaemia as compared 
with the idiopathic variety. Lal and Speiser (1957) found 
48 of their 97 cases of the warm antibody type to be sympto- 
matic; van Loghem, van der Hart and Dorfmeier (1958), 67 
of 122 cases; Revol, Lejeune, Brizard, Jouvenceaux and 
Perrin (1958) 7 of 27 cases; and Dausset and Colombani 
(1959), 35 of 128 cases. In Dacie's (1962) series of 175 
ases, 108 were found to be of the idiopathic variety and 
symptomatic; the remaining 8 patients, who had paroxys- 
cold haemoglobinuria (sometimes referred to as the "cold 
aemagglutinin syndrome"), were separated because of 
their different clinical behaviour. The relative incidence 
f the warm and cold antibody type of autoimmune haemolytic 
naemia has also been studied in large series; Dausset and 
olombani (1959) found the ratio of warm to cold type in the 
diopathic group was 8 :1 and in the symptomatic group 2:1; 
acie's/ 
63. 
Dacie's (1962) results (excluding the patients with paroxys- 
mal cold haemoglobinuria) show a ratio of warm to cold type 
in the idiopathic group of 4.7:1 and in thè symptomatic 
group of 2 :1. The need to distinguish between these two 
types of antibody is based on clinical experience; while a 
cold antibody may cause a haemolytic process identical with 
that of the warm type, it is most frequently seen in high 
titre in the serum in elderly subjects when increased blood 
destruction is only a minor part of the clinical picture 
( Dacie 1962). 
Autoimmune haemolytic anaemia has been most frequently 
described in Caucasian subjects and is not generally regard- 
ed as having any familial basis. However, Dacie (1962) 
refers to an account by Kissmeyer -Nielson, Bent- Hansen and 
Kieler (1952) of the development of an autoimmune type-of 
haemolytic anaemia in mother and daughter. The idiopathic 
disease seems to affect all ages and in an analysis of 125 
of his own cases of autoimmune haemolytic anaemia of warm 
antibody type by Dacie (1962), the youngest patient was 
five months and oldest 78 years at the time of first 
diagnosis. Most authors have found an excess of female 
patients in their series. For example, Lal and Speiser 
(1957) found that 55% of 49 patients with idiopathic disease 
and 62.5% of 48 patients with symptomatic disease were 
females. In Dacie's (1962) series, the females accounted 
for/ 
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for 58% of 108 cases of idiopathic disease and 66% of 59 
patients in the symptomatic group. 
2. Composition of the group of patients with 
autoimmune haemolytic anaemia and mode of 
presentation. 
Twenty -three patients with autoimmune haemolytic 
anaemia have been studied; the main details at the time of 
diagnosis are summarised in Table S. Of this group, the 
disease was of the idiopathic variety in 16 and symptomatic 
in 7. The primary condition in the latter patients was 
lympho- proliferative disease in 4, disseminated lupus 
erythematosus in 2, and an unusual reticulosis, which has 
.een described in the literature (Farquhar and Claireaux 
1952 and Farquhar, MacGregor and Richmond 1958) and termed 
"familial haemophagocytic reticulosis", in one. 
In both the idiopathic group and the symptomatic group, 
there was a wide age distribution, being 9 months to 76 
years in the former and 4 months to 64 years in the latter. 
elve of the 16 patients (75 %) with idiopathic disease 
ere females, whereas only 2 of the 7 (29 %) with symptomatic 
sisease were female patients. 
The duration of symptoms prior to diagnosis was 
- xtremely variable. Six patients (one in the symptomatic 
Troup) presented with a haemolytic crisis; in two children 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































had been present for one month and two months respectively; 
two elderly patients (Cases 1 and 13) who suffered from the 
'cold haemagglutinin syndrome" had complained of Raynaud's 
phenomena for many years; in the remainder the symptoms of 
anaemia had been developing insidiously for periods up to 
three years. Only in one patient (Case 23) in the sympto- 
matic group did the diagnosis of the primary disease ante- 
date the recognition of the haemolytic process. In Case 
8 it was the accidental finding of splenomegaly that led to 
diagnosis. 
Clinical anaemia was found in all but three patients 
at the time of first examination; one of these three was in 
partial remission when the diagnosis was made. Clinical 
icterus was encountered slightly less frequently, being 
definitely present in 15 patients, doubtful in 3 patients 
and absent in the remaining 5. 
The physical findings relating to the spleen during the 
initial illness are detailed and illustrated in Table S. 
The only patient showing gross splenomegaly was Case 17, a 
man with lymphosarcoma in whom the great enlargement of the 
spleen would almost certainly be due to infiltration with 
the primary disease. In the idiopathic group, moderately 
enlarged spleens were found in only three patients, being 
approximately 10-15 cm. below the left costal margin. In 
7 of the 16 patients in this group there was, however, no 
palpable enlargement of the spleen at the time of diagnosis; 
one/ 
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one of these was a patient (Case 1) with the cold haemagg- 
lutinin syndrome, and splenomegaly is known to occur in only 
a minority of these subjects (Dacie 1962); four patients 
without splenomegaly had a history of less than three months 
but in the other two the haemolytic process appeared to have 
been present for three years (Case 11) and fourteen months 
(Case 15) respectively. 
With the exception of Case 21, there was no evidence of 
any familial predisposition-to haemolytic disease. Other 
haematological disorders featured in the family history of 
only three patients; the mother of Case 4 suffered from 
hereditary haemorrhagic telangiectasia, the mother of Case 9 
had proven Addisonian pernicious anaemia and the father and 
sister of Case 10 also have definite pernicious anaemia. 
3. 3. The main haematological and biochemical findings 
at the time of diagnosis. 
The data discussed in this section are summarised in 
Table (o. 
Peripheral blood examination. 
As would be expected, the haemoglobin level at the time 
of diagnosis varied within a wide range from 21% to 85% in 
the idiopathic group and 30% to 84% in the patients with 
symptomatic haemolytic disease. As is the general exper- 
ience, the two patients with the "cold haemagglutinin 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































disease and presented with haemoglobin levels of 80% and 
85% respectively. Excluding these two patients, Case 18 
who was in partial remission when first seen and Case 22 
in whom the diagnosis depended on red cell survival measure - 
gent (Table (o ), significant anaemia was always present, the 
lowest haemoglobin levels being found in the six patients 
hose illness began with a haemolytic crisis (Case 3, 34 %; 
ase 7, 21 %; Case 9, 30%; Case 12, 42 %; Case 16, 34 %; 
ase 19, 49%). With the exception of Case 22 (who had a 
ypoplastic bone marrow) and Case 13 (cold haemagglutinin 
yndrome), a reticulocyte count in excess of 2% was present 
n all the patients with autoimmune haemolytic anaemia; the 
figures ranged from 2.6% to 36.5 %, and this reticulocytosis 
Formed a most useful diagnostic indicator in the early 
tages of illness. A reticulocytosis of 68% was recorded 
n Case 5 during the first few days of investigation. No 
orrelation existed in the group of patients between the 
.uration of the history (Table S ) or the severity of the 
aemolytic process as measured by the TiCr and the reticulo- 
ytosis; the most acute illness was seen in Cases 3 and 16, 
d their reticulocyte counts were initially only 2.6% and 
% respectively, but this may merely reflect the delay of 
he marrow in beginning compensatory activity in a previous - 
y healthy subject. 
I t/ 
68. 
It is evident (from Table ` ) that spherocytosis and 
the appearance of primitive red and white cells in the 
circulation is extremely common. Spontaneous haemagglutina 
tion was also noted relatively frequently, occurring in the 
blood collecting tube in the two patients with the cold 
haemagglutinin syndrome, and being found in blood films or 
during attempts to perform a red cell count in Cases 3, 7, 
12 and 14. One peripheral blood finding is, however, at 
variance with other experience. Dacie (1962) states, from 
his extensive studies of autoimmune haemolytic disease, that 
"in acute haemolytic episodes, however caused, leucocytosis 
is characteristic, unless there is concomitant marrow 
failure ". However, in only 4 of the 16 patients with idio- 
pathic disease was the leucocyte count raised in the examina- 
tions of peripheral blood that led to diagnosis. One of 
these patients was Case 13 (cold haemagglutinin syndrome), 
and in another (Case 3) the leucocyte counts was probably 
influenced by previous splenectomy. The two other patients 
with high white cell counts (Cases 7 and 16) were among the 
group who had had a haemolytic crisis; Cases 9, 12 and 19 
had also had a haemolytic crisis but their initial leucocyte 
counts were 6,600, 8,800 and 5,000 respectively. 
The erythrocyte sedimentation rate (E.S.R.) is worthy 
of comment. This is frequently high in patients with auto - 
immune haemolytic anaemia and the tendency to spontaneous 
haemagglutination/ 
69. 
haemagglutination seems to be one possible explanation for 
this occurrence. It will be seen from Table b that in 
only three patients with idiopathic disease was the value 
less than 45 mm. in the first hour. In seven patients it 
was 100 mm. or more and the mean figure for the idiopathic 
group was 82 mm. This is in contrast to the finding in 
congenital spherocytosis (p. 175 ), in which condition the 
value tends to be low. Since acholuric jaundice, spleno- 
megaly, reticulocytosis and spherocytosis are common to both 
the congenital disease and autoimmune haemolytic anaemia, 
this disparity in the F.S.R. level is also a useful indi- 
cator in the early steps towards diagnosis. 
Thrombocytopenia was observed in three patients of the 
idiopathic group and three patients in the symptomatic group 
The severe thrombocytopenia in Case 3 presented a unique 
problem and will be the subject of special discussion on 
p.03. 
The bone marrow 
Smears of bone marrow aspirate (bone marrow trephine 
was necessary in Case 17) were examined in all patients. 
In the symptomatic group this was of diagnostic value in 
three of the patients, showing lymphocytic infiltration in 
Cases 17 and 19 and lymphocytic infiltration and hypoplasia 
in Case 22. 
Megaloblastic erythropoiesis was demonstrated in Case 8 
Case/ 
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Case 14 (a patient who had previously had a gastroenter- 
ostomy) and Case 19. Case 7 (who is the subject of special 
discussion on p.Lo8 ) developed megaloblastic erythropoiesis 
at a later stage of illness at the time of a haemolytic 
crisis in the early stages of pregnancy. The details of 
vitamin B12 and folic acid metabolism, in the period of the 
marrow finding, that are available for these patients are 
given in Figs. I2- and 13. In Cases 8 and 14 the serum 
vitamin B12 level was subnormal, being 130 and 133 µµg. /ml. 
respectively; in Case 19 the serum vitamin B12 level was 
433 µµg. /ml. and conditioned deficiency of folic acid is 
presumed. In Case 7 folic acid deficiency is likely to 
have been the main factor since the serum folic acid level 
was depressed to 4.45 µµg. /ml. (normal ranged 4.5 to 15.0 
µµg. /ml.). 
The red cell survival measurements. 
Red cell survival measurements were undertaken in 18 of 
the 23 patients. The TiCr ranged from 1.5 to 17 days 
(mean 11.7 days). Individual results are listed in Tablet:). 
Further consideration is given to the data obtained with 
chromium -51 on p. (OL 
Bile pigment metabolism and liver function. 
The average serum bilirubin level at the time of 
diagnosis in the 22 patients with autoimmune haemolytic 
anaemia in whom the measurement was made was 2.16 mg. /100 ml 
The/ 
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The level ranged from 0.6 to 6.0 mg. /100 ml. but in only two 
patients (Cases 1 and 16) did it exceed 3.5 mg. This is in 
accord with.the general experience that serum icterus is not 
severe in haemolytic disease. Allusion has already been 
made to the implication of liver function and red cell mass 
in the levels of bilirubin in the serum and the amount of 
urobilinogen in the urine, but it remains difficult to 
explain why in Cases 14, 15, 17, 18 and 22 the serum bilirù- 
bin should be normal and why in Cases 4, 13, 15, 17 and 20 
there should be no increase of urobilinogen in the patient's 
urine. The only theories that can be advanced in explana- 
tion of these findings is that the excretory capacity of the 
liver for bile pigment is equal to the demand in these 
particular patients, or that in these patients haemoglobin 
is catabolised beyond the bilirubin and urobilinogen stage 
to compounds such as dipyrrholes that are not being measured 
y present techniques. The work of Bingold (1949) indicate 
the latter possibility. 
With the exception of Cases 4 and 9, in whom no data 
ere available, and Case 8, who had a slight unexplained 
- levation of the serum alkaline phosphatase, the convention- 
1 tests of liver function gave normal results in all 
atients with idiopathic disease. In the symptomatic group 
hanges in hepatic function are difficult to interpret since 
t is difficult to exclude effects attributable to the 
rimary/ 
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primary disease; however, only two of the patients in this 
group showed abnormalities and these are detailed in Table 6, 
Plasma proteins. 
No plasma protein pattern has been found to be typical 
of autoimmune haemolytic disease. Various minor abnormali- 
ties have been reported in small series of patients by 
Charbonnier and Dausset (1953), Fine, Vincon, Eyquem and 
Groulade (1954), Hennemann and Gillert (1954) and Sussman 
and Sang (1957). The largest series has been described by 
Christenson and Dacie (1957); of 38 patients suffering 
from idiopathic disease most showed normal plasma proteins 
but a tendency was found for the albumen and a2 and ß 
globulin fractions to be low; of 9 patients with sympto- 
matic haemolytic anaemia one showed macroglobulinaemia and 
two with lupus erythematosus had hypergammaglobulinaemia. 
The result of serum protein electrophoresis is 
available in 15 of the 23 patients with auto - immune haemo- 
lytic anaemia; 10 of these were in the idiopathic group 
and in none of these patients was any abnormality found. 
Changes that could be ascribed to the primary disease were 
found in the symptomatic group; both patients with dissemi- 
nated lupus erythematosus (Cases 18 and 23) showed hyper - 
gammaglobulinaemia, Case 17 (with lymphosarcoma) had 
secondary macroglobulinaemia and Case 19 (with lymphosarcoma 




Several reports have appeared of the incidence of the 
different A130 blood groups in relation to autoimmune haemo- 
lytic anaemia. IIunt and Lucia (1953) found that 78% of 27 
patients with acquired haemolytic disease were group O 
compared with 45% of their controls; Clemens and Walsh 
(1954 -55) also obtained a significantly higher incidence of 
group O, 62% of their 66 patients with positive direct 
Coombs' tests being so classified. Information from larger 
series has however tended to refute these early observations 
In Lal and Speiser's (1957) series group O accounted for 
only 39% of 97 patients and Dunsford and Owen (1960) 
reported group 0 in 47.2% of their 127 patients. Dacie 
(1962) gives the following incidence of blood groups for 
120 patients: group 0, 40%; group A, 44 %; group B, 13.5%; 
and group AB, 2.5 %. The results for the present series al9 
suggest that the incidence of any particular ABO blood group 
is not significantly increased in patients with autoimmune 
haemolytic anaemia: group 0, 12 patients, 52 %; group A, 
9 patients, 39 %; group B, 1 patient, 4.5 %; group AB, 1 
patient, 4.5 %. 
Nature of the red cell antibody 
Reference has already been made to the two patients 
with the cold haemagglutinin syndrome. In one patient with 
symptomatic/ 
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symptomatic disease a positive direct antiglobulin test was 
not obtained in the period of investigation prior to death; 
it has, however, been felt justified to include him in this 
chapter on autoimmune haemolytic anaemia since he clearly 
suffered from a familial reticulosis (Case 4 of Farquhar, 
MacGregor and Richmond 1958), which had been responsible for 
the production of auto -antibodies in siblings. This 
family is discussed on p.lot. In the remaining 20 
patients the red cell antibody was of warm type in 12 and of 
cold type in 8; in the latter number 2 patients appeared 
to have multiple auto -antibodies of which a cold type 
incomplete agglutinin appeared to predominate. 
3. 4. The methods of treatment of autoimmune 
haemolytic anaemia. 
Blood transfusion. 
It is now believed that the therapeutic effect of 
transfusion, reported by Lederer (1925, 1930), is not a 
frequent occurrence. Although he considered that 11 of 
his 12 patient had responded, it seems likely from present 
experience that transfusion merely corrected the acute 
anaemia of the initial illness and that spontaneous remiss- 
ion was the major factor. One early problem in the 
management of autoimmune haemolytic anaemia does, however, 
relate to blood transfusion. By the nature of the haemo- 
lytic process, transfused blood cells are likely to suffer 
the same fate as the patient's own, and evidence points to a 
more/ 
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more rapid rate of destruction of the donor cells than of 
those already circulating (Mollison 1959); this increases 
the amount.of haemoglobin breakdown products that have to be 
metabolised and excreted. An exception exists where the 
auto -antibody is specific for a particular blood group 
substance, e.g. anti -c, anti -e; the transfusion of blood 
which does not contain the antigen in question would then 
be expected to have a normal survival in patients with this 
finding. (In the examples cited, blood of Rh genotype 
CDE /CDE if available should be suitable) Transfusion 
studies in one patient with a specific auto- antibody (Ley, 
,Mayer and Harris 1958) confirm that normal survival of 
blood of restricted genotype can be obtained. However, 
the propensity which patients with autoimmune haemolytic 
,anaemia show for developing iso- antibodies against incom- 
patible Rh blood group antigens, make it likely that this 
kind of carefully selected transfusion (which inevitably 
means introducing foreign Rh groups) could not be given 
more than once or twice to any given patient, and has 
therefore very little practical value. 
In most patients the presence of non -specific auto - 
antibodies makes the cross matching of blood exceedingly 
difficult and it may be impossible to find blood that is 
wholly compatible. This difficulty combined with the very 
transient benefit and the increased load of haemoglobin 
breakdown products from increased corpuscular destruction 
that/ 
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that is likely to follow the giving of blood sometimes 
causes doubt about the wisdom of transfusion. Fortunately 
in practice, if blood, homologous in respect of the ABO and 
Rh blood groups, is given, and the best possible cross 
match with the patient used, this seldom causes severe 
transfusion reactions in these patients and is frequently 
life saving. 
Steroid therapy 
Since the introduction of adrenocortico -steroids, there 
has been no question that they form the main line of treat- 
ment in patients with autoimmune haemolytic anaemia. The 
first enthusiastic reports came from Dameshek (1950) and 
Gardner (1950); the first results in Britain (M.R.C. 
Haematology Panel 1952, 1953) were less convincing, almost 
certainly because smaller doses were employed. The report 
of Dameshek (1952), in which 14 of his 22 patients so far 
treated had shown complete haematological remissions, 
indicated that this was a major therapeutic development; 
Dameshek described that suppression of haemolysis could 
almost always be achieved but this might require cortisone 
or adrenocorticotrophic hormone (ACTH) in doses of 300 mg. 
per day. Further experience has shown that in the idio- 
pathic disorder, complete and frequently rapid relief from 
anaemia can be expected in 70 to 90 per cent of patients 
with the warm type of antibody ( Dameshek and Ifomninos 1956, 
Dausset and Colombani 1959). In the symptomatic disease 
results/ 
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results are less good and when cold antibodies are present 
(Dausset and Colombani 1959) remission is much less frequent. 
The mode of action of adrenocorticosteroids is not 
definitely established. The evidence for interference with 
the reaction between erythrocyte antigen and antibody is 
inconclusive. A number of clinical studies have, however, 
indicated diminution in the strength of the Coombs' test 
(Evans 1955, Dameshek and Komninos 1956, and Pisciotta and 
Hinz 1957), and disappearance of antibody from the serum in 
patients obtaining remission from steroid therapy, indicating 
that inhibition of antibody production might be one impor- 
tant effect. In spite of good clinical and haematological 
response, however, the direct antiglobulin test seldom 
becomes negative. 
There are conflicting views about the relative merits 
of different steroid preparations. De Gruchy (1954) and 
Dausset and Colombani (1959) found ACTII to be effective in 
occasional patients in whom an oral preparation had failed, 
but this has not been the experience of Wintrobe (1961). 
Dameshek and IComninos (1956) were impressed with prednisone 
in comparative studies with cortisone and hydrocortisone, 
and Dausset and Colombani (1959) regarded prednisone as the 
best drug for use in the average patient. Particularly in 
view of its low salt retaining effect, prednisone now seems 
to be the drug that is most widely used; according to 
Dacie (1962) prednisolone has no additional advantage and 
there/ 
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there is as yet insufficient evidence to suggest that the 
newer analogues of cortisone (methylprednisolone, triam- 
cinolone, dexamethasone) are in any way superior to 
prednisone. Dacie (1962) quotes from a recent review by 
Horster (1961) of 167 patients with idiopathic autoimmune 
haemolytic anaemia; 6.8% were "cured ", 31.7% were still in 
remission twelve months after stopping treatment, 51% were 
in remission only during treatment and 17% were not benefit- 
ed. 
The data from Horster highlight the recurring thera- 
peutic dilemma. In little more than one third of his large 
series of patients was lasting remission from steroid 
therapy achieved. In a large proportion of the remainder 
the question of splenectomy would arise, either because no 
remission had been achieved or because it was not possible 
to subdue the haemolytic process without maintaining the 
steroid therapy in doses that would inevitably cause side 
effects. It seems from experience that maintenance doses 
of prednisone exceeding 10 mg. per day in the adult cannot 
be contemplated without misgiving. 
Splenectomy 
Splenectomy was probably the earliest form of treatment 
for autoimmune haemolytic anaemia, the first report of a 
successful result being ascribed to Micheli (1911). 
Isolated accounts followed but it was Dameshek (1943) who 
first gave some index of the remission rate when he des- 
cribed/ 
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described good results in 10 of his 18 patients. Prior to 
the introduction of steroids this was the only treatment 
and it was .considered that splenectomy was beneficial in 
approximately 50% of cases (Welch and Dameshek 1950). 
According to Young, Miller and Swisher (1957), two thirds of 
their 18 patients did well; Crosby and Rappaport (1957) 
had good responses in 10 of their 27 patients; Dausset and 
Colombani (1959) undertook splenectomy in 31 patients of 
whom 8 recovered and these authors indicate that a good 
result from splenectomy is less likely when cold antibodies 
are present than with the warm variety; Richmond_(1961) 
found a good result from operation in 6 out of 22 patients 
treated by splenectomy in Edinburgh, and Dacie (1962) 
obtained clinical cure in 7 of his 26 patients so treated, 
adding that a "fair" result was obtained in 4 others. 
When steroid therapy has failed completely or has 
failed to sustain remission in acceptable doses, then 
splenectomy is usually undertaken. It seems from the 
foregoing that substantial benefit or clinical cure occurs 
in a variable proportion of patients but can probably be 
expected in only about one third. It is a general exper- 
ience that an additional number will get some reduction in 
the haemolytic process, and their haemoglobin value may 
stabilise at a subnormal level where red cell destruction 
and marrow activity can continue in equilibrium; alter- 
natively this may be achieved by a smaller dose of steroids 
than/ 
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than was required before operation. Chertkow and Dacie 
(1956) drew attention to the lack of any clinical criteria 
from which .the outcome of splenectomy could be predicted, 
but reference has already been made (p.4-7 ) to the assess- 
ment of the role of the spleen in the haemolytic process by 
measuring the relative splenic uptake of chromium -51 labelled 
red cells. However, even when the latter procedure suggest 
that splenectomy may not be helpful, the problem of dealing 
with the patient, with relentless haemolytic disease un- 
controlled by steroid therapy, still remains and usually 
surgery is always recommended in the last resort. 
The possible role of the spleen in autoimmune haemolytiç 
anaemia has been the subject of much investigation. That 
the spleen is an important source of antibody is suggested 
by the observation of Wright, Dodd, Bouroncle, Doan and 
Zollinger (1951) who found that in patients with autoimmune 
haemolytic anaemia there was a higher titre of antibody in 
the spleen substance than in the peripheral blood. Wagley, 
Shen, Gardner and Castle (1948) and Jandl, Richardson, 
Jones and Castle (1957) to some extent supported this by 
observing that red cells leaving the spleen in the splenic 
vein tended to be more heavily sensitised than cells in 
peripheral venous blood. Studies in patients with auto - 
immune haemolytic anaemia using 51Cr labelled red cells and 
experiments in normal subjects (Jandl, Richardson, Jones 
and Castle 1957, and Mollison and Hughes -Jones 1958) have 
clearly/ 
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clearly shown that the spleen removes cells from the circula- 
tion that are coated with incomplete antibody, and in 
normal recipients of sensitised cells this action is extreme4 
ly rapid; on the other hand coarsely agglutinated cells 
are taken out of the circulation mainly in other areas, 
particularly the liver. 
From the earliest definite recognition of autoimmune 
haemolytic anaemia (Dameshek and Schwartz 1938, 1940), the 
existence of a fulminating type of disease has been known. 
t the present time there is still a small proportion of 
patients who, despite adequate steroid therapy and splene- 
ctomy, persist with a violent haemolytic process, who 
require frequent transfusion for survival and who proceed 
to a fatal termination which is often accelerated by the 
side effects of treatment. An entirely new approach has 
recently been proposed for the management of this group. 
ntineoplastic agents 
In 1951 Dameshek reported the use of intravenous nitro- 
gen mustard therapy in four patients with autoimmune haemo- 
lytic anaemia with a view to suppressing/antibody production; 
the desired result was achieved in the first patient treated, 
the antibody titre fell and a remission persisting for four 
years followed. A similar therapeutic attack was tried 
ith encouraging results by Wang, Bowman and Tocantins (1954) 
nd Tocantins and Wang (1956), when they used intravenously 
dministered radioactive gold. Following evidence that 
-mercaptopurine/ 
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6- mercaptopurine and thioguanine were potent inhibitors of 
immunity responses in experimental animals (Schwartz, Stack 
and Dameshek 1958, Schwartz and Dameshek 1959), Dameshek 
and Schwartz (1960) described the use of these agents in 
the treatment of autoimmune haemolytic anaemia. The later 
report of these authors (Dameshek and Schwartz 1962) gives 
some ground for optimism in that 14 patients were treated 
with 6- mercaptopurine or thioguanine or both and 9 showed a 
response; in some of these, haematological remission was 
sustained for periods up to fourteen months, even after 
withdrawal of antimetabolite therapy. The remarkable effec 
of this type of treatment, using new antineoplastic prepara- 
tions, will be described in Case 3 of this series. This 
patient had a fulminating haemolytic process in the presence 
of severe thrombocytopenia. 
3. 5. Summary of the management of individual patients 
in the present series. 
The main lines of treatment that have been employed in 
the 23 patients with autoimmune haemolytic anaemia, studied 
in the present series, are summarised in Table 7. 
Additional details are given in the brief accounts of indi- 
vidual patients which follows: - 
Case 1. M.B. 73 years; An elderly lady with the "cold 
haemagglutinin syndrome ". Steroid therapy was tried inter- 
mittently in 1956 without significant benefit. She 







































































































































































































































































































































































































































































































































































































Case 2. H.D. 61 years: A male patient who presented in 
1955. After an initial response to transfusion and corti- 
sone therapy, remission could not be sustained and splene- 
ctomy was undertaken three months later. Operation 
controlled haemolysis for approximately twelve months after 
which time a chronic partially compensated haemolytic proces 
returned. Steroid therapy was not reintroduced and the 
patient died after a further three years following myo- 
cardial infarction. 
Case 3. M.F. 35 years: Fulminating haemolytic anaemia 
developed in this young female patient due to a cold type 
antibody while she was receiving steroid therapy for relapse 
of idiopathic thrombocytopenic purpura, previously success- 
fully treated by splenectomy in 1956. Control of the 
haemolytic process could not be achieved with large doses of 
prednisone or cortisone and copious blood transfusion was 
necessary for survival. Improvement was eventually 
achieved after irradiation and the use of antineoplastic 
drugs (p. U3 ). 
Case 4. J.F. 9 months: An infant girl in whom haemolysis 
could only be controlled by large doses of steroids; 
repeated attempts to reduce the prednisolone, to a level 
which would allow growth to proceed, were made over a period 
of five months. Splenectomy was then undertaken with only 
transitory improvement in the disease and the child died 
f our/ 
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four months later during an attempt at exchange blood 
transfusion. 
Case 5. C.H. 46 years: A severe haemolytic anaemia which 
was not controlled on steroid therapy and for which blood 
transfusion was required. After six weeks on prednisone 
(see p.:T$. for complications) splenectomy was undertaken. 
The haematological findings in the next three months suggest- 
ed that this had been unsuccessful, but coincident with 
gradual withdrawal of prednisone, the haemoglobin level 
improved and the reticulocyte count fell; the patient 
remains well twelve months later with compensated haemolytis, 
the haemoglobin level being in the range 80-90% and the 
reticulocyte count 2 -4%. 
Case 6. I.H. 72 years: An elderly female patient who 
required blood transfusion for survival and in whom predni- 
sone was ineffective. Splenectomy could not be considered 
because of ischaemic heart disease and congestive cardiac 
failure, and she died of the latter two months after 
diagnosis. 
Case 7. H.L. 24 years: A girl who presented after a 
haemolytic crisis due to a cold type antibody in 1955. 
Multiple blood transfusions were required initially and 
then cortisone produced a partial remission. After three 
months splenectomy was undertaken without further influence 
on the haematological findings. Since then (now seven 
years)the patient has remained in comparatively good health. 
A/ 
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A chronic haemolytic process persists and the two further 
haemolytic crises which she has had have been dramatically 
responsive.to the giving of prednisone (p.log). Two normal 
pregnancies have been supervised during the course of her 
illness. 
Case 8. M.L. 71 years: The chronic haemolytic process in 
this elderly woman was discovered coincidentally during 
examination for a respiratory infection. The initial 
response to prednisone was excellent but withdrawal to a 
maintenance dosage produced relapse. A further temporary 
remission followed splenectomy but the patient died five 
months after diagnosis of abdominal infection, believed to 
be caused by steroid treatment (p.''- ). 
Case 9. N.L. 31 years: An acute haemolytic process 
following throat and skin infection. Remission followed 
transfusion and steroid therapy. The patient remains well 
with normal haematological findings and negative direct 
Coombs' test nine months after the initial episode. 
Case 10. R.L. 48 years: A sustained remission followed 
the use of prednisone alone in this patient. She has 
persistently normal haematological and serological findings 
after seven years and is clinically well. 
Case 11. I.L. 76 years: An elderly lady whose illness 
has now been followed for six years. The haemolytic proces 
runs a chronic relapsing course; three exacerbations 
apparently associated with urinary tract infection have 
shown/ 
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shown a satisfactory response to prednisone. Steroid 
therapy is not given on a maintenance basis. 
Case 12. M.M. 48 years: A fulminating haemolytic proces 
due to a cold non)(-globulin type of antibody in a female 
patient. Frequent blood transfusions and large doses of 
prednisone (to 200 mg. per day) were used. The illness was 
complicated by acute renal failure, phlebothrombosis and 
pulmonary embolism, and the patient finally died of staphy- 
lococcal pyaemia after one month, before splenectomy could 
be undertaken. 
Case 13. H.O. 65 years: The cold haemagglutinin syndrome 
in an elderly male patient. Anaemia is not severe and he 
remains in moderately good health through avoidance of cold. 
Small doses of prednisone have been used intermittently 
since 1957 without definite benefit. 
Case 14. J. R. 50 years: This male patient had an acute 
haemolytic anaemia due to a warm type antibody. There has 
been a complete remission on steroid therapy which is 
persisting after one year; the dose of prednisone has been 
less than 10 mg. per day for eight months and is now 2.5 mg. 
daily. 
Case 15. C.S. 63 years: A chronic haemolytic process 
which had probably been present for fourteen months at the 
time of diagnosis. Transfusions had been found to have 
only transitory effects on the haemoglobin level. Predni- 
sone was given for six weeks after which time splenectomy 
was/ 
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was undertaken. The latter had no effect and the patient 
died in congestive cardiac failure after a further nine 
months, following a series of respiratory infections which 
had probably been aggravated by persistent prednisone 
treatment. 
Case 16. I.S. 27 years: This is the only patient in the 
series shown definitely to have a specific auto -antibody 
(anti -c). She presented after a severe haemolytic crisis. 
Transfusion and steroid therapy induced a complete remissio 
The direct Coombs' test was found to be negative three 
months after diagnosis, at the time steroid therapy was 
withdrawn, and the patient remains in perfect health in the 
five years since then. 
Case 17. A.B. 52 years: This male patient who has lympho 
sarcoma presented with gross splenomegaly. He has been 
treated with betamethasone and has been in sustained 
remission, with marked regression of spleen size, for twelv 
months. He is maintained on Betnelan, 2 mg. daily. 
Case 18. I.B. 32 years: This girl with disseminated lupu 
erythematosus was first seen in remission but she had had 
episodes of haemolysis in the previous twelve months which 
had responded to transfusion and the giving of prednisone. 
She was maintained on a prednisone dosage of 10 mg. daily 
for twelve months, 7.5 mg. daily for four months and in the 
eighteen months since then on 5 mg. daily. Complete haema 
tological remission continues. 
Case/ 
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Case 19. G.D. 62 years: A patient with lymphosarcoma 
showing a cold haemolysin of Donath -Landsteiner type. He 
has received prednisone therapy for six months and has had 
a course of splenic irradiation without significant benefit. 
Case 20. D.M. 64 years: This man had symptomatic 
haemolytic anaemia in association with giant follicle lymph- 
oma. No improvement followed steroid therapy and on the 
basis of studies with chromium -51, splenectomy was under- 
taken. Although operation produced no demonstrable 
improvement in red cell survival (p.98 ) the patient is 
still moderately well after two years; the haemoglobin 
level is in the region of 70% without recourse to prednisone. 
Case 21. I.M. 4 months: A male child with "familial 
haemophagocytic reticulosis" who showed no response to 
splenectomy, exchange transfusion or prednisone therapy and 
died five weeks after diagnosis (p.tO( ). 
Case 22. J.S. 49 years: A mild haemolytic process, no 
splenomegaly and a hypoplastic bone marrow infiltrated by 
lymphocytes were the main features of this patient. 
Frequent blood transfusions were required and prednisone 
therapy had no effect on the transfusion requirement. He 
died of the primary disease three months after diagnosis. 
Case 23. E.W. 30 years: This young woman with dissemina- 
ted lupus erythematosus gave a long history of arthralgia 
and two years' history of anaemia at the time of diagnosis 
in 1956. She required blood transfusion for the correction 
of/ 
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of acute anaemia at the onset. She has remained in complete 
or near complete remission for the last seven years on pred- 
nisone therapy, and currently receives 5 mg. per day. 
An analysis of the effects of the various forms of 
treatment, the selection of patients for splenectomy, the 
handling of fulminant haemolytic disease that defies ortho- 
dox measures, and the natural history of disease as seen in 
the foregoing 23 patients, is considered in the sections 
that follow. 
3. 6. The effect of blood transfusion. 
In no case can it be stated that blood transfusion alon 
induced remission in the haemolytic process. Despite the 
possibility of transfusion reactions in patients with auto - 
immune haemolytic anaemia to which reference has already 
been made, it is considered that this is much less important 
than leaving a patient in a hypoxic state from persisting 
severe anaemia, and it has been a policy in the present 
series to keep the haemoglobin level above 50% wherever 
possible. Accordingly, 16 patients of the 23 studied have 
required transfusion at one time or another during their 
management. In Cases 2, 5, 7, 9, 16, 18, 20 and 23, the 
giving of blood was only necessary to correct the initial se 
ere anaemia, and in Cases 2, 5, 7 and 20, during the period 
of splenectomy. In the others (Cases 3, 4, 6, 8, 12, 15, 
21 and 22), recurrent transfusion was necessary and in Cases 
3/ 
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, 4, 12 and 21 it was believed to be necessary for survi- 
val. Severe transfusion reactions were not seen in any of 
the patients, although minor febrile reactions were common; 
n urticarial response occurred during one transfusion in 
ase 3 but this responded promptly to an antihistamine 
reparation and several litres of blood were given to this 
atient subsequently without difficulty. 
Cases 3 and 12 required unusually large volumes of 
lood; the first received 38 litres during the first forty - 
lye days of treatment, and the second 9.5 litres in seven 
ays. Both of these patients showed haemoglobinaemia, 
ethaemalbuminaemia and haemoglobinuria and in both, bile 
ppeared in the urine, and the serum bilirubin rose to levels 
f 10-15 mg. /100 ml. It might be argued that the develop - 
ent of an obstructive type of jaundice was due to the large 
gment load which the liver was required to handle; 
owever, liver inefficiency might equally have been due to 
ypoxia from the recurring severe anaemia, and the evidences 
lof intravascular haemoglobin catabolism indicate the 
fulminating nature of the haemolytic process in these two 
atients. 
In all the patients suffering from autoimmune haemolytic 
naemia in this group, the effect of transfusion was short 
ived. One constant effect was suppression of reticulo- 
ytosis; this occurred promptly on raising the haemoglobin 
èvel and is well illustrated by Case 6 (Fig.IL ). Since 
his/ 
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this patient had also suffered some bleeding from a hiatus 
hernia, the disappearance of reticulocytosis early in the 
course of investigation led to some diagnostic confusion. 
Because of the general belief that transfusion may be 
hazardous in patients with autoimmúne haemolytic anaemia, 
there is a tendency to cautiously give small transfusions. 
The consequence of too timid management in a severe haemo- 
lytic process is illustrated by Case 12 in Fig.14- In this 
patient the haemoglobin level fell to 25% and was again at 
this level five days later despite the giving of 1 litre of 
blood on each day in the meantime, and despite the administr 
ation of large doses of prednisone. The giving of 4.5 
litres of blood in one transfusion (Fig.t- ) then had a 
very satisfactory effect; the haemoglobin level was raised 
to 65% and it stayed in this range for several days there- 
after. 
The impression has been gained in this (Case 12) and in 
other severely anaemic patients that the giving of large 
amounts of blood is the correct procedure in the initial 
illness. Not only does a large transfusion raise the 
haemoglobin to safe levels, but also it appears to tempor- 
arily reduce the rate of blood destruction and this might 
tide the patient over a critical period until other measures 
such as steroid therapy become effective. It is not known 
pow such reduction in the severity of haemolysis arises; 
it is possible that the transfusion of large numbers of 
ealthy/ 
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Two patients with autoimmune haemolytic anaemia 
who required blood transfusion. Both illustrate the 
suppressive effect of transfusion on reticulocytosis; 
Case 12 also illustrates that a large transfusion may 
temporarily suppress the severity of the haemolytic 
process. 
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healthy cells "mops up" free circulating antibody, or alter- 
natively that the antibody coating red cells may be redis- 
tributed from heavily sensitised cells to donor cells; in 
either event some improvement would be expected to follow 
and there is experimental evidence in favour of the latter 
possibility. Both Mollison (1959) and Evans, Bingham and 
Boehni (1961) have shown that incomplete Rhesus antibody can 
be transferred in vitro from sensitised cells to normal 
cells that are incubated with them. 
3. 7. The effect of steroid therapy. 
All 23 patients in the present series have received 
steroid therapy during the course of their illness. Cases 
1, 2, 3, and 7 have received cortisone; every patient 
given steroids since 1956 has received prednisone as the 
main preparation, except Case 3 in whom cortisone was also 
tried, Case 4 who was treated with prednisolone and Case 17 
who received betamethasone. 
The clinical effects of steroid therapy may be sum- 
marised as follows: 
(i) No significant benefit, 11 patients (Cases 1, 3, 
5, 6, 12, 13, 15, 19, 20, 21 and 22). Of these, 6 had a 
cold type antibody, 4 a warm type; in Case 21, as has been 
stated, a positive direct Coombs' test result is not 
available. 
(ii) Transitory benefit, 4 patients (Cases 2, 4, 7 
and/ 
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and 8). Of these, 3 had a warm type of antibody and 1 a 
cold type. 
(iii) .Significant benefit in that steroid therapy 
formed the main line of treatment, 8 patients (Cases 9, 10, 
11, 14, 16, 17, 18 and 23). Of these, 5 had a warm type 
of antibody and 3 a cold type. 
The experience of response in respect of the type of 
antibody is slightly different from that of others (p.70 ) 
in that only 8 of the 12 patients (67%), with a warm type 
of antibody, showed a sustained or a transitory response to 
steroid treatment. 
In those patients who showed remission from steroid 
therapy, three patterns of response were noted. These are 
illustrated in Fig. I. In the first pattern (Case 11), 
there was a gradual rise of haemoglobin level and fall in 
reticulocyte count, but the steroid therapy had to be 
continued in a small dose to sustain the remission. In the 
second pattern (Case 7) the same satisfactory effect was 
observed. After reaching normal peripheral blood values 
the steroid therapy could be completely withdrawn and 
remission was sustained either indefinitely (seven years in 
Case 10) or for many months. In the third pattern (Case 2) 
the initial response was equally good but the steroid 
therapy could not be withdrawn to a level which could be 
contemplated for long term management without inducing 
relapse. This problem is even better illustrated in Fig.(b 
which/ 
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Fig. 15 
The patterns of response to steroid therapy in autoimmune 
haemolytic anaemia. Case 11 required a small maintenance 
dose of steroid therapy to sustain remission; in Case 7 
remission continued after withdrawal of therapy, while in 
Case 2 anaemia is seen to return when the dose of steroids 
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An infant with autoimmune haemolytic anaemia who showed 
dramatic response to the giving of prednisolone; each 
attempt to withdraw steroid therapy to a maintenance level 
caused return of severe anaemia. 
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which shows the course of a child aged nine months (Case 4). 
In this patient the blood picture could be corrected rapidly 
with the giving of high doses of prednisolone, but on 
repeated attempts to reduce the dose of the steroid to a 
level which would allow growth to proceed, severe haemolysis 
returned. 
Figs. IS and R. illustrate the very rapid improvement 
that is often seen when steroids are exhibited. This was 
particularly evident in Case 7 (Fig. IS ) in whom the haemo- 
globin level rose from 34% to 71% in four days indicating 
the tremendous compensatory activity of the healthy bone 
marrow during haemolysis. Another point which is worthy of 
comment is the very prompt suppression of reticulocytosis 
(similar to that found after blood transfusion) when 
steroids are given; this is a useful indication of the 
effectiveness of treatment, since a falling reticulocyte 
count sometimes precedes significant change in the haemo- 
globin level. 
Complications. 
Except in Cases 1 and 13 (the two patients with the 
cold haemagglutinin syndrom), steroids have always been used 
in large doses in the first instance, either 300 mg. of 
cortisone or 60 mg. of prednisone (the exceptions are 40 mg. 
of prednisolone in Case 4 and 8 mg. of betamethasone in 
Case 17) being given. These amounts were not continued 
for longer than three weeks (except in Case 3), being 
gradually/ 
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gradually reduced after this time or earlier if remission 
had occurred. Perhaps because of the high doses that are 
employed some side effects from treatment are inevitable, 
but the frequency and severity of these are worthy of 
mention: 
(i) Fluid retention. Cases 2, 3 and 12 developed 
marked oedema while receiving steroid therapy. In Cases 
2 and 3 cortisone was being given at the time. In Case 12 
the complication arose during the administration of predni- 
sone; anasarca developed in this patient but acute renal 
failure was also implicated. 
(ii) Perforation of a viscus. Case 5 perforated an 
acute duodenal ulcer while being treated with prednisone; 
although this had undoubtedly occurred on 7.9.61, the 
clinical features were so atypical and the inflammatory 
response so mild that the diagnosis was not made until the 
abdomen was opened for splenectomy on 26.9.61. Case 12 
developed low grade peritonitis from rupture of a pyometra 
while on prednisone. This, which followed an unsuccessful 
splenectomy, and the subsequent laparotomy are believed to 
have been the immediate reasons for the patient's death. 
(iii) Burst abdomen following surgery. This compli- 
cated the course of two patients, Case 4 who was receiving 
prednisolone at the time and Case 15 who was on prednisone. 
:oth patients were convalescing from splenectomy. 
(iv)/ 
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(iv) Miscellaneous complications. Case 12 developed 
extensive phlebothrombosis which was succeeded by a pulmon- 
ary embolism; this particular patient went on to die from 
staphylococcal pyaemia, and it seems reasonable to believe 
that this might also have been aggravated by prednisone 
therapy. The terminal illness of another patient, Case 15, 
was also influenced by (recurrent respiratory) infection. 
Case 8 who had been showing mild features of senile dementia 
became frankly psychotic. 
In summary, 7 (30%) of this series of 23 patients with 
autoimmune haemolytic anaemia developed one or more major 
complications at some stage in their illness, apparently 
directly due to their management with a steroid preparation. 
Reference will be made in the next chapter on symptomatic 
non - immune haemolytic anaemia to a further patient who 
developed severe diabetes mellitus while taking prednisone 
(p.(4-*). This very high incidence of side effects in 
these patients with haemolytic disease and the illustration 
that long continued steroid therapy might even interfere 
with the patient's successful management by splenectomy 
(Cases 4 and 16), influence one to use the smallest possible 
dose for the shortest possible time. 
3. 8. The selection of patients for splenectomy and the 
results of operation. The "Spleen Number ". 
Nine patients from the whole group have had a splenec- 
tomy undertaken. In Case 3 the spleen had been removed 
before/ 
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before the haemolytic process started (p.(13 ), in Case 21 
operation was undertaken at an early stage because of 
previous experience with two siblings who had had the same 
disease; in the other seven patients splenectomy was 
recommended because of failure to control the haemolytic 
process with steroid treatment. It should be stated that 
Cases 6 and 12 would also have proceeded to surgery had 
their condition allowed. 
In three patient (Cases 3, 15 and 21) there was no 
evidence of any beneficial effect from operation; in 
another two (Cases 4 and 8) improvement was so short lived 
as to be of no value. Of the other four patients, none 
has shown clinical cure but Case 5 is significantly better, 
maintaining a high haemoglobin level after fifteen months; 
Cases 2, 7 and 20 became stabilised at a moderate level of 
anaemia and have remained in fair health for two to seven 
years; in Case 7 the haemolytic crises that did occur after 
operation were more responsive to steroid therapy than 
previously. 
Body surface measurements of radioactivity over liver, 
spleen and praecordium, during the course of estimation of 
red cell survival with chromium -51, were undertaken in 12 
of the patients with autoimmune haemolytic anaemia. The 
results in terms of spleen sequestration index and spleen/ 
liver ratio at TiCr (p 4g ) are set out in Table 3. 






























































































































































































































































































































































































































































































































































splenectomy are marked with an asterisk. Of these five 
patients, red cell survival measurement was repeated after 
splenectomy in two, Case 20 who had a partial remission and 
Case 5 who may be described as having a good result; the 
data obtained in the studies with chromium -51 in these two 
patients is illustrated in Fig. (7. While Case 5 shows 
significant reduction in the rate of destruction of red 
cells, Case 20 shows none and it must be assumed that in the 
latter patient his better ability to maintain the haemoglobi 
level in the region of 70% without transfusion and without 
steroid therapy after operation is due to more effective 
compensatory activity on the part of the marrow. 
Study of Fig. [7 and of the earlier Fig. (o (p.65 ) 
which was used to describe the determination of the spleen 
sequestration index and of the spleen/liver ratio at TCr, 
indicates that neither of these measurements adequately 
describe the sequestration of 51Cr labelled red cells by 
the spleen in relation to the other area which has been 
monitored, the liver. A patient might have a high spleen 
sequestration index (this value being derived solely from 
the increment of radioactivity in the spleen area) and at 
the same time show a high uptake of radioactive labelled 
erythrocytes in the liver, a factor which would give a low 
spleen/liver ratio. Alternatively, a patient might have a 
high spleen/liver ratio and a low spleen sequestration index 
(Case 8, Tables ). This latter could occur if the patient 
had/ 
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Fig. 17 
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DAYS 
Red cell survival measurement in two patients with 
autoimmune haemolytic anaemia before and after splenectomy. 
Both were expected to show reduction of the haemolytic 
process on the basis of splenic sequestration measurements 
(see text); however, while improvement in cell survival 
is seen in Case 46, none is seen in Case 64. 
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had a large vascular spleen, causing a high amount of radio- 
activity in the spleen area in the initial part of the 
study, but subsequently the spleen showed little increment 
of radioactivity from sequestration of labelled red cells. 
When the patients are classified according to response 
to splenectomy - no response e, "transitory response', 
"partial remissione and 'good result" - and the data 
available for the spleen sequestration index and the spleen/ 
liver ratio are studied, no definite pattern of response is 
seen (Table ̀ i ). The spleen/liver ratio in Case 5 (2.3) 
who had a good result is only marginally better than that 
in Case 8 (2.1) who had but transitory benefit from operatic 
the highest spleen/liver ratio is in Case 20 (6.0) but he 
had only a partial remission and no measurable improvement 
in red cell survival following removal of the spleen. 
Reference has already been made to the observation of 
Goldberg (1960) who found that when the spleen sequestration 
index exceeded 2.4, a good result from splenectomy could be 
anticipated. With regard to the spleen sequestration 
index, there is little difference between the value of 80 
in Case 15 who showed no response, 70 in Case 8 who had a 
transitory response and 90 in Case 20 who had a partial 
remission. On the other hand, the highest value, 150, is 
seen in Case 5 who had the best result. 
From the foregoing it seems necessary to consider 
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(the sequestration index, A in Table ) and the relative 
amounts of radioactivity in liver and spleen (the spleen/ 
liver ratio, B in Table 9 ) in deriving a figure which can 
more adequately evaluate the role of the spleen in the 
haemolytic process. By the simple expedient of multiplying 
A and B, this requirement seems to be satisfied and it is 
seen from Table R that in the only two patients for whom 
data are available, who have had any remission from splene- 
ctomy, this multiple exceeds 300, being 540 in Case 20 and 
342 in Case 5. 
The body surface measurements have been treated in the 
same way for the patients who did not have a splenectomy 







A x B 
Case 10 F.L. 245 2.8 734 
Case 11 I.L. 60 1.2 72 
Case 12 M.M. 15 1.87 28 
Case 13 H.O. 78 1.68 127 
Case 14 J.R. 300 1.51 753 
Case 17 A.B. 40 1.86 74 
Case 19 G.D. 125 3.5 438 
Cases 17 and 19 both had lymphosarcoma with lymphocytic 
infiltration of the bone marrow, and in view of the multiple 
factors concerned in the causation of their anaemia and of 
the/ 
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the varying effects of steroid therapy on the lympho- 
proliferative disease, they are best considered separately. 
For the idiopathic cases the two highest figures for the 
multiple A x B (Cases 10 and 14 in both of whom the figure 
exceeded 700) were found in patients who had excellent 
remissions on steroid therapy. Case 12 who had a very low 
value for A x B had a severe haemolytic disorder which was 
completely unresponsive to large doses of prednisone. 
Further consideration of this multiple of the spleen 
sequestration index and the spleen/liver ratio at T2Cr will 
follow in the chapter on symptomatic non - immune haemolytic 
anaemia. For brevity and to avoid confusion, the figure 
will be referred to in subsequent discussion as the "Spleen 
Number "; it can be derived from the following equations:- 
Spleen Number = (St - So) x 100 x 
St 
Lt 
100 St2 - 100 St So 
Lt 
where S denotes the radioactivity over the spleen, L the 
radioactivity over the liver, t is TiCr and o is the first 
day of study. 
3. 9. An unusual family. 
Mention has already been made of the familial nature of 
the illness affecting Case 21. Since the condition appea - 
to be quite unique and since the main feature was excessive 
red/ 
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red cell destruction due to an unusual degree of erythro- 
phagocytosis, it is proposed to describe it in more detail. 
The title "familial haemophagocytic reticulosis" has 
already been given by Farquhar and Claireaux (1952) to the 
disease they had encountered in two older siblings of Case 
21. These two infants had both developed anorexia, vomiti 
irritability and pallor, associated with hepatic and splenic 
enlargement, at the age of nine weeks. Peripheral blood 
examination revealed pancytopenia, progressive anaemia and 
large numbers of "smear" cells in blood films. The first 
infant, a male, died at the age of ten weeks. More 
investigation was possible in the second; as a result the 
condition was considered to be a symptomatic haemolytic 
anaemia due to some form of reticulosis and the direct 
Coombs' test was found to be positive. The second infant 
showed temporary response to the giving of ACTH but she died 
at the age of twenty -two weeks. 
Autopsy revealed, in both children, a remarkable 
histiocytic proliferation in reticulo -endothelial tissues 
which had not been apparent in antemortem marrow smears. 
These histiocytes showed most striking erythrophagocytosis 
and less marked ingestion of white cells. The histological 
picture was not that of Letterer -Siwe's disease, nor was it 




The third child of the family, a girl, was normal 
clinically at birth, but peripheral blood examination showed 
the presence of numerous smear cells; a high percentage of 
atypical large lymphocytes appeared in the blood between the 
ages of six and eight weeks, and at ten weeks she developed 
severe anorexia. The spleen and the liver were at no time 
palpable but mild anaemia and the atypical lymphocytes were 
present until the age of eighteen months. At this stage 
the direct Coombs' test was weakly positive but thereafter 
became negative again, and after the age of eighteen months 
the peripheral blood picture became normal. Since then, 
development has been normal and the child is now apparently 
healthy, aged ten years. 
The fourth child (Case 4 of Farquhar, MacGregor and 
Richmond 1958) is Case 21 of the present series. Iie was 
admitted to hospital aged eighteen weeks, having developed 
anorexia, irritability and pallor in the previous four weeks 
s in the first two children hepatosplenomegaly was evident. 
The haemoglobin level was 65 %, W.B.C. 2,500 of which 64% 
were large lymphocytes and 16% smear cells, and platelets 
32,000. The direct Coombs' test was negative but the serum 
contained a strong platelet agglutinin. Marrow examination 
revealed marked normoblastic hyperplasia and the smears 
also showed many abnormal cells; some of the latter 
contained abundant clear cytoplasm, others were more primi- 
tive with basophilic cytoplasm and frequent nucleoli. 
In/ 
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In view of the prominence of erythrophagocytosis in 
the spleen in the first two children, it was decided to 
proceed tosplenectomy and this was performed six days after 
admission. The spleen weighed 110 g. and the principal 
histological feature was marked proliferation of endothelial 
phagocytes in the pulp sinuses and in smaller numbers in the 
lymphoid tissue of the Malpighian bodies. The phagocytes 
were large and most of them contained numerous erythrocytes. 
There was no significant improvement after splenectomy 
and prednisone therapy was therefore started five days after 
operation; this was continued without apparent benefit 
until the baby died thirty -five days after admission to 
hospital. Nine days before this an exchange transfusion, 
using 1,200 ml. of fresh donor blood was also tried without 
influencing the course of the disease. Opportunity was, 
however, taken during this procedure to start a red cell 
survival measurement; the TiCr of the donor cells was five 
days. 
Autopsy, which had to be confined to the abdomen, 
revealed changes identical to those found in the first two 
children; the main feature was the presence in various 
organs of phagocytic histiocytes. The histiocytes were 
conspicuous in the bone marrow, lymph nodes, liver, and less 
so in the intestinal wall, adrenal cortex and pancreas. 
In the bone marrow and lymph nodes there had been phago- 
cytosis of nucleated cells, but it could not be determined 
105. 
if these were normoblasts or lymphocytes; however, through- 
out all tissues the outstanding finding, and clearly the 
most significant from the haematological point of view, 
was the intense erythrophagocytosis; the phagocytes were 
large with abundant clear, often vacuolated, cytoplasm and 
most contained one to ten red cells. 
Plates I to (o illustrate the unusual histological 
features of Case 21 and show the infiltration of liver, 
spleen and bone marrow by disease and the erythrophagocytosis. 
As far as is known, there are no other examples of 
this familial type of haemophagocytic reticulosis leading 
to symptomatic autoimmune haemolytic anaemia in the litera- 
ture. There are, however, many reports of leukaemia and 
other varieties of reticulosis occurring in several members 
of a family. Some evidence of abnormality in the father 
of the children was obtained in this family. When first 
examined at the time of the death of the second child, his 
Coombs' test was positive. When re- examined five years 
later after the death of the fourth child (Case 21) the 
direct Coombs' test was now negative, the peripheral blood 
was normal, the marrow was normal and there was no bilir- 
ubinaemia or urobilinogenuria; there was, however, 
shortening of the survival time of the father's red cells, 
T1Cr twenty days. Similar detailed examination of the 
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Plate 1 
Case 21 Bone marrow. Haematoxylin and eosin x 250. 




Case 21 Lymph node. Haematoxylin and eosin x 450. 
Histiocytic proliferation with erythrophagocytosis. 
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Plate 3 
Case 21 Liver. Haematoxylin and eosin x 450. 
Infiltration of portal tracts. Histiocytic 
proliferation and erythrophagocytosis. 
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Plate 4 
Case 21 Spleen. Haematoxylin and eosin x 1200. 
Intense erythrophagocytosis. 
Case 21 Lymph node. Haematoxylin and eosin x 1200. 
Erythrophagocytosis and possible leucophagocytosis. 
Plate 6 
Case 21 Bone marrow. Haematoxylin and eosin x 2000. 
Erythrophagocytosis and possible leucophagocytosis. 
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3. 10. Self limitingidiopathic autoimmune haemolytic 
anaemia. 
In three patients, Cases 9, 10 and 16, a severe 
haemolytic process has been followed by complete clinical 
and haematological recovery with conversion of a positive 
direct Coombs' test to a negative reaction. In all three 
patients remission followed the giving of prednisone; in 
Cases 9 and 16 the initial anaemia was so severe that trans- 
fusion was also required. The antibody was of cold type 
in Case 10 and of warm type in Cases 9 and 16. The 
haemolytic crisis followed a skin and throat infection in 
Case 9 but no unusual features distinguished the other two; 
however, the abrupt onset of illness in all three patients 
and their complete recovery raised the possibility of an 
infective aetiology. 
Although the implication of bacterial and more parti- 
cularly viral infections in the initiation of autoimmune 
haemolytic anaemias is not proven, the relationship of 
virus pneumonia and infectious mononucleosis to a self 
limiting type of disease is well known; Dacie (1962) also 
refers to reports of acute haemolytic anaemia following 
influenza, Coxsackie infection, measles, varicella, 
encephalitis and herpes simplex. 
The course of Case 10 is illustrated in Fig.L . 
It will be seen that the Coombs' test became negative two 
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Fig. 18 
The course of a patient with self limiting idiopathic 
autoimmune haemolytic anaemia. A strongly positive 
direct Coombs' test became negative and the patient has 




ow been completely well for seven years. The follow -up 
eriod in Case 9 is only nine months but Case 16 is also in 
erfect health after five years. 
3. 11. Chronic relapsing idiopathic autoimmune 
haemolytic anaemia. 
Three patients (Cases 2, 7 and 11) may be described as 
following a chronic relapsing course extending over many 
years. Case 2, whose condition was due to a warm type 
antibody, had an initial response to steroid therapy which 
was not sustained when the dose was reduced to maintenance 
levels. Subsequently splenectomy produced a good result 
for approximately twelve months, after which time a moderate 
ly compensated haemolytic process returned. In the next 
three years, prior to death from myocardial infarction, 
the haemoglobin level persisted in the range 50-70% and 
reticulocytosis in the range 5- 30%,except for exacerbations 
of anaemia, the haemoglobin level tending to fall to the 
40-50% range after respiratory infections. Case 11, whose 
disease was also due to a warm type antibody, was not 
entirely similar. She has been followed for six years and 
splenectomy has not so far been undertaken. For most of 
this time the haemoglobin has been at a normal level 
without the need for treatment, but there have been three 
well defined haemolytic crises, each of which has been 
associated with urinary tract infection and each of which 
has responded satisfactorily to the giving of prednisone. 
A/ 
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A patient who illustrates the complications of pregnancy 
and megaloblastic erythropoiesis. 
Case 7 who has followed a chronic relapsing course for 
more than seven years and has had a positive Coombs' test 
throughout this time has presented unusual problems and 
warrants more detailed discussion. The main events are 
illustrated in Fig.19. 
This patient presented at the age of twenty -four years 
in the autumn of 1955 following a severs haemolytic crisis. 
There was no indication of antecedent illness; the initial 
anaemia was profound, Hb. 21 %, reticulocytes 15% and there 
was mild acholuric jaundice. The spleen could not be 
palpated. The Coombs' test was strongly positive and 
further serological studies showed a high titre cold agglu- 
tinin to be present. Transfusion was given and cortisone 
therapy (in a dose of 300 mg. daily) was started. There 
was indication of suppression of the haemolytic process but 
the haemoglobin level was never higher than 72% and the 
lowest reticulocyte counts were in the 5 -10% range. 
Gradual reduction of cortisone produced return of severe 
anaemia and reticulocytosis, and two months after the 
initial diagnosis it was decided to proceed to splenectomy. 
The spleen was not large, weighing only 230 g.; many 
splenunculi present in the splenic pedicle were also removed 
In the light of present knowledge it might now be 
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The course of a patient with chronic relapsing autoimmune 
haemolytic anaemia. The points that are illustrated are 
the long periods of compensated haemolysis without recourse 
to steroid therapy, two haemolytic crises, one while 
receiving folic acid and vitamin B12 supplements, the other 
associated with folic acid deficiency, the prompt response 
to steroid therapy in these two crises and the effect of 
two pregnancies on the disease. 
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patient (p. 77 ); the spleen was small, the antibody was 
of cold type and there had been marked autoagglutination of 
the patient's red cells in vitro. In fact, transfusion 
was required in the immediate post -operative period and in 
the succeeding days the haemoglobin stabilised in the range 
60-70%, reticuloctyes 10-15%. The high doses of steroids 
(now prednisone) used at the time of operation were gradu- 
ally withdrawn to be stopped after four months, and it was 
clear (Fig. I ) that while both steroid therapy and splene- 
ctomy had had a disappointing effect, an equilibrium between 
the haemolytic process and the bone marrow's compensatory 
capacity with a moderate degree of anaemia had been achieved. 
This clinical picture (Hb. 50 -70%, reticulocytes 5 -45 %) 
persisted without change for the next four years until 1960. 
A 2 litre blood transfusion was given in February 1958 in 
association with dental extraction; this had the usual 
transitory effect (Fig.t ). 
In 1960 the patient started in her first pregnancy. 
Antenatal progress was entirely uneventful. During preg- 
nancy the same degree of compensated haemolysis persisted. 
The usual supplements of iron and vitamin supplements were 
given, and at the fifth month of gestation, folic acid 5 mg. 
orally, three times daily, and vitamin B12 injections 250 µg. 
once per month were added empirically. The patient was 
confined at full term and gave birth to a male infant who 
showed no clinical or haematological abnormality; in 
particular/ 
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particular there was no anaemia, reticulocytosis, abnormal 
bilirubinaemia or abnormality of the Coombs' antiglobulin 
reaction. 
The early puerperium was uneventful but then after two 
months, while still receiving vitamin B12 and folic acid, 
the patient had a severe haemolytic crisis, the haemoglobin 
level falling to 34 %. The only possible reason for this 
development was infection; members of the patient's family 
and of neighbouring families had recently suffered from 
virus hepatitis. There was, however, no evidence of 
hepatic parenchymal disease in the patient. 
Reference has already been made to the dramatic and 
prompt response to prednisone (Figs. 1S and N ); this 
remission was much more than anything that had been seen 
prior to, or at the time of, splenectomy. After the initial 
good effect prednisone was gradually withdrawn over two 
months and there was a gradual return of anaemia and retic- 
ulocytosis to the levels of the previous four years. Folic 
acid and vitamin B12 therapy were discontinued in June 1961., 
Later in the same year (November 1961) the patient started 
a second pregnancy and towards the end of the second month . 
after the last menstrual period, i.e. after only six weeks' 
gestation, a second haemolytic crisis supervened (the 
haemoglobin level falling to 38 %). Definite megaloblastic 
erythropoiesis was now observed in the bone marrow, presum- 
ably due to conditioned folic acid deficiency; the level 
of/ 
of folic acid in the patient's serum was 4.45 µµg. /ml. 
(normal range 4.5 - 15.0 µµg. /ml.). It is noteworthy in 
this regard-that when folic acid deficiency occurs in normal 
pregnancy, it is not usually significant till the third 
trimester, and this patient had received vitamin B12 and 
folic acid supplements as recently as seven months earlier. 
Moreover, the reticulocytopenia emphasised by Chanarin, 
Dacie and Mollin (1959) in their patients with megaloblastic 
erythropoiesis was not seen in this patient; the reticulo- 
cyte count was 32 -43% during this time. 
A prompt remission was again obtained on prednisone 
therapy, 60 mg. being used in the first instance. This 
treatment was gradually reduced and stopped over a two 
month period; pregnancy thereafter proceeded uneventfully 
and again the patient was delivered of a normal infant 
(August 1962) at full term. Since then the patient has 
remained in moderately good health with return to the now 
familiar picture of compensated haemolysis (Fig. l9 ). 
Comment on Case 7. 
A number of interesting points are implied by the 
management of the foregoing patient. 
(i) It has not been necessary to maintain continuous 
steroid therapy. The patient is not disabled by her 
average degree of anaemia and prednisone has had a quick 




(ii) The two crises observed must have been of 
different aetiology. It has been suggested that some of 
the crises seen in haemolytic disease might be due to marrow 
failure consequent on relative folic acid deficiency; this 
has for example been recognised as a rare complication of 
thalassaemia (Chanarin, Dacie and Mollin 1959). Folic acid 
deficiency cannot, however, have been the mechanism for the 
first episode since the patient was taking folic acid 
supplements at the time. However, folic acid deficiency 
was a very likely mechanism for the second since, not only 
was the patient established in pregnancy (although at a very 
early stage), but also she showed a subnormal serum folic 
acid level and megaloblastic erythropoiesis. 
(iii) The patient has successfully been through two 
normal pregnancies, giving birth without difficulty to two 
normal children. 
(iv) Although high doses of prednisone were required 
in the first trimester of the second pregnancy and were 
used with some apprehension, this treatment clearly had no 
effect on the foetus. This accords with the experience of 
Frumin, Smith, Taylor and Dratman (1953) who describe the 
only other reported cases of steroid therapy for autoimmune 
haemolytic anaemia during pregnancy; their patient received 
ACTH and cortisone from the second week of pregnancy until 




3. 12. Fulminating autoimmune haemolytic anaemia; its 
development in a patient who had previously had 
a splenectomy for idiopathic thrombocytopenic 
purpura, its suppression with thymic radiation 
and subsequent control with a combination of 
Actinomycin -C and BW 57 -322 ( "Imuran "). 
Fulminating haemolytic anaemia leading within weeks or 
months to a fatal termination is described in most'accounts 
of large series of patients with autoimmune haemolytic 
anaemia. It was certainly known to Dameshek and Schwartz 
(1940) who suggested a classification of haemolytic anaemia, 
which included division of the acquired group into chronic, 
sub -acute, acute and acute fulminating, on the basis of the 
course of the patient's illness. 
Cases 4, 12 and 15 of the present series showed this 
type of relentless disease for which no therapy appeared to 
have anything to offer. 
Case 3 presented the same such problem but was unusual 
in that the violent haemolytic process developed after 
relapse of idiopathic thrombocytopenic purpura previously 
successfully treated by splenectomy. Eventually her 
haemolytic disorder and thrombocytopenia were satisfactorily 
controlled by the combined use of new antineoplastic drugs 
(Actinomycin -C and Imuran), and for these reasons, the 
patient is described in detail. 
The patient, an unmarried woman of thirty -five years, 
was admitted to hospital on 18.10.62 for the second time. 
She had been known since December 1955 when she was first 
seen/ 
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seen with idiopathic thrombocytopenic purpura (the diagnosis 
being based on megakaryocytic hyperplasia in the bone 
marrow which was otherwise normal and on the absence of 
splenomegaly). The patient showed no response to predni- 
sone therapy and splenectomy was undertaken in January 1956. 
There was a satisfactory rise in the platelet count in the 
post operative period and this remission was sustained duri 
out -patient follow-up, the last regular visit being on 
15.10.58, at which time the Hb. level was 89 %, platelets 
380,000 per c.mm. 
When the patient reappeared on 18.10.62 she stated that 
for some months she had complained of aches and pains in the 
shoulder girdle; for ten days prior to her visit she had 
applied Ung. Methyl. Sal. N.F. on her family doctor's pres- 
cription. This, after a few days, produced petechiae in 
the skin over the shoulders, the first time that purpura 
had been seen since 1956. However, on closer enquiry it 
transpired that the menses had been abnormally heavy in the 
previous four months. The initial blood counts were as 
follows:- Hb. 86 %; W.H.C. 10,300 with normal differential 
count; platelet count less than 10,000 per c.nmi.; E.S.R. 
2 nun. in the first hour. Later the blood was examined for 
E cells on three occasions with negative results, the 
Marrow was found to be cellular but showed a moderate 
increase of megakaryocytes, and serological study on 
..11.62./ 
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+.11.62. confirmed that a platelet agglutinin was present. 
series of agglutination reactions for Brucella and sal - 
onella, the Paul -Bunnell reaction and routine blood culture 
ere negative. 
Treatment with prednisone 60 mg. per day (and with 
ral supplements of potassium chloride) was started on entry 
o hospital. The steroid therapy was without effect and 
'fter two weeks on this dosage gradual reduction of predni- 
-one was arranged. Repeated full blood examination showed 
o important change except moderate leucocytosis; an 
- xample is the result dated 5.11.62: Hb. 89 %, W.B.C. 16,5 
(of which 86% were neutrophil polymorphs, 9% lymphocytes, 
% monocytes); platelets < 10,000 c.mm.; E.S.R. 2 mm. 
n the first hour. 
Because of the possibility that the patient's condition 
as being perpetuated by infection, it was decided to give 
short course of antibiotic therapy; significant infection 
as excluded in the lungs, the genital and the urinary tract, 
ut the culture of the throat swab grew mixed organisms, 
ensitive to penicillin and to erythromycin. Since the 
.atient had had a previous skin reaction to the former, a 
ourse of erythromycin was started on 9.11.62. This anti - 
+iotic treatment is believed to be irrelevant to the main 
-vents because on 8.11.62 it is certain that there was slight 




Over the next two to three days she became progressively 
nore ill, with increasing pallor, acholuric jaundice and 
throbbingin the ears. 
On 12.11.62, the peripheral blood findings were as 
'follows: FIb. 34 %; P.C.V. 14%; W.B.C. 44,000 (neutrophil 
olymorphs 78%, lymphocytes 19 %, monocytes 2%, myelocytes 
%, 2 normoblasts per 100 W.B.C.); reticulocytes 2.6 %; 
platelets < 10,000; E.S.R. 142 mm. in the first hour. 
the direct Coombs' test which had been negative on 5.11.62 
Was now strongly positive; the reaction was not neutralised 
by Y globulin and since the antibody in the patient's serum 
Showed some specificity against red cells containing E- 
ntigen and the eluate from sensitised cells did not, it was 
oncluded that more than one antibody was present. The main 
eature was that a severe haemolytic crisis had developed, 
ue to auto -antibodies in a patient who was receiving high 
doses of steroid (30 mg. of prednisone per day at the time) 
d who had already had a splenectomy. 
Erythromycin was discontinued, the prednisone was 
hanged to cortisone in a dose of 300 mg. per day and the 
.atient was transfused frequently, as necessary. This 
egime was continued until 30.11.62, when cortisone was 
educed to 200 mg. per day; in the intervening eighteen 
says an extremely severe haemolytic process continued and 
he administration of 16 litres of blood was required to 
seep the haemoglobin level above 50%. The blood picture 
n/ 
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on 30.11.62, which was typical of others, was: Hb. 67%; 
P.C.V. 31 %; W.F.C. 12,500 (neutrophils 33 %, lymphocytes 9 %, 
monocytes. 1%, basophils 2 %, 3 normoblasts per 100 W.r.C.); 
reticulocytes 1.7 %; platelets < 10,000 per c.mm.; F.S.R. 
54 mm. in the first hour. The large amounts of blood 
administered and the uncontrolled haemolytic process had 
induced methaemoglobinaemia, rise of the serum bilibubin 
level to 9.0 mg. per 100 ml. and the appearance of bile 
pigment in the urine. There was no evidence that the large 
doses of steroids which had now been in use for six weeks 
were having any effect. 
Although her primary illness was idiopathic thrombo- 
cytopenic purpura and thrombocytopenia was still persisting, 
the patient's survival was more concerned with arrest of 
the haemolytic process, and consideration was given to the 
use of antineoplastic agents in view of the encouraging 
results obtained in autoimmune haemolytic anaemia with 
6- mercaptopurine and thioguanine by Dameshek and Schwartz 
(1962). The regime which was now employed developed from 
discussion with, and on the advice of Professor M. F. A. 
Woodruff; the patient was treated first by irradiation to 
the area of the thymus gland and later by the administration 
of Actinomycin -C and Imuran, but before describing the 
further course of the patient a short explanatory digression 
on the reasons for these measures is necessary. 
With/ 
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With regard to the thymus, it is only in the last two 
years that an important function has been ascribed to it. 
Burnet (1962) and Miller, Marshall and White (1962) have 
formulated the hypothesis on the basis of recent experiment 
that the cells necessary for various functions concerned 
with the maintenance of bodily integrity and recognised by 
their capacity to mediate homograft rejection are descend- 
ents of cells, which are differentiated for this function 
in the thymus. These cells normally begin to pass from the 
thymus into the circulation at the time of birth and are 
seeded to the spleen and probably lymph nodes where they 
multiply and develop full immunological tolerance. In 
addition to this suggested role, the thymus has also been 
found to show the characteristic changes of iumunological 
ctivity in examples of autoimmune disease. The most 
relevant evidence for this is in the mouse strain NZB /BL 
hich spontaneously develops autoimmune haemolytic anaemia 
ith positive direct Coombs' test; in a large proportion of 
these mice the thymus shows enlargement of the medulla with 
_erminal centres, incomplete lymph follicles and accumulation 
f plasma cells and mast cells (Burnet and Holmes 1962). 
the basis of these early findings, Burnet and Holmes 
elieve that the thymus is the region in which the process 
f autoimmune disease is initiated. 
Because of thrombocytopenia in Case 3, thymectomy 
ould not be contemplated but it seemed reasonable from the 
oregoing/ 
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foregoing to try the effect of thymic irradiation. 
Imuran (BW 57 -322) is one of a group of purines 
related to 6- mercaptopurine (6MP) in which an imidazole 
ring replaces the hydrogen of the sulphydryl group of 6MP. 
Metabolic studies in mice, dogs and humans (Elion, Callahan, 
Hitchings and Rundles 1960) have shown that Imuran is 
extensively split, but not instantaneously or completely, 
in vivo into 6MP and this may permit a steady slow action 
which is not possible with the parent compound. In 
preliminary clinical and haematological studies (Rundles, 
Laszlo, Itoga, Hobson and Garrison 1961), Imuran was admin- 
istered to twenty -eight patients with various types of 
and autoimmune disease. While there was little 
to suggest that the agent was qualitatively different from 
other related compounds in its antitumour activity, 
platelet suppression rarely occurred, any anaemia was mild 
in degree and cytopenias produced were rapidly reversed by 
reduction of dose or suspension of therapy. 
Actinomycin -C is a mixture of three related antibiotics! 
isolated from Streptomyces chrysomallus. Experimental 
evidence indicates (Reich, Franklin, Shatkin and Tatum 1961) 
that Actinomycin interferes with a portion of RNA synthesis 
and not DNA synthesis, it has a cytostatic effect on 
lymphoid tissue and may therefore be an inhibitor of anti- 
body production. When used in combination with Imuran, 
the incidence of side effects is no greater than when 
Actinomycin -c/ 
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Actinomycin -C is given alone. Because of the different 
modes of action of these drugs, they might be expected to 
produce an additive beneficial effect without additive 
toxicity. In the only published report which refers to 
the simultaneous administration of Imuran and Actinomycin -C, 
Murray, Merrill, Dammin, Dealy, Alexandre and Harrison (1962 
(and this deals with renal homotransplantation in eighteen 
patients and 300 dogs) indicate that the combined use of 
these drugs (and of Imuran and Azaserine) to induce chemical 
suppression of immune response produced their most encourag- 
ing results. Professor Woodruff (personal communication) 
agrees with this view. 
These recent data were the basis for treating Case 3 
with Actinomycin -C and Imuran. 
The course of the patient's illness during irradiation 
of the thymus, during the administration of Actinomycin -C 
and Imuran and during her remission is illustrated in Figs. 
2o Ft and in Table ICI. 
At the beginning of treatment (4.12.62) the survival 
time of fresh donor red cells gave a TÌCr of 1.5 days. 
Irradiation of the thymus was undertaken by Dr. J. 
Newall through an anterior mediastinal port, beginning on 
4.12.62. A total of 500 rads. was given in divided doses. 
There were certain immediate effects: - 
(i) The temperature became normal from the day 
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Fig. 20 
A patient with fulminating autoimmune haemolytic anaemia 
which supervened after relapse of thrombocytopenia 
previously cured by splenectomy. The control of the 
haemolytic process by the combined use of Actinomycin -C 
and Imuran is illustrated. 
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The effect of thymic irradiation and combined Actinomycin -C 
and Imuran therapy on thrombocytopenia, E.S.R., bile 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































first time since the onset of the haemolytic process. 
(ii) The transfusion requirement fell from an average 
of 0.8 litres per day in the twenty days preceding irradia- 
tion to an average of 0.5 litres per day in the ten days 
beginning with the first day of radiotherapy. 
(iii) The quantitative Coombs' test titre fell from 
1/1280 on 4.12.62 to 1/160 on 6.12.62 to 1/40 on 11.12.62. 
(iv) The L.S.R. which had been 130, 54, 96 and 82 mm. 
in the first hour in the ten days preceding irradiation was 
85, 94, 4, 25, 95, 3 and 1 mm. in the first hour in succeed- 
ing readingsfrom 4.12.62 to 14.12.62. 
(v) The platelet count reached a level of 90,000 per 
c.nun. on 11.12.62, the highest value recorded since the 
patient's admission to hospital on 18.10.62. 
These indices of improvement were not sustained and 
from 14.12.62 there was a rapid return to the previous 
transfusion requirement, and the titre of the Coombs' test 
gradually increased, the reaction being positive at 1/60 on 
17.12.62 and at 1/320 on 22.12.62. A second measurement 
of survival time of fresh donor cells, starting on 17.12.62 
(too late for the maximum remission) gave a Cr of 1.5 days 
Encouraged by the first response it was decided to use 
further thymic irradiation; 500 rads. were again given 
through the same anterior chest port in divided doses betwe- 
20.12.62 and 24.12.62. On this occasion there was no 
response that could be measured; if anything the trans- 
fusion/ 
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fusion requirement accelerated, the pyrexia which had 
returned did not settle, there was no improvement in the 
platelet count or in the E.S.R. and the titre of the direct 
Coombs' test remained the same. In addition the serum 
bilirubin rose to 11.2 mg. /lO0 ml. and methaemalbinaemia 
and bilirubinuria returned. 
On 28.12.62 the following regime was started: 
Actinomycin -C, 250 µg. by intravenous infusion at weekly 
intervals (this was given on three occasions), and Imuran 
150 mg. daily for four days, reducing to 100 mg. thereafter. 
Subsequent events are best seen in Figs. aoi-2( 
Immediately the serum bilirubin level and bile pigment 
excretion began to fall as did the transfusion requirement. 
(By 2.1.63 42 litres of blood had been given and only one 
transfusion had produced any reaction, an urticarial rash 
mentioned on p. lo ). In the first three weeks of drug 
therapy, only 2.5 litres of blood were required and on 
16.1.63 a third estimate of red cell survival gave a TL-Cr of 
12 days. The titre of the direct Coombs' test again fell 
to 1/40 and ten days after starting drug treatment the 
temperature became normal. 
Cortisone which had been maintained at a level of 
200 mg. daily till 3.1.62 was now gradually reduced, no 
further Actinomycin -C was given after 11.1.62 and the dose 
of Imuran was varied between 50 and 100 mg. as illustrated. 
From/ 
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From 1G.1.63 no further blood transfusion has been 
necessary, the haemoglobin level has risen to levels above 
80%, the serum bilirubin level has returned to normal and 
there has been no bile pigment in the urine. This 
situation has persisted to the time of writing, 28.2.63 (i.e. 
for six weeks), and all the investigative findings suggest 
that the haemolytic process has been suppressed. The 
patient, at the time of writing (28.2.63), is receiving 
Imuran 50 mg. on alternate days and cortisone 25 mg. per day. 
The red cell survival measurement started on 11.2.63 gave a 
TiCr of 18 days. 
Frequent marrow sampling has not been undertaken and 
did not seem to be necessary. The last aspirate (from the 
ilium) on 17.1.63 showed a hypercellular picture with 
ormoblastic hyperplasia and an excess of megakaryocytes. 
here is no indication that the drug therapy has induced any 
leucopenia, regular white cell counts (at the time of 
vriting) being in the range 6,900 to 14,800 per c.mm. with 
ormal differential count. 
Apart from the dramatic remission in the haemolytic 
process the thrombocytopenia has also been corrected by drug 
therapy. 
In the early stages there were transient increases in 
the platelet count into the normal range, a peak following 
each infusion of Actinomycin -C. However, beginning on 
19.1.63 (after the third and last infusion of Actinomycin -C) 
a/ 
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a sustained remission of thrombocytopenia was noted. The 
platelet count reached a level of 900,000 on 2.2.63 and has 
since then (till 28.2.63) been maintdined in the region of 
400,000. 
Apart from some fluid retention during the period of 
cortisone treatment and the isolated transfusion reaction 
referred to above, there were no side effects from any of 
the therapeutic measures and the patient considers that she 
has been returned to normal health (28.2.63.). 
Comment on Case 3. 
(i) Considerable interest attaches to the simultan- 
eous appearance of autoimmune haemolytic anaemia and 
thrombocytopenia. Evans and Duane (1949) and Evans, 
Takahashi, Duane, Payne and Liu (1951) drew attention to the 
frequent association and postulated that when leucopenia and 
thrombocytopenia co- existed with a haemolytic process, auto - 
antibodies might also be implicated in the suppression of 
white cells and platelets. Several authors, notably 
Crosby (1955), Crosby and Rappaport (1957), Dacie (1954), 
Chertkow and Dacie (1956) and Dacie (1962), have emphasised 
the sinister prognosis which the presence of thrombocytopeni 
purpura with haemolytic anaemia carries. The precise 
incidence of the association is not known but it reached 
13.2% in the series of 83 cases of idiopathic disease of 
warm antibody type in the series of Dausset and Colombani 
(1959). The sequence of events varies in that haemolytic 
disease/ 
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disease may precede the appearance of thrombocytopenia or 
vice versa, or they may appear simultaneously. The most 
unusual patients are those in whom a fulminating haemolytic 
process has followed at an interval after splenectomy for 
idiopathic thrombocytopenic purpura; an example of this 
rare occurrence was described by Waugh (1932) and Dacie (196 
refers to two others in his own experience which were 
described in his earlier papers (Dacie and De Gruchy 1951, 
Dacie 1954). The foregoing case appears to be the only 
additional example in the literature. 
(ii) The fulminating nature of the haemolytic process 
is illustrated in this patient by the very large transfusion 
requirement. Forty -two litres of blood were given in six 
weeks with only one minor reaction. 
(iii) The autoimmune haemolytic anaemia supervened 
while under observation and while the patient was receiving 
large doses of prednisone. 
(iv) Significant but transitory improvement in 
transfusion requirement, Coombs' test titre, temperature, 
E.S.R. and platelet count succeeded irradiation of the 
thymic region but could not be repeated by a second course 
of radiotherapy. 
(v) The patient's successful management confirms the 
possibility of arresting autoimmune haemolytic disease, 
which is otherwise uncontrollable by steroid therapy and 
splenectomy, using antineoplastic drugs. This is believed 
to be the first patient in which Actinomycin -C and Imuran 
have/ 
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have been employed for this purpose. 
(vi) Since idiopathic thrombocytopenic purpura may be 
caused by an autoimmune reaction, the experience in this 
case suggests that antineoplastic drugs may have a place in 
the management of this condition also, when other measures 
have failed. 
3. 13. Main conclusions from the studies on patients 
with autoimmune haemolytic anaemia. 
(i) No particular clinical features have marked the 
group of 23 patients with autoimmune haemolytic anaemia 
that has been discussed. The mode of presentation has 
varied, being usually due to acute (the illness being judged 
to begin with a haemolytic crisis in 6 patients) or chronic 
anaemia. Acholuric jaundice was definitely present in only 
15 of the patients initially; the serum bilirubin level was 
within the normal range in 5 patients and there was no 
urobilinogenuria in the early stages of examination in 
another 4, despite evidence of a moderately severe haemo- 
lytic process. 
Gross splenic enlargement was encountered only once and 
this was in a patient with lymphosarcoma. In 7 of the 16 
patients with idiopathic disease the spleen was actually 
impalpable at the time of diagnosis. 
The most useful indicators of a possible autoimmune 
haemolytic process in the early stages of investigation are 
considered to be anaemia, unexplained.reticulocytosis 
(present/ 
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(present in all but two patients) and a raised E.S.R. 
With regard to the last, the mean value for the patients 
with idiopathic disease was 82 mm. in the first hour; in 
only three instances was it less than 45 mm. when first 
estimated. 
(ii) Megaloblastic erythropoiesis was encountered on 
four occasions; ine one patient this developed during the 
course of her illness, in the other three it was present 
initially. This finding appeared to have different causes. 
In two subjects (one of whom had previously had a gastro- 
enterostomy, and the other was over 70 years of age), the 
serum vitamin B12 level was subnormal; in the third, the 
change in the marrow was observed after a haemolytic crisis 
in the initial stages of pregnancy, at a time when the serum 
folic acid level was subnormal; in the fourth patient the 
serum vitamin 812 level was well within the normal range 
and the development was presumed to have been due to 
conditioned folic acid deficiency. 
(iii) There were no significant changes in the plasma 
protein pattern, except those in the symptomatic group 
which could be ascribed to the underlying disease; there 
was no indication of preponderance of a particular blood 
group in this series of patients; the experience of the 
nature of the red cell antibody and the incidence of warm 
and cold types corresponded with that of others. 
(iv) While the course of illness in the patients in 
the symptomatic/ 
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symptomatic s mainly dependent on the underlying disease, 
the natural history of the autoimmune haemolytic process in 
the series of patients studied has followed distinct paths: 
(a) Self limiting disease with conversion of the 
direct Coombs' test to a negative reaction, 3 patients; 
(b) Sustained remission for weeks, months or 
years with complete suppression of signs of haemo- 
lysis or well compensated haemolysis, 7 patients; 
(c) Chronic relapsing course, 5 patients (2 of 
these have the cold haemagglutinin syndrome); 
(d) Uncontrolled relentless haemolytic disease, 
8 patients (all but one of these patients have died). 
(v) Transfusions have been employed frequently 
because of recurring severe anaemia and in four patients 
the giving of blood at intervals was necessary for the 
patient's survival. Despite the difficulty of cross match- 
ing blood due to the presence of red cell antibodies and the 
frequency with which these patients develop iso- antibodies, 
only minor transfusion reactions have been encountered; one 
patient with a fulminating haemolytic process required 42 
litres of blood in the course of six weeks. The impression 
has been gained that the giving of a large transfusion in 
the initial stages of illness may temporarily subdue the 
haemolytic process and this might gain time until steroid 
therapy became effective; possible reasons for this effect 
of transfusion have been advanced. 
(vi)/ 
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(vi) All of the 23 patients received steroid therapy 
at some stage of their illness. This was found to have no 
benefit in 11, very transitory benefit in 4, but has formed 
the main line of treatment, producing sustained remission 
on acceptable maintenance doses or on withdrawal of treat- 
ment, in the remaining eight. Attention is drawn to the 
high incidence of serious side effects; 7 patients had one 
or more important complications, which included significant 
fluid retention (in 3), perforation of a viscus (in 2) and 
burst abdomen after splenectomy (in 2). 
(vii) Nine patients in the series were submitted to 
splenectomy; this can be judged to have produced partial 
remission in only three and a good result (but not clinical 
cure) in only one. 
In 12 of the 18 patients in whom red cell survival 
ieasurements were made with chromium -51, data were also 
ollected using body surface measurements of radioactivity 
to evaluate the sequestration of red cells by the spleen in 
the haemolytic process. In the five patients for whom 
these results are available, who proceeded to splenectomy, 
he spleen sequestration index alone or the spleen /liver 
patio at TiCr alone (p. 44 ) does not adequately describe 
he role of the spleen. The first does not take into 
recount the uptake of radioactivity by the liver and the 
-econd excludes the effect of a high blood flow through the 
. pleon/ 
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acid and might have been precipitated by infection, 
the second occurred early in the second pregnancy 
and was almost certainly due to folic acid 
deficiency. Loth of these crises were rapidly 
responsive to steroid therapy; the initial crisis 
prior to splenectomy was only partially influenced 
by cortisone. 
Large doses of prednisone were given in the 
first trimester of the second pregnancy without 
any adverse effect on the mother or foetus. 
(c) Case 3 developed a fulminating autoimmune 
haemolytic anaemia after relapse of thrombocyto- 
penia, previously successfully treated by splene- 
ctomy six years earlier. No remission was 
evident following large doses of adrenocortico- 
steroids and massive blood transfusion was 
required. The disease was definitely but 
transiently influenced by irradiation of the 
thymus; remission was finally secured by the 
combined use of Actinomycin -C and Imuran. This 
is believed to be the first account of control of 
an autoimmune haemolytic process using these 
particular drugs and the first account of correc- 
tion of antibody - induced thrombocytopenia using 
any form of anti -neoplastic agent. 
132. 
CIIAPTER FOUR 
SYMPTOMATIC NON - IMMUNE HAEMOLYTIC ANAEMIA 
4. 1. Introduction. 
Dameshek and Schwartz (1940) are believed to have 
introduce the term "symptomatic ", later popularised by 
Singer and Dameshek (1941), to designate those cases where 
an aetiological relationship appeared to exist between 
acquired haemolytic anaemia and an underlying disease process. 
These investigators were aware that the role of haemolysis 
as an important cause of anaemia in various conditions had 
been widely accepted; the first accounts of the occurrence 
in leukaemia are attributed to Hirschfeld (1906) and 
Pappenheim (1906), and after these reports a haemolytic 
syndrome was noted, particularly in other cases of leukaemia' 
(Brill 1924, Watson 1939), in reticuloses (Davidson 1932), 
carcinomatosis (Waugh 1936) and liver disease (Lovibond 
1935); sarcoidosis and tuberculosis had also been implica- 
ted. Attention was drawn to the frequency and significance, 
of this haemolytic anaemia in the diseases cited by the 
!further accounts of Davis (1944) and of Stats, Rosenthal and 
Wasserman (1947). 
These earlier descriptions dealt with clinically 
evident haemolytic anaemia, usually with reticulocytosis andl 
acholuric jaundice, and emphasis was often placed on the 
presence of macrocytosis in the peripheral blood (Davidson 
1932/ 
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spleen relative to the liver. These criticisms are met by 
using a multiple of the spleen sequestration index and the 
spleen /liver ratio which has been termed the "Spleen Number': 
The only remissions from splenectomy were seen when the 
Spleen Number exceeded 300. The same treatment of data for 
patients who were managed with steroids alone showed that 
the two patients with the highest Spleen Numbers had had 
the most satisfactory remissions from steroid therapy. 
(viii) Three exceptional patients have been encountered 
and have been described in detail. 
(a) Case 1 suffered from a condition termed 
"familial haemophagocytic reticulosis ". Two 
of his three siblings had already died of the 
disease and evidence of abnormalities were 
obtained in the father (positive Coombs' test 
on one occasion; reduced red cell survival). 
The outstanding feature of the condition was 
very marked histiocytic proliferation with 
erythrophagocytosis. 
(b) Case 7 has been followed for seven years 
with a chronic relapsing haemolytic process. 
She has been observed through two pregnancies 
with partially compensated haemolysis. She 
has had two haemolytic crises, apparently of 
different aetiology; the first occurred while 
receiving supplements of vitamin B12 and folic 
acid/ 
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1932, Lovibond 1935). The extended use of red cell sur- 
vival measurements subsequently demonstrated, however, that 
decreased erythrocyte life span was present relatively 
frequently in leukaemias and reticuloses and disorders of 
connective tissue, whether or not the patient gave evidence 
of overt haemolysis, and also in an additional number of 
conditions not previously regarded as showing any haemolytic 
component; the latter included inflammatory diseases (e.g. 
rheumatoid arthritis, Freireich, Ross, Bayles, Emerson and 
Finch 1954; Alexander, Richmond, Roy and Duthie 1956), 
chronic renal disease (Emerson and Burrows 1949, Chaplin and 
Mollison 1953) and miscellaneous anaemias (Brown, Hayward, 
Powell and Witts 1944 and Brown 1950). 
The subject was extensively reviewed by Wasserman, 
Stats, Schwartz and Fudenberg (1955) who emphasised that, 
while reduction of red cell life span was the central 
feature in a miscellany of symptomatic anaemias, there seem- 
ed to be two distinct groups both clinically and haematologi 
tally. There were those patients on the one hand who 
usually presented classical signs of haemolysis with bili- 
rubinaemia, reticulocytosis and marrow hyperplasia in whom 
the haemolytic process was clearly the main cause of anaemia. 
On the other hand there was an ill- defined group in whom 
overt signs of haemolysis were not conspicuous and the main 
features were those of the primary disease; the recognition 
of a haemolytic process in them was based solely on red cell 
survival/ 
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survival measurement, the marrow was not hyperactive and 
increased blood destruction appeared to be only a contri- 
butory factor in the production of a subnormal haemoglobin 
level. Moreover, Wasserman and his colleagues observed 
that in the first group there was frequently a positive 
Coombs' test, the form of red cell destruction tended to be 
an exponential function and there was often a good effect 
from steroid therapy; in the second group there was no 
evidence for an auto - immune mechanism, although the shorten- 
ed red cell life span was due to extracorpuscular factors, 
red cell destruction was a linear process and only improve- 
ment in the underlying disease had any influence on the 
anaemia. 
Studies in auto -immune haemolytic anaemia have been 
described in the previous chapter; the "symptomatic" group 
accounted for approximately one third of the total series 
of patients, and it is re- emphasised that the development of 
a red cell antibody is only common when the primary disease 
is a lymphoproliferative condition or disseminated lupus 
erythematosus. This chapter deals with a selected group of 
patients in whom excessive blood destruction could not be 
explained by an auto -immune process. 
Examples of the writer's findings of reduced red cell 
survival in carcinomatosis, uraemia, hepatic cirrhosis and 
ddisonian pernicious anaemia were illustrated in Fig.a 
(p. S3 ); collaborative studies of the haemolytic element 
in/ 
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in the anaemia of rheumatoid arthritis have been reported in 
the literature (Alexander, Richmond, Roy and Duthie 1956, 
Richmond, Alexander, Potter and Duthie 1961). Particular 
experience has been obtained, in addition, of red cell 
survival measurements in cases of leukaemia, reticulosis 
and primary myeloid metaplasia. These last patients were 
studied either because they had some indicators of overt 
haemolysis (bilirubinaemia, reticulocytosis), or because 
they had a large transfusion requirement, or because they 
had significant anaemia which could not be adequately 
explained. Twenty -seven patients with these diseases were 
found to have adequate data and because of the relationship 
between the primary diseases and the similar problems of 
management which they create it has been felt justifiable to 
restrict the considerations in this chapter to this group; 
the basis for inclusion has been reduction of red life span 
below the normal range (TCr less than 24 days) and negative 
direct Coombs' test. In the absence of any pathogenetic 
mechanism implicating red cell antibodies, the haemolytic 
process has been termed "symptomatic non-immune haemolytic 
anaemia" since this, in the present state of knowledge, 
most adequately describes the condition. The haemolytic 
process will be shown to vary from mild in degree to severe; 
anaemia may be considerable and disabling and possible 
therapeutic measures are discussed. 
4. 2./ 
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4. 2. Main clinical features of the group of twenty -seven 
patients with symptomatic non - immune haemolytic 
anaemia and reasons for study. 
The details considered in this section are summarised 
in Table U. Case 24 was observed over a six year period. 
In the first stages of illness a haemolytic process was 
associated with myelofibrosis; terminally re- investigation 
was required because of the return of symptomatic haemolytic 
anaemia due to transformation of the primary condition to 
acute leukaemia. The observations in the latter period 
were distinct from the first and will be described under 
Case 24b. 
Since the group of patients was selected no importance 
is attached to age and sex distribution; there were 15 
female patients and 12 males, the age range was 22 years to 
89 years, mean 53.8 years. 
The numbers of patients suffering from each of the 
diseases studied were : - 
Acute leukaemia 
(following post -tuberculous 
myelofibrosis) 
1 
Chronic myeloid leukaemia 3 
Chronic lymphatic leukaemia 6 
Hodgkin's disease 8 
Lymphosarcoma 4 
Myeloid metaplasia with and 5 
without myelofibrosis 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































months to twelve years, but in twenty -two patients the 
primary condition had been present for two years or more 
before the clinical picture led to suspicion of a symptomati 
haemolytic process. 
It will be seen from Table 11 that the degree of spleni 
enlargement was very variable. In five patients (Cases 25, 
29, 32, 44 and 48) the spleen was impalpable at the time of 
investigation but was moderately to considerably enlarged in 
eighteen of the others. Only one patient;(Cas04) was 
clinically jaundiced. 
The reasons for consideration of haemolytic disease in 
individual patients fell into four categor.es:- 
(i) Signs suggesting overthaemolysib; reticulocytosi 
or bilirubinaemia or both. Four patients (Cases 30, 44, 
46 and 50). (It should be stated that reticuldcytosis 
need not have any significance in patients.with myeloid 
metaplasia since, in this condition, primitive vthite cells 
and red cells are regularly found in the circuldtion). 
(ii) Large transfusion requirement. Eight patients 
(Cases 24, 26, 28, 33, 36, 40, 42 and 45). 
(iii) Moderate to severe anaemia. Twelve patients 
(Cases 25, 31, 32, 34, 35, 37, 3S, 39, 41, 43, 48 and 49). 
(iv) History of recurring anaemia in recent months. 
Three patients (Cases 27, 29 and 47). 
4. 3./ 
133. 
4. 3. Red cell survival time in relation to clinical 
and routine investigative findings. 
One of the problems in evaluating the significance of 
the haemolytic process in symptomatic non - immune haemolytic 
disease is the multiplicity of factors that are also affect- 
ing erythropoiesis. The obvious confusions arise from 
invasion of the marrow by foreign cells, the unknown action 
of splenomegaly and the residua of treatment, notably with 
alkylating agents and radiotherapy, on the bone marrow. 
In addition, the common occurrence of thrombocytopenia makes 
it essential to exclude occult bleeding from the alimentary 
tract. 
The TiCr which has been taken as the only criterion 
for excessive blood destruction in this series of patients 
ranged from 1.5 days to 23 days; the mean value was 15.3 
days. When the 112-Cr is 20 days or more, haemolysis cannot 
be seen as having more than a minor role in the genesis of 
anaemia in these patients with leukaemia, reticulosis and 
myeloid metaplasia. Such a value was obtained in ten 
subjects; five of these (Cases 25, 26, 28, 29 and 33) had 
lymphocytic infiltration of the bone marrow, one (Case 4G) 
had myelofibrosis and one (Case 37) had a hypocellular 
marrow which was possibly due to previous treatment with 
nitrogen mustard. It will be noted that two of these 
patients with T1Cr exceeding 20 days (Cases 26 and 28) were 




Below this arbitrary value for T¿Cr of 20 days, it 
seems reasonable to accept the red cell survival time as 
having increasing importance in determining the patient's 
haemoglobin level, and below 15 days (ten patients) it is 
probably the major factor. 
The haemoglobin level in the series varied from 21% to 
85% (mean 58.6%) and in seven patients it was below 50% at 
the time of investigation. The reticulocyte count exceeded 
2% in only six patient but two of these had myelofibrosis 
in which condition the appearance of primitive white cells 
and red cells in the circulation has already been mentioned; 
that too much importance should not be attached to reticulo- 
cytosis in myeloid metaplasia is illustrated by Case 46 who 
had a reticulocyte count of 3.3%, but in whom the TlCr was 
20 days. Conversely, it is notable that the most marked 
reduction of TCr (Case 36, TL-Cr 1.5 days), observed in a 
patient with chronic myeloid leukaemia, was associated with 
no reticulocyte response. 
The serum bilirubin level exceeded 1.0 mg. per 100 ml. 
in only four patients. This measurement is also difficult 
to evaluate in a group of subjects in whom liver infiltratio 
by the primary disease occurs commonly; in only one of 
these patients (Case 44) were routine tests of liver functio 
entirely normal. In Case 44 there was acholuric jaundice; 
this patient also had reticulocytosis and is the only one in 
the/ 
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the whole series of twenty -seven patients in whom it can be 
stated that overt signs of haemolytic disease were present. 
Study of the data in Table II suggests that there is no 
correlation between spleen size and the haemolytic process 
in this series; the extreme examples are Cases 23 and 44. 
In the former the spleen was greatly enlarged and the TzCr 
20 days, in the latter the spleen was impalpable and the 
TlCr 3 days. 
Examination of the clinical and routine investigative 
data relating to these twenty -seven patients confirms the 
view that in a symptomatic non - immune haemolytic process, 
signs of haemolysis (increased pigment turnover and compen- 
satory activity on the part of the marrow) are rarely 
present even when the red cell life span is markedly short- 
ened. In this context increased red cell breakdown is only 
demonstrable from measurement of red cell survival. 
4. 4. Mechanisms of haemolysis in symptomatic non - immune 
haemolytic anaemia. 
In their consideration of symptomatic haemolytic 
anaemia not due to circulating red cell antibodies, 
Wasserman, Stats, Schwartz and Fudenberg (1955) made much of 
the linear form of the red cell survival curve in their 
patients compared with the exponential curve indicating 
random destruction of red cells seen in the autoimmune dis- 
ease. The linear removal of cells differed only in slope 
from that seen in normal subjects, and since the removal of 
ormal/ 
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normal cells from the blood is believed to be the consequ- 
ence mainly, if not solely, of ageing, they argued that 
these red cell survival data suggested accelerated ageing 
of the cells as the mechanism of increased red cell destruc- 
tion in symptomatic non - immune haemolytic anaemia. 
Although no experimental evidence has been obtained in 
support of this view, Dameshek and Schwartz (1959) also 
regard this explanation as the likely effect of "the sick 
circulation" (haemopathic haemolysis). 
In this regard Crosby and Benjamin (1957) have been 
successful in demonstrating that abnormal haemolysis occurs 
in vitro in the blood of patients with leukaemia and mali- 
gnant disease during sterile incubation for twenty -four 
hours; the effect is not seen until after a latent period 
of six to eight hours; haemolysis is inhibited by excess 
glucose, by a low pH and by removal of calcium from the 
plasma. Later Crosby, Vullo and Garriga (1961) found, 
however, that this haemolytic system in the patient's plasma 
cannot be correlated with shortened red cell survival. 
There seem to be no other experimental data indicating that 
an extracorpuscular factor may alter red cell integrity in 
symptomatic non - immune haemolytic anaemia. 
The relationship of the haemolytic tendency to spleno- 
megaly has been stressed (Berlin 1951) but this was not 
constant in the experience of Desforges, Ross and Moloney 
(1960) and is not evident from the features of the present 
series/ 
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series of patients. Nevertheless, in many reports dealing 
with the subject, splenectomy has been found to be benefi- 
cial in occasional patients; this was the experience, for 
example, in a series of patients with leukaemia and leuko- 
sarcoma (Fisher, Welch and Dameshek 1952), various malignant 
diseases, (Stats, Rosenthal and Wasserman 1947), myelogenous 
leukaemia (Jonsson, Hansen -Pruss and Rundles 1950) and 
Hodgkin's disease (Sykes, Karnofsky, McNeer and Craver 1954) 
There is also evidence that in myeloid metaplasia, despite 
the role of the spleen in extramedullary haemopoiesis in 
this condition, splenectomy may sometimes successfully 
reduce a haemolytic process (Loeb, Moore and Dubach 1953, 
Green, Conley, Ashburn and Peters 1953, Cartwright, Finch, 
Loeb, Moore, Singer and Dameshek 1955, Richmond and Duncan 
1956). The very variable and unpredictable results of 
splenectomy are, however, illustrated in the data of 
Wasserman and his colleagues who discuss twenty -nine patien 
with symptomatic haemolytic anaemia; splenectomy or 
irradiation of the spleen was undertaken in sixteen patients 
Nine of these were in the "non - immune" group, two obtained 
a "good" result and two a "fair" result; in the remainder 
no remission was found. Of the remaining seven with auto - 
immune haemolytic anaemia only two showed benefit from 
either form of treatment. 
4. 5./ 
143. 
4. 5. Basic therapeutic measures. 
The data discussed in this section are summarised in 
Table IL. 
With the exception of the six patients who were suffer- 
ing from myeloid metaplasia (Cases 24, 33, 40, 45, 46 and 50) 
and one with chronic myeloid leukaemia (Case 30), each 
individual had received or was receiving chemotherapy or 
radiotherapy (other than to the spleen) for his primary 
disease at the time shortened red cell survival was demon- 
strated. The patients studied in America were more readily 
treated with chemotherapeutic agents and received a wider 
variety of these drugs than did the patients investigated 
in Edinburgh; this was, however, due to the fact that the 
Memorial Hospital, New York, was a centre for the clinical 
trial of antineoplastic preparations. Local irradiation 
was widely applied to the patients with reticulosis and 
chronic lymphatic leukaemia for the treatment of local 
accumulation of disease (e.g. in gland masses, lungs, 
retroperitoneal space). 
Eighteen patients required blood transfusions and in 
eight of these (p.137 ) the requirement was large and 
frequent because of recurring severe anaemia. Seventeen 
patients (TableM) were given steroid therapy, either as 
part of the management of their primary disease or in an 
attempt to correct their anaemia. While it was impossible 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































several different therapeutic measures were being applied, 
it was considered that steroids had been successful in 
raising the haemoglobin level and inducing a sustained 
remission from anaemia lasting six months or more in only 
two patients (Cases 29 and 48). Both of these received 
prednisone 40 mg. per day initially, reducing over a two 
month period to 5 -10 mg. per day, and in both the haemo- 
globin improved by more than 15% above the initial value. 
One patient (Case 50) developed severe diabetes mellitus 
while taking prednisone, after which she rapidly deteriorat- 
ed and died in two months. 
4. 6. Observations suggesting implication of the spleen 
in the haemolytic process in some patients. 
The first two patients (Cases 24 and 40) studied in 
this series, showed evidence that the spleen might be 
implicated in the haemolytic process, and because their 
management stimulated further interest in symptomatic non - 
immune haemolytic anaemia, and because each had some unusual 
clinical and haematological features, they will be described 
in further detail. 
Case 24. E.B., illustrating the effect of splenic 
irradiation. 
This patient had had pulmonary tuberculosis in 1949, 
the diagnosis being based on infiltration of the upper zone 
of the left lung, with possible cavitation, and the recovery 
of acid fast bacilli from gastric lavage. Anti - tuberculous 
chemotherapy/ 
145. 
chemotherapy was given in the form of streptomycin and PAS 
for six months, she recovered well and during subsequent 
follow -up the pulmonary lesion became calcified and the 
patient's name was removed from the Tuberculosis Register in 
1956. Within two to three weeks (November 1956) she began 
to deteriorate, complaining of fatigue, loss of appetite, 
loss of weight and breathlessness. The appearance of a 
soft homogenous opacity in the upper zone of the left lung 
(in the area of the previous lesion) indicated recurrence of 
pulmonary tuberculosis. This relapse was associated with 
high fever, small lymph glands in most node bearing areas, 
splenomegaly and high E.S.R. (the first record was 115 mm. 
in the first hour). There was marked anaemia, Hb. 50%, 
normal white cell count (7,400) and normal differential 
count. The bone marrow aspirate was also normal and later 
grew no tubercle bacilli on culture. A large (2 cm.) 
supraclavicular gland was biopsied; this showed the typical 
histological features of caseating tuberculosis, a few 
tubercle bacilli being present. 
Treatment with streptomycin, isoniazid and PAS was 
started forthwith. There was rapid subjective improvement, 
the lung lesion cleared and the spleen became impalpable; 
the temperature did not, however, settle for six weeks and 
after three months the haemoglobin level was still in the 
range GO- 70%0. During this period the white cell count had 
been gradually rising; it was now 25,000 and primitive 
granular/ 
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granular cells were appearing in the circulation. Over the 
next six weeks, despite continuance of chemotherapy, the 
spleen which once regressed became quite large, the white 
cell count increased to 58,000, the platelet count also 
increased into the region of 1 million, and the peripheral 
blood picture was entirely compatible with chronic myeloid 
leukaemia. The marrow which had only four months earlier 
been normal was now also consistent with this diagnosis. 
The patient came under the observation of the writer in 
June 1957 when aged twenty -six years. The clinical and 
haematological picture had shown no important change over 
the previous three months. Marrow could not now be aspira- 
ted from the sternum or ilium, however, and bone marrow 
trephine showed definite evidence of myelofibrosis. It was 
concluded that the patient was suffering from secondary 
myelofibrosis consequent on the healing of miliary tuber- 
culosis. (This rare complication is well founded in autopsy 
experience, Crail, Alt and Nadler 1948, but does not appear 
to have been previously encountered in life). The question 
of myeloid leukaemia could not be definitely excluded but 
seemed unlikely in view of the marrow transformation and 
less likely when the patient's leucocytes were later shown 
to have no Philadelphia chromosone and to have a normal 
content of alkaline phosphatase (by courtesy of Dr. A. G. 
isaikie, M.R.C. Unit, Western General Hospital, Edinburgh). 
Anti -tuberculous chemotherapy was continued and the 
patient/ 
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patient remained moderately well for a further two months. 
The patient then became ill with high fever, enlarging spleen 
and anaemia, the haemoglobin level falling to 40%. After a 
2.5 litre blood transfusion, the haemoglobin level improved 
to 80% but fell again to 66% after only five days. A 
further 6 litres were given in the next three months because 
of recurring anaemia but the haemoglobin level was raised 
bove 50% for only temporary periods. There was, during 
this time, no reticulocytosis and no acholuric jaundice but 
in November 1957 the TzCr was 9 days confirming the presence 
f a severe haemolytic process. 
It was decided to try the effect of irradiation of the 
pleen. This was supervised by Dr. J. Newall, Consultant 
adiotherapist, Royal Infirmary of Edinburgh. A total of 
25 rads. were given through an anterior port to cover most 
f the surface area of the large spleen. The patient's 
aemoglobin level fell to 49% from 65% in the week after 
his treatment and a 1.5 litre blood transfusion was given. 
hereafter a most remarkable effect was observed; the 
atient's spleen became quickly smaller, being only just 
alpable under the right costal margin and the haemolytic 
process was completely arrested. The patient remained well 
for four- and -a -half years until June 1962 (p.(S3 ), the 
haemoglobin level persisting constantly in the region of 
80%. The only abnormal haematological features were a 
tendency to leucocytosis with occasional myelocytes and an 
excess/ 
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excess of basophils in the circulation and thrombocythaemia, 
the platelet count reaching levels of 1.5 to 2 million per 
c.mm. The thrombocythaemia was successfully controlled 
with radioactive phosphorus which the patient received in 
3 mc. amounts in August 1959, August 1960 and September 
1961. 
Case 40. J.R., illustrating the effect of splenectomy. 
This patient was first seen in November 1955, following 
increasing disability from tiredness, breathlessness, weight 
loss and generalised aches and pains in the previous four 
years. She was found to be anaemic, Hb. 64 %, the peripher- 
al blood showing a leucoerythroblastic picture and there 
was moderate splenomegaly. Several attempts to aspirate 
bone marrow were unsuccessful and a presumptive diagnosis of 
myelofibrosis was made; however, subsequent marrow trephine 
(and later autopsy) showed that the marrow was normally 
cellular and the condition could more correctly be described 
as "primary myeloid metaplasia" (Bowdler and Prankerd 1961). 
duodenal ulcer also demonstrated could not be implicated 
in the anaemia. 
In February 1956, the haemoglobin level fell to 39% 
nd blood transfusion was given. Afterwards transfusion 
as required at shortening intervals and by August of that 
ear the patient was requiring approximately 4 litres of 
lood per month. At the end of July 1956 it had been 
ecided to irradiate the spleen; a dose of 400 rads. was 
iven/ 
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given through an anterior port and although considerable 
shrinkage of the spleen was achieved (and the platelet 
count fell from 110,000 to levels of 40- 60,000 per c.mm.), 
no remission in the haemolytic process was observed. 
Despite the continuing large transfusion requirement, there 
was only transitory increase in urobilinogenuria, the serum 
bilirubin remained in the normal range (the highest value 
was 0.7 mg. /100 ml.) and there was no reticulocytosis. 
In August 1956 the red cell survival time was measured 
and gave a TiCr of 12 days; a typical peripheral blood 
picture at this time was as follows: Hb. 67%; R.B.C. 
3.92 m.; C.I. 0.85; P.C.V. 34%; M.C.V. 86.7 c.µ.; 
M.C.H.C. 29.1%; W.B.C. 7,800 (occasional myelocytes and 
normoblasts were present but otherwise the differential 
count was normal); reticulocytes < 1 %; platelets 55,000 
per c.mm. 
Prednisone therapy was used in the next six weeks, 
initially 60 mg. daily for three weeks and gradually reduc- 
ing the dose to 15 mg. daily in the succeeding three weeks. 
This was without any effect on the rate of fall of the 
haemoglobin level or on the transfusion requirement. 
During this period epigastric pain strongly suggested 
activation of the patient's duodenal ulcer. 
It was decided to proceed to splenectomy which was 
undertaken in September 1956. This was complicated by 
haematoma/ 
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haematoma formation under the left diaphragm, which had to 
be drained, but there was no doubt that the haemolytic 
process was significantly reduced by operation. Only 1 
litre of blood was given in October and a further 1 litre 
in November, and prior to the patient's discharge home at 
the end of this month a second measurement of red cell 
survival time showed considerable improvement, the TzCr 
being 22 days. 
The patient remained well for only three weeks, 
however. Readmission was occasioned by hepatocellular 
jaundice (which was considered to be due at the time to a 
serum hepatitis); two weeks later, while liver disease was 
persisting, she had copious and repeated haemorrhage from 
the duodenal ulcer. Bleeding continued for three days, 
repeated transfusion being required, and laparotomy was 
advised. Partial gastrectomy was undertaken and after 
initial improvement the patient gradually deteriorated and 
died in three weeks. The cause of death was generalised 
peritonitis from dehiscence of the gastro -jejunal anastomo- 
sis. 
Evidence for a splenic contribution to the haemolytic 
process using measurements of splenic uptake of blCr- 
labelled red cells. 
The experience of the foregoing two patients, together 
with that in the literature, suggested that at least in some 
with symptomatic non - immune haemolytic anaemia there might 
be a splenic component to the haemolytic process. The 
first/ 
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first (Case 24) had lasting benefit from small doses of 
splenic irradiation; the second was not helped by radio- 
therapy but splenectomy was followed by measurable lengthen- 
ing in red cell survival time. Unfortunately, the latter 
patient could not be followed for a long enough period to 
allow useful conclusions. However, the observations in 
these two patients were the reason for measuring the splenic 
uptake of 51Cr labelled red cells in twenty -three of the 
patients with a symptomatic haemolytic process who were 
subsequently seen. 
The results of these measurements are summarised in 
Table 13. Data listed under Case 24b refer to the further 
study of this patient (p. 1S3 ) when a haemolytic process 
supervened for the second time, consequent on the trans- 
formation of her condition to acute leukaemia. 
The observations show a number of features. Firstly 
there are eight patients (Cases 24b, 27, 32, 35, 41, 44, 47, 
and 49) in whom the spleen sequestration index at TiCr 
exceeds 100, above which level Jandl and his colleagues 
(1956) concluded that splenic sequestration was "moderate" 
to "severe". Secondly there are thirteen patients (Cases 
24b, 25, 27, 29, 32, 33, 35, 37, 38, 39, 41, 44 and 49) in 
whom the spleen /liver ratio exceeds 2.4, above which level 
Goldberg (1960) indicated that splenectomy was beneficial 
in acquired haemolytic anaemia. Thirdly, it was only in 






































































































































































































































































































































































































































































































































































































































































































































































































indices (Cases 24b, 27, 32, 35, 37, 41, 44 and 49) that the 
Spleen Number (p.lot ) exceeded 300; this was the figure 
above which the only remissions from splenectomy in auto - 
immune haemolytic anaemia were seen. 
The different patterns of uptake of 51Cr labelled red 
cells by spleen and liver are illustrated by four patients 
in Fig. 22. Each has a moderate to severe reduction of red 
cell survival time, but there is clearly a wide spectrum of 
splenic sequestration of labelled cells. The most rapid 
destruction of red cells occurs in the first patient (Case 
36, TiCr 1.5 days), an elderly subject with chronic myeloid 
leukaemia. In him there is no rise in the spleen/prae- 
cordium or liver /praecordium ratio during the course of the 
study, and it must be concluded that neither spleen nor 
liver is the main site of red cell destruction but that 
transfused red cells are being removed from the circulation 
widely throughout the body, presumably by the reticulo- 
endothelial system. In the second (Case 47) and third 
patient (Case 35) there is an increasing spleen/praecordium 
ratio, suggesting increasing importance of splenic seques- 
tration, while in the fourth patient (Case 44) a most 
dramatic rise in the curve of this ratio against time is 
seen. Fig. 2,1 also illustrates the importance of not 
relying solely on visual interpretation of data. The 
magnitude of the spleen/praecordium ratio becomes increasin 
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Fig. 22 
The range of splenic sequestration of 51Cr labelled red 
cells in 4 patients with symptomatic non - immune haemolytic 
anaemia. The best line has been drawn through the data 
for illustrative purposes. 
153. 
study continues; hence while the fourth patient (Case 44) 
appears to have the most severe degree of splenic seques- 
tration, the Spleen Number at TxCr in this patient, 646, 
was actually less than that of the third patient (Case 35) 
at 1056. 
4. 7. Observations on the effect cf splenic irradiation 
on the haemolytic process in patients showing 
varying degrees of splenic sequestration of 
red cells. 
Opportunity arose for studying the effects of splenic 
irradiation on the haemolytic process in four of the 
patients (Cases 24b, 33, 44 and 47) in the present series. 
The observation was not influenced by other treatment 
except in Case 24b, who was receiving prednisone in a 
constant dose of 20 mg. daily at the time. Red cell sur- 
vival measurement was made in these patients before and aft 
radiotherapy. Because of their different behaviour there 
follows a brief account of each. 
Case 24b. Acute leukaemia. Spleen Number 434. 
The course of this patient has been described (p.144-) 
until June 1962. Her haemoglobin level had remained satis- 
factory for four- and -a -half years following splenic irradia- 
tion and she was now in the eighth month of her first 
pregnancy. Pregnancy had proceeded uneventfully, although 
there was some concern for the foetus since conception must 
have occurred approximately ten days after her last treat- 
ment with radioactive phosphorus. Then in June 1962 
anaemia/ 
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anaemia suddenly developed, the patient's haemoglobin level 
falling from 75% to 40% in a period of three weeks. 
Following transfusion on two occasions, the patient was 
delivered of a normal child in mid July and after confine- 
ment further blood was required. Transfusion of 3 litres 
of blood was repeated in mid August and again in mid Sept- 
ember. During this period, June to September 1962, there 
had been a gradual fall in the platelet count from 425,000 
to 61,000 and simultaneous increase in the white cell 
count from 10,500 to 104,000. The latter was associated 
with the appearance of blast cells in the peripheral blood 
which now accounted for 92% of the total white cell count; 
this change in the peripheral blood, together with the 
appearances in the bone marrow, confirmed that the patient 
was suffering from acute myelogenous leukaemia. 
Steroid therapy was started (initially prednisone in a 
dose of 40 mg. per day) but this was found to have no effec 
on the rate of fall of the haemoglobin level and repeated 
blood transfusions continued to be required. Prednisone 
was maintained in a dose of 20 mg. per day. The TLCr in 
October 1962 was 13-days, and because of the earlier good 
result from splenic irradiation (p.144.0 this treatment 
was tried for a second time, despite the transformation of 
the underlying disease. A total of 100 rads. was given 
through an anterior port. This reduced the size of the 
spleen/ 
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spleen but had no effect on the transfusion requirement and 
a further measurement of red cell survival two weeks after 
the end of radiotherapy showed the TACr to be worse at 5 
days (Fig.23 ). Despite continuance of prednisone and the 
giving of 6- mercaptopurine the patient died one month later 
Case 47. Hodgkin's disease. Spleen Number 264. 
This young woman with Hodgkin's disease had involve- 
ment mainly of liver, spleen and para- aortic lymph nodes. 
The condition had presented with cervical lymph gland 
enlargement, but there had been no recurrence in this area 
over a three year period, following local irradiation. 
The patient's main symptom at the time of investigation was 
profuse night sweating, the temperature reaching levels of 
106 -1070 F. Anaemia was not prominent (Hb. 81%) but in 
recent months had usually been in the range 55-70%; 
however, the T1Cr was found to be 13 days. She was 
treated with a course of bipiperidyl, a new intravenously 
administered alkylating agent under trial. At the end of 
this time the TiCr was unchanged (14 days, see Fig. -) 
and the fever and sweats continued. The patient then 
received splenic irradiation to a total dose of 2,000 rads. 
through anterior and posterior ports. This produced 
marked regression of spleen size, almost immediate correc- 
tion of pyrexia and some reduction in the haemolytic proces 
The measurement of T ¡Cr which was started four weeks after 
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Red cell survival measurements in Case 24b before and after 
splenectomy. This patient's body tissues were studied for 
content of radioactivity at subsequent autopsy (p. 159). 
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x -x Before treatment. -- After Bipiperidyl. 
o--0 4 weeks after splenic irradiation. 
+ -+ 12 weeks after splenic irradiation. 
Fig. 24 
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DAYS 
The effect of splenic irradiation on red cell survival 
in two patients with symptomatic non - immune haemolytic 
anaemia. Note the delay in suppression of the haemolytic 
process in Case 47. 
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Case 44. Hodgkin's disease. Spleen Number 646. 
This patient who had a relatively short history 
(eighteen months) of illness had already received local 
irradiation of neck, axillary and groin lymph nodes, chemo- 
therapy (TEM) and steroids prior to the development of an 
overt haemolytic process. This is the only patient in the 
series who showed the classical signs of reticulocytosis 
and acholuric jaundice. 
In the three months prior to investigation, she had 
required 6 litres of blood; the TiCr was found to be 
markedly shortened, being 3 days. There was evidence of 
considerable splenic uptake of 51Cr labelled red cells, the 
spleen sequestration index being 170, the spleen/liver rati 
at TiCr being 3.8 and the Spleen Number 646. Accordingly 
irradiation of the spleen was recommended, a total of 700 
rads. being given through anterior and posterior ports. 
This was succeeded by striking clinical remission, the 
reticulocyte count and serum bilirubin returned to normal 
and a further estimate of the TiCr, four weeks after the e 
of radiotherapy, gave a value of 18 days (Fig. 2S ). 
During the six months' follow -up that was possible in this 
patient, no further blood transfusion was required. 
Case 33. Myelofibrosis. Spleen Number 26. 
This man first attended hospital because of back pains 
and joint pains in 1959. At that time, he had marked 
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Fig. 25 
Satisfactory response to splenic irradiation in a patient 
with symptomatic non - immune haemolytic anaemia who showed 
a very high degree of splenic sequestration of 51Cr 
labelled red cells before treatment. 
157. 
in the lumbar spine and sacro -iliac joints suggesting early 
ankylosing spondylitis. The peripheral joint pains were 
attributed to secondary gout and certainly considerable 
symptomatic relief was obtained in the subsequent three 
years from the use of uricosuric agents, notably colchicine 
and "Anturan ". Haematological investigations revealed a 
moderate pancytopenia, Hb. 70 -80%, primitive white cells 
and red cells in the peripheral blood, and after failure to 
obtain marrow, the diagnosis was shown to be myelofibrosis. 
The patient remained in a steady state, both clinically 
and haematologically, for two - and -a -half years; then in 
January 1962 he began to complain of increasing fatigue, 
diarrhoea and weight loss. Detailed investigations failed 
to reveal any new development other than the anaemia. 
This was treated empirically with iron, vitamin B12 and 
folic acid without effect and blood transfusion became 
necessary. The transfusion requirement increased over the 
next seven months, at the end of which time the patient was 
receiving 2 to 2.5 litres per month. 
In August 1962 there were none of the usual signs of 
haemolytic disease but red cell survival measurement showed 
the TiCr to be considerably reduced at 13 days. Despite 
the lack of evidence of splenic sequestration (Spleen 
Number 26, see Table l3 ), it was decided to try the effect 
of splenic irradiation. A total of 125 rads. was given 
through an anterior port at the end of August. There 
seemed/ 
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seemed at first to be acceleration of the haemolytic proces 
in that the patient's haemoglobin level fell to 50% on 
11.9.62 and 2 litres of blood were given, then to 40% on 
2.10.62 when a further 2.5 litres were required. A second 
measurement of T1Cr at this time gave the same figure as 
that obtained before treatment, namely 13 days. Subseque- 
ntly no further transfusion has been required during the 
past four months to the time of writing (28.2.63) and 
re- assessment of the red cell survival time in December 
1962 showed improvement in the T Cr to 18.5 days, (Fig.2Lf ) 
Comment on the patients receiving splenic irradiation. 
(i) Of the four patients treated by splenic irradia- 
tion, three have shown significant improvement in red cell 
survival time and have received clinical benefit. One 
patient (Case 24) who had acute leukaemia did not respond, 
the TiCr being actually less after treatment than before. 
(ii) The impression had been gained from earlier 
experience (p.14.7 ) that if the haemolytic process were to 
respond to splenic irradiation this might not occur 
immediately. In one patient (Case 33) the transfusion 
requirement increased immediately following radiotherapy 
and, although improvement in red cell survival occurred 
subsequently, no change in TACr was found in the immediate 
post- irradiation period. 
(iii) The response to splenic irradiation bore no 
relation/ 
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relation to the splenic uptake of 51Cr labelled red cells. 
The result in Case 33 with a low Spleen Number of 26 appear 
to be just as good as that in Case 44, Spleen Number 646. 
4. 8. The uptake of 51Cr labelled red blood cells by 
different body tissues measured at autopsy 
related to in vivo assessment of the splenic 
role in the haemolytic process. 
Two patients (Cases 24 and 49) in the present series 
died at a short enough interval after a red cell survival 
study with chromium -51 to permit measurement of the con- 
centration of radioactivity in various body tissues 
obtained at autopsy. The interval between the administra- 
tion of radioactive chromium and death was 36 days in Case 
24 and 21 days in Case 49. The data regarding red cell 
survival and body surface measurements have already been 
illustrated for Case 24 in Fig.23 ; those for Case 49 are 
shown in Fig. 24. Table 13 gives the figures for spleen 
sequestration index, spleen/liver ratio and Spleen Number. 
The radioactivity in the different tissues per unit of wet 
weight for the two patients are summarised in Table (4-. 
In each case the radioactivity of a given tissue was 
obtained in a weighed amount (approximately 5 g.), using a 
well type scintillation counter, and measurement continued 
until a total of at least 5,000 'counts' was registered. 
In Case 24 all but three tissues were found to give 
40 or less 'counts' per minute per g. For the stomach 
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The data obtained regarding red cell survival and splenic 
and liver uptake of radioactivity in Case 49. This 
patient's tissues were subsequently analysed for content 
of radioactivity at autopsy (p. 159). 
TABLE 14- 
THE CONTENT OF RADIOACTIVITY IN DIFFERENT BODY TISSUES 
AT AUTOPSY FOLLOWING RED CELL SURVIVAL MEASUREMENT WITH 
51Cr LABELLED RED CELLS IN TWO PATIENTS WITH SYMPTOMATIC 
NON - IMMUNE HAEMOLYTIC ANAEMIA 
Counts of Radioactivity per Minute per Gm. 
Wet Weight of Tissue 
Case 24 Acute leukaemia 
Gall bladder 4 
Ileum 7 
























Small bowel 44 
Pancreas 49 
Duodenum 50 
Large bowel 53 
Heart 57 
Gall bladder 71 
Lung 80 
Suprarenal 85 









much the highest, 694. When consideration is given to the 
weight of liver and spleen, the total organ content of 
radioactivity can be calculated. The former weighed 2115 
g. and the latter 1100 g.; hence the total amount of radio 
activity in the liver was 296100 counts per minute and in 
the spleen 763400 counts per minute. This gives a spleen/ 
liver ratio of 3.58 which compares favourably with the 
spleen /liver ratio at TCr in vivo of 3.1. 
In Case 49 a different pattern of uptake is seen. 
In most tissues there is a small amount of radioactivity 
ranging from 24 to 89 counts per minute. The liver, 
oesophagus and retroperitoneal tumour showed a similar 
uptake labelled cells (145 -158 counts per 
minute); the presence of oesophagus in this intermediate 
group may have been due to invasion by contiguous media - 
stinal tumour. The spleen contained much more radioactiv- 
ity than these other tissues with 1100 counts per minute. 
The significant feature in the study of this patient was 
the equally high amount of radioactivity in the bone marrow 
In Case 49 the liver weighed 2350 g. and the spleen 
750 g. Hence the total amount of radioactivity in these 
organs was respectively 371300 counts per minute in the 
liver and 825000 counts per minute in the spleen. These 
data give an actual spleen /liver ratio of 3.22 compared witl 
the in vivo measurement at TItCr of 2.8. 
It/ 
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It is not possible to estimate the total amount of 
radioactivity in the bone marrow in this patient. Mechanil 
(1926) found that the bone marrow accounted for 3.4 to 5.9% 
of body weight or 1600 to 3700 g. Assuming a marrow 
weight, arbitrarily, of 2500 g. then the marrow in Case 49 
would have contained 2625000 counts per minute of radio- 
activity at the time of death which is approximately four 
times more than that found in the spleen. These data 
suggest that in some patients the marrow may well be a more 
important site of erythroclasis than any other tissue in 
the body, a possibility already indicated by animal experi- 
ment (Meischer 1956, Ehrenstein and Lockner 1958). 
4. 9. Main conclusions from studies of patients with 
symptomatic non - immune haemolytic anaemia. 
(i) In this group of twenty -seven patients with 
symptomatic non -immune haemolytic anaemia, recognition of 
the haemolytic process has depended solely on estimation of 
the red cell survival time. The TL-Cr has varied widely in 
the range 1.5 days to 23 days, with a mean value of 15.8 
days. In leukaemia, reticulosis and myeloid metaplasia, 
conditions which offer multiple causes for anaemia, it has 
been considered to be unlikely that increased red cell 
destruction is more than a contributory factor to a low 
haemoglobin level when the T¿Cr exceeds 20 days. However, 
in seventeen patients the TICr was less than 20 days and in 
ten/ 
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ten of these it was considerably shortened, being less than 
15 days. Despite marked increase in the rate of red cell 
destruction in these latter patients, only one in the entir 
series showed the classical signs of an overt haemolytic 
process, acholuric jaundice and reticulocytosis. 
(ii) From the management of the first two patients in 
the series, the impression was gained that the spleen might 
be implicated in the haemolytic process, at least in some. 
The first, who had a large transfusion requirement main- 
tained a satisfactory haemoglobin level for four- and -a -half 
years without the need for further blood after splenic 
irradiation; the second showed correction of the red cell 
survival time (T1Cr of 12 days improving to TCr of 22 days) 
following splenectomy but died shortly afterwards from 
post -operative complications, consequent on gastrectomy and 
long follow -up was not possible. 
(iii) The uptake of radioactive labelled cells by the 
spleen was studied subsequently in twenty -three patients. 
It was found that the degree of sequestration of 51Cr 
labelled red cells could be just as great in this group of 
patients as had been encountered in the patients with auto - 
immune disease. Seven patients were found to have a Spleen 
Number in excess of 300. 
(iv) After the initial experience referred to in (ii 
four additional observations were made of the effect of 
splenic/ 
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splenic irradiation on the haemolytic process with measure- 
ments of the red cell survival time before and after treat- 
ment. Three patients (two with Hodgkin's disease and one 
with myelofibrosis) showed clinical and haematological 
improvement for periods of observation up to six months; 
the fourth patient who had acute leukaemia was not benefit - 
ted, the T¿Cr being 5 days after treatment compared with 13 
days before. 
The response to splenic irradiation in these patients 
bore no relation to the assessments of splenic involvement 
in sequestering 51Cr labelled red cells. Case 33, whose 
Spleen Number was 26, did just as well as Case 44 whose 
Spleen Number was 646. No explanation is available for 
this finding. It is, however, possible that in addition 
to affecting haemolysis by reducing the size of the spleen, 
splenic irradiation may have had indirect effects on ery- 
thropoiesis; analogous remote effects on leucopoiesis are 
the basis for the treatment of chronic leukaemia by radio- 
therapy. Evidence for interference with red cell producti 
by irradiation is suggested by the course of one patient 
(Case 33) who had a temporary increase in transfusion 
requirement in the period immediately after treatment 
without showing any change in the T -Cr; subsequently the 
haemoglobin level became steady, no further blood was 




(v) Finally opportunity arose of measuring the 
uptake of radioactive labelled red cells by different body 
tissues in two patients with symptomatic non - immune haemo- 
lytic anaemia, who died shortly after red cell survival 
measurement using radioactive chromium. The data showed 
reasonable correlation between the spleen /liver ratio of 
radioactivity at autopsy and the spleen /liver ratio at TiCr 
obtained earlier during life. However, in the second 
patient the concentration of radioactivity in the spleen 
was the same as that in the bone marrow, indicating that 
the role of the latter in red cell destruction (assuming a 
marrow weight of 2500 g.) was probably about four times 
greater than that of the spleen. Since this activity of 
the bone marrow in erythroclasis cannot be assessed in vivo 
and since the results in these two patients indicate that 
there is considerable variation in the sites of uptake of 
red cells between individuals and between different disease 
the present methods for evaluating the role of the spleen 
in the haemolytic process in symptomatic non-immune haemo- 
lytic anaemia do not form a useful guide to the patient's 
management. 
Experience in this small number of patients suggests 
that splenic irradiation should be .considered in doses up 
to 400 rads. when there is myeloid metaplasia, and up to 
2000/ 
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2000 rads. when the spleen is believed to be infiltrated 
by a reticulosis, if a patient's anaemia is disabling and 
there is shown to be a significant contribution from 




5. 1. Introduction. 
Although congenital spherocytosis is encountered 
infrequently, it is the most important haemolytic disorder, 
resulting from an intrinsic red cell defect, that occurs in 
Great Britain. It was probably the first blood disorder in 
which excessive red cell destruction was recognised to be 
the mechanism of production of anaemia. Reference has 
already been made to the most significant early reports, 
notably that of Vanlair and Masius (1871) and Minkowski 
(1900) who respectively first described and characterised 
the condition and later that of Chauffard (1907) who drew 
attention to the abnormal fragility of the erythrocytes in 
hypotonie dilutions of saline. 
All large studies of congenital spherocytosis have been 
in Caucasian subjects; however, there have been isolated 
reports of its occurrence in negroes, Kline and Holman (1957 
finding six examples in one American family and Metz (1959) 
describing two in the South African Bantu. 
While the condition is congenital, it cannot always be 
proved to be familial. A number of investigators have 
observed patients, neither of whose parents appeared to be 
affected (Debree, Lamy, See, Schrameck 1938, Race 1942, 
Young, Izzo and Platzer 1951). Young (1955) found that in 
f ive/ 
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five out of twenty -eight families with the disease, the 
blood of both parents of the propositus could not be dis- 
tinguished from normal; Race (1942) also reported this 
finding in four of his twenty -eight families. In the 
former series, spherocytosis was, however, discovered in a 
maternal grandmother in one family where the parents of the 
patient were unaffected, and in a maternal aunt in another. 
On the other hand, several detailed family trees have been 
published showing many affected individuals in three and 
four generations (Gänsslen, Zipperlen and Schüz 1925, Debre, 
Lamy, See and Schrameck 1938, Young, Izzo and Platzer 1951). 
The gene for the red cell abnormality in these families 
appears to behave as a Mendelian dominant transmissible 
through either parent, although there is usually a defici- 
ency in the expected number of affected siblings. Race 
(1942) attributed this latter finding to an unusually high 
miscarriage rate and infant mortality; Race also considered 
that variation in penetrance and expression of the defective 
gene was a likely explanation, both for the shortage of 
siblings with signs of disease and for the high incidence of 
unaffected parents. Dacie (1960) was also inclined to 
regard limitation of penetrance in a carrier parent rather 
than gene 'm ütation as the more likely explanation for 
instances of "sporadic congenital spherocytosis", but 
proposed that those patients differing in the mode of 
inheritance/ 
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inheritance of the disorder may also differ in the nature 
of the red cell defect, and that there may be more than one 
variety of congenital spherocytosis. 
The sexes have been equally affected in reported series. 
The condition has been recognised for the first time in the 
early hours of life (Stamey and Diamond 1957, Burman 1958) 
and at the other extreme of age, in a seventy -seven year old 
man, (Race 1942). In the experience of Young and his 
colleagues (1951) anaemia or jaundice was detected in the 
first five years of life in 50 per cent of patients and 
before the age of forty -five years in most of the remainder. 
It seems highly probable, however, that some affected sub- 
jects with mild disease pass through life without the 
diagnosis ever being made. 
Apart from the presence of congenital spherocytosis, 
the condition is usually characterised by a varying degree 
of chronic anaemia and icterus. The spleen is almost 
always enlarged and may be huge (Wintrobe 1961); it was 
readily palpable in twenty -three of the twenty -eight 
patients of Young, Izzo and Platzer (1951). Gánsslen and 
his colleagues (1925) stated that the spleen may not be 
palpable in 30 per cent of cases, but Wintrobe (1961) 
considers that this high proportion must have been due to 
the inclusion of relatives with mild disease and "formes 
frustes" in these authors' series. 
Two/ 
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Two aspects of congenital spherocytosis require special 
mention. The first is the "haemolytic crisis ". This may 
occur at any time, even for the first time in late adult 
life. It is an acutely developing illness and anaemia, 
with prostration, vomiting, fever, tachycardia and abdominal 
pain, often simulating an acute abdominal surgical emer- 
gency. The episodes have been attributed to sudden 
acceleration of red cell destruction, but Owren (1948) 
suggested that the mechanism was more likely to be acute 
bone marrow arrest with paradoxical cessation of haemolysis; 
this was based on the return of serum bilirubin and urine 
urobilinogen values to normal, and sudden reticulocytopenia, 
thrombocytopenia and leukopenia and acute erythroid hypo - 
plasia in studies in four cases at the height of the crisis. 
Dameshek (1941) had earlier suggested that the crisis might 
be produced by a combination of increased haemolysis and 
bone marrow inhibition, consequent on increased splenic 
activity. This view was reaffirmed in a later report 
( Dameshek and Bloom 1948). 
The second is biliary tract disease. Cholelithiasis 
from increased bile pigment production has been found to 
have a very high incidence in large series of patients, 
varying from 43 per cent (Bates and Brown 1952) to 85 per 
,cent (Young, Izzo and Platzer 1951). Gairdner (1939) 
reported gall stones in a three year old child. 
Quite apart from the disability from chronic anaemia, 
the/ 
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the possibility of these two complications, haemolytic crisis 
and gall stone production, both of which are potentially 
serious, is the main indication for definitive treatment of 
the haemolytic process (p.(940. 
A number of developmental abnormalities have been 
described in different series of patients (Gänsslen, 
Zipperlen and Schüz 1925, Hansen and Klein 1934). The most 
common of these are tower shaped skull, epicanthus, mis- 
placed teeth, polydactyly and brachydactyly. An uncommon 
complication which may be the chief complaint and which has 
no known explanation is chronic leg ulceration, just above 
the malleoli (Eppinger 1930, Taylor 1939). In other 
untreated patients a chronic dermatosis may persist in the 
same situation ( Beinhauer and Gruhn 1957). 
The precise nature of the red cell defect in congenital 
spherocytosis has still to be established. That the haemo- 
lytic process is due solely to a corpuscular abnormality has 
been suspected since the time of Naegeli (1931), and was 
conclusively shown in the pioneer cross transfusion experi- 
ments of Dacie and Mollison (1943); these latter investi- 
gators demonstrated that normal erythrocytes had a normal 
survival time in the circulation of recipients with con- 
genital spherocytosis, but that cells from a patient with 
the condition were destroyed rapidly in the circulation of a' 
healthy recipient (with a spleen). 
The/ 
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The rapid spontaneous haemolysis of spherocytes in 
vitro gave the first indication of a biochemical abnormality 
lam and Castle 1940, Dacie 1941). Later Selwyn and Dacie 
(1954) and Selwyn (1955) demonstrated that the addition of 
glucose retarded the corpuscular potassium loss and reduced, 
but did not abolish, this excessive autohaemolysis in vitro; 
Young, Izzo, Altman and Swisher (1956, 1958) then found that 
the effect of glucose could be neutralised by the addition 
of inhibitors of glycolysis, e.g. iodoacetate, and that a 
number of purine ribosides were even better than glucose in 
reducing haemolysis. 
More recently, using radioisotope and chromatographic 
techniques, Prankerd, Altman and Young (1955, 1957, 1960) 
have demonstrated abnormalities of intracorpuscular glycoly- 
sis; these investigators found, using phosphorus -32, that 
there is a smaller flux of labelled phosphorus into adenos- 
ine triphosphate and into 2,3- diphosphoglyceric acid than 
in normal cells at the same time as there is increased fI= 
into inorganic orthophosphate. These observations have 
been confirmed (Motulsky, Giblett, Coleman, Gabrio and 
Finch 1955). Since 2,3- diphosphoglycerate, one of the 
triose phosphates, accounts for as much as 50 per cent o:f 
the total acid soluble organic phosphate in the red cor- 
puscle and is an important store of energy (Hughes -Jc s '77f 
Robinson 1957), the defect in phosphorylation in cori__-_ -- 
spherocytosis can be seen as a most likely cause of 
red/ 
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red cell survival. Possible enzyme deficiencies to explain 
these observations have been postulated by Prankerd (1959) 
but have yet to be proved. 
Allusion has already been made (p. 11 ) to changes in 
the phospholipid component of the spherocyte membrane which 
might have even greater importance than disordered glycolysi 
in the genesis of the haemolytic process; whatever the 
fundamental defect (or defects) is found to be, the con- 
sequence is that the red corpuscles become increasingly 
spheroidal with senescence and have a very much reduced 
survival time in the patient's circulation. The importance 
of recognising congenital spherocytosis lies in the univer- 
sally good effect of splenectomy in arresting excessive 
red cell destruction and in producing clinical cure of the 
disability. 
5. 2. Composition of the group of patients with 
congenital spherocytosis and their main 
clinical features. 
The data considered in this section are summarised in 
Table IS. 
Twenty -six patients with congenital spherocytosis have 
peen studied; eight of these were members of one family. 
There were fourteen males and twelve females and the age 
distribution at the time of diagnosis ranged from 18 months 
to 62 years. 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































later (p. 177 ) but the duration of symptoms ranged widely 
from a few days (Cases 54, 55, 63, 63 and 75) to many years 
(Cases 56, 57, 60, 62 and 67). In the latter group were 
patients who had followed a chronic relapsing course (e.g. 
Case 60) and others who had had symptoms in childhood which 
were attributable to the disease, followed by a long period 
of good health, prior to the which led to diagnosis 
(e.g. Case 62). 1 
Only eleven patients had a definite family history of 
the condition at the time of diagnosis, but six others were 
discovered to have affected relations in subsequent studies. 
Further consideration is given to the data on inheritance of 
disease in this series of patients on page 204.., 
There was a considerable degree of pallor and icterus 
at the time of first examination. Fourteen patients were 
considered to be anaemic while tv4ielve were definitely 
jaundiced; in another four patients jaundice was doubtful. 
The spleen was definitely palpable in all but two patients 
(Cases 55 and 62), being usually enlarged approximately 
5 - 15 cm. below the left costal margin; however, in two 
patients (Cases 60 and 76) the spleen tip extended to the 
level of the umbilicus. In the two patients not showing 
clinical splenomegaly the spleen size was assessed 
subsequent operation. In both, the organ was enlarged; in 
Case 55, a child of four years who presented after a haemo- 
lytic crisis, the organ weighed 139 g. and would only have 
been/ 
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been palpated with difficulty; in Case 62 the spleen was 
stated to be three times normal size and would have been 
palpable but for a rather obese abdominal wall. 
A number of miscellaneous clinical features are worthy 
of mention. The only developmental defect noted in the 
series of patients was in Case 61 who had a hare lip. 
Amentia was encountered twice; Case 63 is a high grade 
mental defective capable of a routine type of work in a 
biscuit factory, Case 70 is a mongol requiring institutional 
care. Cases 57 and 60 have each had three miscarriages 
and have childless marriages. Case 64 has Addisonian 
pernicious anaemia; this developed ten years before the 
patient was recognised to have congenital spherocytosis and 
has been confirmed by the finding of histamine fast gastric 
achlorhydria and malabsorption of radioactive cobalt - 
labelled vitamin B12, which is corrected by the giving of 
intrinsic factor. 
Chronic le g ulceration was not encountered in any of 
the patients; however, in two (Cases 62 and 65) a chronic 
dermatosis was present. In Case 65 the condition was a 
scaly psoriatic type of lesion which encircled the lower one 
third of each leg above the malleoli. In Case 62 there was 
papulo -erythematous eruption and atrophy in the skin on 
the medial aspect of each leg above the internal malleolus. 
This is illustrated in Plate 
5. 3./ 
Plate 7 
Case 62 Congenital spherocytosis. 
Chronic dernatosis affecting the legs. 
175. 
5. 3. ,Main haematological and biochemical features 
at the time of diagnosis 
The data referred to in this section are summarised in 
Table lb. 
The haemoglobin level at the time of diagnosis ranged 
from 1S% (Case 54) to 95% (Case 59); the former presented 
after a haemolytic crisis, the latter was discovered after 
the condition had been recognised in his mother at the age 
of sixty -two years; he was thirty -eight years old and had 
never had any symptoms of disease. The mean value for the 
haemoglobin level was 64.6 %. The reticulocyte count was 
not significantly raised in five patients; in Case 53 
conditioned folic acid deficiency was probably present 
(p. Mt ); Cases 54 and 55, a brother and sister, developed 
a haemolytic crisis within days of each other and were first 
seen with profound anaemia (p.179 ), they did not, however, 
show signs of aplasia or maturation arrest on marrow exam- 
ination; Cases 56 and 59 only had mild anaemia when first 
seen. In the remaining patients, the reticulocyte count 
ranged from 4.5 to 29 %, the mean value being 12.2 %. 
Measurements of E.S.R. are available in all but six 
patients. In contrast to the finding in idiopathic auto- 
Immune haemolytic anaemia (p. 6T ) marked elevation of the 
r.S.R. appears to be uncommon in the patients with congeni- 
tal spherocytosis, being above 50 mm. in only two (the 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































a haemolytic crisis). In the whole series, the E.S.R. 
value ranged from 2 to 75 mm. in the first hour, the mean 
being 19.5 mm. 
Spherocytosis was seen in films of the peripheral blood 
in all but four patients and normoblastaemia was frequently 
present; the morphological appearance of the red cells 
correlated well with the results of osmotic fragility tests 
(Table l6) in the eighteen subjects for whom these data 
were obtained; the exception is Case 60 who showed markedly 
increased osmotic fragility but in whom spherocytosis was 
not convincingly present in blood films. It was only in 
the four patients not showing spherocytosis in blood films 
(Cases 56, 59, 60 and 64) that osmotic fragility tests 
were held to contribute towards the diagnosis. The indica- 
tion for osmotic fragility tests after twenty -four hours' 
auto -incubation of the patient's blood was discussed on 
page 36 and was used to advantage in Cases 59 and 64. 
The bone marrow was examined in twelve patients and 
usually showed the expected normoblastic hyperplasia; 
however, in three subjects (Cases 52, 53 and 62) definite 
megaloblastic erythropoiesis was present. One of these 
(Case 52) had a serum vitamin B12 level of 80 µµg. /ml. and 
has been described in the literature (Delamore, Richmond and 
Davies 1961). The implication of folic acid deficiency in 
the haematological findings in Cases 52 and 53 is discussed 
on page l8(. 
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Acholuric jaundice was almost always present; it will, 
however, be seen from Table lb that in three patients the 
serum bilirubin level was below 1 mg. /100 ml. The serum 
bilirubin level was never high, being in the range 0.5 -4.5 
mg., mean 2.1 mg. /100 ml. 
In the twenty patients for whom a result is available, 
the direct Coombs' test was never positive. The data also 
suggest that there is no significant preponderance of a 
particular ABO blood group; there were thirteen patients in 
Group 0, five in Group A and two in Group B. 
Red cell survival was measured using chromium -51 in 
thirteen of the patients; the range for the Tier was four 
to sixteen days, mean 10.4 days. 
5. 4. Modes of presentation of disease 
Since the clinical manifestations of congenital sphero- 
cytosis are protean, and since the severity of the haemolytic 
rocess may vary from being so mild that it can be easily 
verlooked to being so intense that it is life threatening, 
he many modes of presentation of the disease that have been 
ncountered in this series of patients will be described 
riefly. 
ith chronic anaemia 
Case 52 (J.C., 21 years) had a mild attack of jaundice 
t the age of twelve years; no information is available 
hat can establish the nature of this illness but it was of 
hort/ 
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short duration and he was absent from school for less than 
two weeks. His health before this and subsequently had 
been excellent until the age of eighteen years when there 
was fairly sudden onset of weakness and lightheadedness. 
These symptoms did not subside during four days rest in bed 
and he was afterwards admitted to the local hospital; 
anaemia was discovered and he gradually improved during a 
two month period on iron therapy. During the next two 
years the boy was in moderately good health but tired easily, 
and then dizziness and fatigue gradually returned. There 
was some improvement while taking iron tablets but the same 
Ili 
symptoms recurred two months later and were associated with 
considerable pallor and breathlessness; on this occasion a 
dragging sensation, worsened by deep respiration, was felt 
in the left hypochondrium for several days. Further iron 
therapy and several weeks' rest appeared to restore his 
fitness, but three months later, after a respiratory infec- 
tion, considerable weakness and pallor led to his admission 
to hospital in Edinburgh and to the diagnosis. 
A similar story, with symptoms of chronic anaemia and 
exacerbations of anaemia with or without a history of 
jaundice extending back for several years, also character- 
ised the mode of presentation of Cases 58, 61 and 67. 
With acute anaemia. 
Case 75 (G.ßß., 48 years) would admit to no past ill - 
health other than occasional respiratory infections when 
he was first seen. He had suddenly developed acute 
breathlessness/ 
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breathlessness on exertion and effort angina one week 
earlier; these symptoms had been particularly noticeable 
on stairs in his work as a Corporation meter reader. The 
patient had considerable anaemia, Hb. 47%, reticulocytosis 
20%, marked spherocytosis, acholuric jaundice and easily 
palpable firm splenomegaly; the last suggested that an 
active haemolytic process had been present for some time. 
o family history of anaemia or jaundice was available, 
there was no evidence of spherocytosis in the patient's 
idower father or any of his five siblings. The patient's 
irect Coombs' test was negative and the diagnosis of 
ongenital spherocytosis was established when definite 
spherocytosis and splenomegaly were found in his only son 
(Case 74). 
A haemolytic crisis was also the mode of presentation 
in five other patients (Cases 53, 54, 55, 63 and 68). 
ase 53 showed megaloblastic erythropoiesis and is discussed 
below. Cases 54 and 55 were brother and sister; they had 
a severe haemolytic crisis within a few days of each other. 
Case 54 (J.C., 7 years) was admitted to hospital on 
5.6.60. His earlier health had been excellent and seven 
nays prior to admission he had complained of a throbbing 
eadache; the headache continued and became associated with 
'ncreasing pallor, listlessness, anorexia and fever. The 
ine and stools became darker in colour. The spleen was 
palpable. The patient's initial haemoglobin level was 18%, 
the reticulocyte count was 2% and subsequent investigation 
showed/ 
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showed marked spherocytosis, normoblastic hyperplasia in 
the bone marrow, acholuric jaundice, and negative Coombs' 
test. Case 55 (M.C., 4 years) was admitted to hospital 
on 2.7.60. She had been disinclined for food and on the 
day prior to admission she had become very pale and exhaust- 
ed; her previous health had also been excellent. The 
clinical picture was similar to that found in her brother. 
The initial haemoglobin level was 37 %, reticulocytes less 
than 1%. The fact that there was no evidence of bone 
marrow aplasia in either of these children may be due to 
the delay of nine days in sampling the marrow in the first, 
and five days in the second. Diagnosis was not difficult 
in this instance because their father was known to have had 
a splenectomy for haemolytic anaemia ten years earlier and 
there was a striking history of the disorder in other 
relatives (p.2-06). 
There are many accounts of this interesting phenomenon 
of haemolytic crises occurring in different members of the 
same family more or less simultaneously. The first of 
these is believed to have cone from Edinburgh (Murray -Lyon 
1935) and attention was also drawn in this report to the 
occurrence of reticulocytopenia at the height of the crisis 
when anaemia was most severe. It is of interest that 
Owren (1948) based his observations on erythroid hypoplasia 
as the mechanism of production of crises on studies in six 
patients, four of whom were members of one family who 
became/ 
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became ill within days of each other. The development of 
"familial crises" strongly supports the suggestion (Greig, 
Metz, Bradlow, Theron and Morris 1958, Wright and Gardner 
1960) that an environmental factor is implicated in 
precipitating the event in some patients, and an infection 
seems the most likely. Although a history of infection 
was not available in Cases 54 and 55 it is notable that 
these were the only two in the series of patients whose 
E.S.R. exceeded 50 mm. in the first hour at the time of 
presentation. 
With megaloblastic anaemia 
Reference has already been made to Case 53 (F.C., 42 
years) because of his presentation with acute anaemia. His! 
past health had been good but there was known to be a high 
incidence of congenital spherocytosis in his family. One 
month before the patient was first seen he had developed an 
acute febrile illness with generalised myalgia and headache. 
Although the fever subsided in two to three days, the 
patient had remained weak and lethargic, and at the time of 
examination he showed considerable pallor, icterus and 
slight splenomegaly. The initial examination of peripheral. 
blood gave the following results:- Hb. 45%, R.B.C. 2.0 m. 
per c.mm., reticulocytes 2.2 %, W.B.C. 6,400 and normal 
numbers of platelets in the blood film. Acholuric jaundice1 
was confirmed biochemically, the serum bilirubin level being 
1.5 mg. /l0O ml. 
The/ 
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The patient was unable to accept hospital admission 
for a further month. By this time the haemoglobin level 
had fallen to 32% and a leucopenia of 800 white cells per 
c.mm. (with normal differential count) had appeared. The 
leucopenia was confirmed, being 1,000 white cells per c.mm. 
four days later, and at this time thrombocytopenia (plate- 
lets 15,000 per c.mm.) was also found to be present. 
Although the bone marrow showed normoblastic hyperplasia, 
megaloblasts were undoubtedly present. Prior to splenec- 
tomy, folic acid 5 mg. t.i.d. was given and within two days 
the white count was raised to 7,000 per c.mm..and the 
platelet count to 130,000; splenectomy was undertaken after! 
three days and the usual rise in white cell and platelet 
counts followed. Repeat marrow examination two weeks 
later showed that megaloblasts were no longer present. 
The relevant studies of vitamin B12 and folic acid 
metabolism on this patient, in relation to the discovery of 
megaloblastic erythropoiesis, later revealed the following : -' 
the serum vitamin B12 level had been subnormal at 80 µµg./ 
ml. (normal range by L. Leichmannii method with added 
cyanide, Girdwood 1960, is 140 -1,000 µµg. /ml.); vitamin 
B12 absorption (Schilling method) was normal; folic acid 
absorption and excretion test (Girdwood 1960) was normal - 
the urinary output of folic acid after a 5 mg. parenteral 
injection of folic acid was 1.95 mg. and after a 5 mg. oral 
dose 2.3 mg., Excretion Index 117.9%; hydrochloric acid 
was/ 
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was produced in the patient's gastric juice on maximal 
histamine stimulation; serum folic acid assays were not 
available at the time time this patient was studied. 
In Case 62 megaloblasts were also found in the bone 
marrow during the period of investigation; in this patient 
no cytopenia was evident, extensive studies of pathogenesis 
were not undertaken, the serum vitamin B12 level was 715 µµg 
/ml. and folic acid supplements were given empirically prior 
to splenectomy. Data are available, however, for a third 
patient (Case 52) who developed megaloblastic change ine 
bone marrow while under observation. 
Case 52 had presented with chronic relapsing anaemia 
in the previous three years and has been mentioned above. 
When first seen, he had a haemoglobin level of 61%, reticu- 
locytes 17.3%, white cell count 6,100 with normal differ- 
ential count, platelets 240,000. Marrow aspiration showed 
normoblastic hyperplasia. Over the next ten days fall of 
the platelet count to 130,000 per c.mm. was associated with 
a fall in the reticulocyte count to 4%; at this time 
megaloblasts were definitely seen in a second marrow smear. 
Folic acid was given in a dose of 5 mg. t.i.d.; this 
reversed the thrombocytopenia and reticulocytopenia as is 
illustrated in Fig.2T. In this patient it was subsequent- 
ly shown that the serum vitamin B12 level had been normal 
at 633 µµg. /ml. but that the serum folic acid level had been 
below the normal range of 4.5 to 15 µµg. /ml. at 4.1 µµg./ 
ml./ 
Mr. J.C. 21 yrs. CASE 52 
Megaloblastic erythropoiesis. 
30- 300 Serum folic acid 4I,upg. /ml. 
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The effect of folic acid supplements on platelet and 
reticulocyte counts in a patient with congenital 
spherocytosis who developed megaloblastic erythropoiesis 




The utilisation of haemopoietic factors in haemolytic 
disease was discussed on page 512. when the data regarding 
folic acid and vitamin B12 metabolism for all patients were 
presented. .The relative frequency of megaloblastic ery- 
thropoiesis is emphasised because it has now been described 
in three patients with autoimmune haemolytic anaemia and in 
a further three patients with congenital spherocytosis. 
Because of the good body stores of vitamin B12 and its long 
biological half life, conditioned folic acid deficiency from 
increased haemopoiesis seems to be the more likely mechanism 
in most patients. This was the experience of Chanarin, 
Dacie and Mollin (1959). However, such may not always be 
the explanation since Case 52 did have a low level of serum 
vitamin B12 without malabsorption of vitamin B12, suggesting] 
conditioned deficiency of this haematinic in his case. 
Moreover, conditioned deficiency of folic acid and vitamin 
B12 may sometimes be the cause of an acute exacerbation of 
anaemia, particularly when leucopenia, thrombocytopenia and 
reticulocytopenia are present (as in Case 52); this cannot 
be the explanation of all crises in haemolytic disease, 
however, since Case 7, with idiopathic autoimmune haemolytic' 
anaemia (p.(O$ ), had a haemolytic crisis while she was 




Case 51 (G.B., 19 years) had an attack of jaundice 
when five years old but had had good health before and after 
that episode until the illness which led to the diagnosis 
of congenital spherocytosis. Nine weeks prior to admission 
to hospital he had developed epigastric pain; this had 
persisted fairly constantly and seemed to be worst after a 
long interval without food and was relieved by the taking 
of food. During this period the patient had been noticed 
to be jaundiced, although the appetite was'good; there had 
been an increase in the depth of colour in the urine and in 
the stools. On examination icterus was clearly evident 
but there was no pallor; the spleen was moderately enlarged 
The haemoglobin level was 91 %, reticulocytes 12.7% (indi- 
cating well compensated haemolysis) and there was marked 
spherocytosis. The serum bilirubin level was 3.4 mg./ 
100 ml. and the urine contained urobilinogen but no bile. 
The direct Coombs' test was negative. Spherocytosis could 
not be shown in the boy's parents or in his three siblings; 
an uncle had, however, had several attacks of jaundice of 
unknown cause in the past but could not be examined because 
of service overseas. 
Acholuric jaundice was also the outstanding feature in 
the history of two other patients (Cases 56 and 72 in the 
series). 
With gall stones 
Case GO (E.H., 42 years) had almost certainly suffered 
from/ 
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from chronic anaemia since early adult life. At the time 
of diagnosis she was pale and icteric, there was considerab 
splenomegaly, the haemoglobin level was 65 %, reticulocytes 
12% and acholuric jaundice was confirmed to be present on 
biochemical investigation. However, anaemia was not the 
clinical feature which led to diagnosis. Two weeks prior 
to admission to hospital the patient had complained of acute 
pain in the right hypochondrium, nausea, vomiting and 
anorexia. She had had similar, though less severe, attacks 
for several years. The attack subsided with exacerbations 
over three to four days and subsequent investigation showed 
the presence of multiple facetted radio - opaque gall stones 
in the gall bladder. While these gall stones may have 
developed on the basis of pigment gall stones, their "mixed" 
nature indicated chronic cholecystitis from recurrent 
infection. 
The incidence of gall stones in this group of patients 
is lower than that reported in other series. Of the 
twenty -two who have proceeded to splenectomy, cholelithiasis 
was evident in only five (23 %). The only feature which 
appeared to have any bearing on this complication was 
duration of disease, the ages of those showing gall stones 
being respectively; Case 60, 42 years; Case 62, 40 years; 
Case 65, 48 years; Case 67, 52 years; Case 76, 29 years. 
With cholangitis following cholecystectomy for gall stones. 
Case 76 (W.W., 29 years) enjoyed good health untilthe 
age/ 
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age of twenty -six years when he developed severe epigastric 
pain, lasting four days, associated with sweating, vomiting, 
shivering and possible jaundice. There were recurrences 
of mild epigastric pain lasting for a day or two in the 
next two years, and then he suffered a very similar attack 
to the first; this was sufficiently severe to warrant 
admission to hospital, because perforation of a peptic ulcer 
was suspected. The incident was considered to be due to 
acute ulcer pain rather than perforation, particularly as 
pylorospasm was later demonstrated during barium meal 
examination. It is of interest that splenic enlargement 
was reported by the radiologist at this time but its 
significance does not seem to have been appreciated. He 
remained well apart from occasional upper abdominal pains 
for four months, and then recurrence of another severe 
attack was associated with jaundice; the diagnosis was 
considered to be infective hepatitis until cholecystography 
showed the presence of multiple non -opaque gall stones. 
While awaiting cholecystectomy, another severe attack of 
pain supervened, again associated with jaundice. After 
allowing time for some improvement, cholecystectomy and 
exploration of the common bile duct was undertaken; 
multiple small pigment stones were found and the gall 
bladder appeared healthy. The correct diagnosis was still 
not entertained and about two months after operation the 
patient again became ill with pallor, shivering, sweating, 
vomiting/ 
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vomiting, right hypochondrial pain and tenderness. 
Cholangitis appeared to be present and the condition quickly 
settled on a course of "Crystamycin ". It was only at this 
stage that the presence of anaemia, reticulocytosis, 
spherocytosis; considerable splenomegaly and acholuric 
jaundice (serum bilirubin 3.4 mg. /100 ml.) suggested con- 
genital spherocytosis and the diagnosis was made. 
A very similar course was followed by Case 65. He 
had recurrent attacks of biliary obstruction with cholangi- 
tis for a year after cholecystectomy before a haemolytic 
process was suspected. 
With splenomegaly and splenic infarction 
Case 57 had been found to have splenomegaly during a 
routine school examination at the age of eleven years. 
She had intermittent mild anaemia during puberty and adol- 
escence but this produced no more than mild disability and 
the diagnosis of congenital spherocytosis was not reached 
until the age of twenty -three years. 
Case 71 (M.S., 36 years) had been easily fatigued 
following the birth of her third child one year previously. 
The main reason for her presentation was, however, sudden 
severe pain in the left upper quadrant of the abdomen, 
leading to admission to hospital as a surgical emergency. 
mass was felt in this region, the nature of which was 
uncertain; it was, however, believed to be an enlarged 
left kidney; accordingly pyelography was undertaken but this 
showed/ 
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showed normal renal outlines. The mass seemed more likely 
to be spleen in the X -rays and the appearance of a friction 
rub during a subsequent attack of pain strongly suggested 
that the patient's symptoms had been due to splenic infarc- 
tion. At subsequent splenectomy, a spleen weighing 620 g. 
was removed and the presence of infarction and perisplenitis 
was confirmed. The diagnosis of congenital spherocytosis 
was reached on the basis of anaemia, Hb. 70%, spherocytosis, 
reticulocytosis (9.5%), acholuric jaundice and family 
history. The patient's father (deceased) was stated to 
have had splenic enlargement and recurrent jaundice (p.2o. ) 
and her three children were found to be affected. 
With pregnancy 
Case 66 (C.M., 18 years) was considered to have been 
anaemic after her first pregnancy, nine months before she 
was seen in the present studies. The reason for her 
examination was moderate anaemia (Hb. 76%) at the sixth 
month of gestation in her second pregnancy. More detailed 
investigation revealed reticulocytosis (9.2 %), spherocytosis 
urobilinogenuria and palpable splenic enlargement. Case 
71 also developed symptoms in relation to pregnancy (p.(S ) 
but no data are available to show the degree of anaemia 
at the time. 
Although Case 66 did not have marked anaemia when the 
diagnosis was made, the possible aggravating role of 
pregnancy in haemolytic disease has been known for some time 
Wintrobe/ 
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Wintrobe (1961) lists pregnancy with "cold ", "emotion" and 
'fatigue" as a cause of exacerbation, while McElin, Mussey 
and Watkins (1950) found that if worsening of a haemolytic 
disorder were to occur in pregnancy it was more likely after 
the third month of gestation than before. In the light of 
earlier discussion on conditioned deficiency of folic acid 
in some patients with haemolytic disease (p.18({ -), the 
occasional exacerbation of anaemia during pregnancy is not 
surprising in view of the evidence that pregnancy may also 
be a cause of folic acid depletion (Chanarin, Dacie and 
Mollin 1959, Girdwood and Delamore 1961). 
With family study 
Finally there were six patients in the series (Cases 
59, 64, 69, 70, 73 and 74) who had no symptoms, who were 
not known to have any abnormality and who were discovered to 
have congenital spherocytosis in family surveys. 
5. 5. The results of splenectomy. 
Introduction. The first splenectomy. 
The unique feature in congenital spherocytosis is that 
apart from rupture of the spleen there is no other condition 
in which splenectomy is followed by such uniformly good 
results. Dacie (1960) reviews the evidence for failure of 
splenectomy in the literature, and considers that in some 
instances the diagnosis was probably congenital non - 
spherocytic anaemia, and in other acquired haemolytic 
anaemia; in those cases where the diagnosis was acceptable, 
the/ 
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the cause of relapse appeared to be splenunculi or aplenic 
fragments left behind at operation (Stobie 1947, Loeb, 
Seaman and Moore 1952, Edwards 1955, McKenzie, Elliot, 
Eastcott, Hughes- Jones, Barkhan and Mollison 1962), except 
in an unusual case described by Freund (1932) in which the 
liver was intensely congested at autopsy and may have taken 
over haemolytic activity. 
According to Lord Dawson of Fenn (1931) the first 
splenectomy for congenital spherocytosís was probably under -1 
taken by Spencer Wells in 1887. Spencer Wells did the 
first splenectomy in England in 1865; his second and third 
splenectomies were performed in 1868 and 1875 but all of 
these were unsuccessful and the patients died. His fourth it 
splenectomy concerned a young women, twenty -seven years old.'I 
From the age of nine this patient had been troubled by 
frequent attacks of jaundice and when she was fourteen she 
was growing "so large in front" that her mother vas disturb- 
ed. At the age of twenty -five a large asominal tumour 
was discovered which was thought to be a fibroid. After 
two years' observation the swelling was noted to be increas- 
ing in size; the attacks of jaundice had become more 
severe and were now accompanied by abdominal pain. Accord- 
ingly, it was decided to remove the tumour. 57:.,,,erecer Wel it s 
found that the mass was a large freely :ova': _ _ 
which weighed nearly 12 lbs. After cperaá.o 
made/ 
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made a complete recovery. The diagnosis was not reached, 
however, for another forty years when the patient still 
showed spherocytes in the peripheral blood and increased 
osmotic fragility of the erythrocytes. Her only son had 
earlier developed haemolytic anaemia in childhood and then 
obstructive jaundice from cholelithiasis; he had also 
made a complete recovery following splenectomy (and chole- 
cystectomy). 
Effect of splenectomy on the haemolytic process 
Dacie (1943, 1960) draws attention to the fact that 
mild bilirubinaemia and reticulocytosis may persist in 
some patients after splenectomy, and considers that this 
may indicate continuance of the haemolytic process. In 
only two patients in the present studies has the reticulo- 
cyte count exceeded 2% after operation; in one, Case 71, 
the count has frequently been between 2 and 3% during the 
six years of follow -up, although the patient has never been 
anaemic; in the other, Case 65, high values were obtained, 
ranging from 6 to 12 %, during a period of investigation 
seven years after splenectomy. The patient was then found 
to have moderate anaemia, Hb. 75 %, and obstructive jaundice. 
Red cell survival measurement was undertaken and gave a 
TiCr of 24 days. Subsequent laparotomy revealed a biliary 
stricture (cholecystectomy and exploration of the common 
bile duct having been earlier performed in this patient) 




In the only data that are known to be available 
regarding erythrocyte life span after splenectomy for con- 
genital spherocytosis (Motulsky, Giblett, Coleman, Gabrio 
and Finch 1955), it was shown that while this may be 
returned to normal in most instances, it remains signifi- 
cantly impaired, although easily compensated, in others. 
Clinical cure of anaemia has been achieved with 
apparent arrest of the haemolytic process in all twenty -two 
patients so far treated by splenectomy in the present series. 
The four patients who have not proceeded to surgery (eases 
58, 59, 64 and 74) all have well compensated haemolytic 
disease, are not disabled and are under regular review. 
The TCr has been measured in eight patients in the present 
series at intervals varying from sixty days to seven years, 
after removal of the spleen. (It will be indicated on 
page 2-00 that red cell survival measurements within a few 
days of splenectomy may show that excessive red cell destruc- 
tion is still persisting.) The results obtained were as 
follows:- Case 53, 28 days; Case 60, 24 days; Case 61, 
30 days; Case 63, 24.5 days; Case 65, 24 days; Case 72, 
26 days; Case 75, 31 days; Case 76, 32 days. The mean 
value for the post splenectomy TzCr in these eight subjects 
was 27.6 days. The data are illustrated in Fig. 28 and 
it has been concluded that the red cell survival time has 
been corrected in all of these patients, despite the 
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Fig. 28 
Red cell survival after splenectomy in 8 patients 
suffering from congenital spherocytosis. 
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The remarkable effect of operation in congenital 
spherocytosis and the confirmation that this condition is 
indeed an intrinsic red cell defect is well illustrated by 
the cross transfusion experiments shown in Fig.21. First, 
in Case 76.it is seen that the patient's erythrocytes have 
a shortened survival time in the circulation of a healthy 
recipient, as well as in his own; in fact, the cells 
appear to be destroyed more rapidly in the normal individual 
than in the patient, the TCr being 8 days in the former 
and approximately 15 days in the latter. In Case 72 the 
patient's erythrocytes after splenectomy now have a normal 
survival time in himself (compared with a TLCr of 11.5 days 
before operation), but when injected into a healthy subject 
with an intact spleen, they are still removed from the 
circulation abnormally rapidly. Similar results have 
earlier been obtained by Dacie and Mollison (1943), Schrumpf 
(1951) and Hughes -Jones and Szur (1957). Emerson (1954) 
went further and demonstrated that the patient's cells were 
incapable of normal survival in a normal subject except in 
the absence of a spleen. 
Selection of patients for splenectomy and complications 
of surgery. 
In view of the tendency to crises of anaemia and to the 
development of gall stones, and because of the good effect 
of splenectomy in congenital spherocytosis, it is generally 
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15 20 
Cross transfusion experiments in patients with congenital 
spherocytosis. The cells of Case 76 have a shortened 
survival in a normal individual and in his own circulation, 
illustrating that this condition is due to an intrinsic 
red cell defect. After splenectomy red cell survival is 
normal in Case 72 but his cells still have a shortened 
survival in a healthy recipient. 
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except in those few who are having no symptoms from the 
disorder and have well compensated haemolytic process. 
This has been the policy in the present series and as stated 
already, has meant that twenty -two of the twenty -six patient 
have had their spleens removed. One patient (Case 62) 
died two days post -operatively from unrecognised acute 
gastric dilatation and the sudden aspiration of copious 
vomitus into the lungs. The only morbidity from operation 
was seen in Case 75 who developed a deep venous thrombosis 
in one leg ten days after splenectomy, in association with 
a transient increase of the platelet count to 900,000 per 
c.mm. 
It has been found necessary to recommend splenectomy 
in six children; in Cases 54, 55 and 68 because of a 
severe haemolytic crisis, in Cases 69, 70 and 73 because of 
failure to thrive and backwardness at school. These chil- 
dren have now been followed for periods varying from four 
months to eighteen months and are doing well. 
There is, however, misgiving about the possible dis- 
position to infection in children after splenectomy, and 
for this reason attempt is made to defer surgery for as 
long as possible. King and Schumaker (1952) were the first 
to draw attention to the problem; they reported five cases 
of congenital spherocytosis requiring splenectomy in the 
first six months of life; in all of them severe infections, 
usually meningitis, later developed and two died. Smith, 
Erlandson/ 
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Erlandson, Schulman and Stern (1957) showed the risk was 
not restricted to splenectomy in infancy, describing infec- 
tions after splenectomy in children and young adults. 
Huntley (1958) then indicated that the danger was not 
confined to splenectomy for any particular disease. Some 
authorities (Miller and Hagedorn 1951) deny an increased 
risk of infection, but this view is not shared by Lowdon, 
Walker and Walker (1962). The latter authors, reviewing 
the literature and analysing their own experience following 
splenectomy undertaken for various reasons in seventy -five 
children (four of whom developed serious infections), 
concluded that splenectomy may predispose to life- threaten- 
ing infection in some cases, and such infection usually 
occurs within two years of operation. The risk, although 
present at all ages, is probably greatest if operation is 
performed in infancy. When infection occurs it is often 
due to the pneumococcus and it may take the form of a 
fulminating septicaemic illness with meningitis and the 
danger of adrenal haemorrhage. The account of Lowdon and 
his colleagues is the only one in British literature. 
5. 6. Possible role of the spleen in congenital 
spherocytosis. 
'Conditioning of spherocytes 
Although the place of splenectomy in the management of 
patients with congenital spherocytosis is unequivocal, the 
precise/ 
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precise function of the spleen in the haemolytic process has 
not yet been established. Characteristically, the spleen 
is enlarged but there is no primary abnormality of the 
spleen, since it has been amply demonstrated, both in vivo 
(p. lief ) and in vitro (Young, Platzer, Ervin and Izzo 1951), 
that a spleen from a patient with hereditary spherocytosis 
and one from a normal individual will both selectively 
remove normal red cells. 
Numerous investigations (Dacie 1943, Young and his 
colleagues 1951, Weisman, Ham, Hinz and Harris 1955 and 
Emerson, Shen, Ham, Fleming and Castle 1956) have indicated 
that this sequestration of spherocytes by the spleen has a 
deleterious or "conditioning" effect on the cells. The 
changes are recognised by abnormally increased osmotic and 
mechanical fragility in blood taken from the spleen pulp or 
splenic veins; the "conditioned" cells may then either be 
destroyed in the spleen, as evidenced by the elevated 
bilirubin level in splenic vein blood (Gripwall 1938, Dacie 
1960), or escape into the peripheral circulation where they 
are identified as the markedly fragile "tail" of cells in 
osmotic curve (p. 35 ). It has long been known (Meulen- 
gracht 1922, Dacie 1943) that these most spheroidal cells 
and most fragile cells are usually no longer present in the 
patient's circulation after splenectomy. This finding has 
been confirmed in six of the present series of patients and 
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Fig. 30 
Osmotic fragility of red cells in congenital spherocytosis. 
Note that the "tail" of the pre- operative curve due to the 
characteristic population of very fragile cells has been 
significantly altered by splenectomy. 
198. 
These several observations have revived an old suggest- 
ion (Whipple 1941) that differential selection of erythro- 
cytes by the spleen might occur on the basis of a geometrica_ 
peculiarity; the spheroidal cells may be easily trapped in 
the spleen because of their abnormal thickness and their 
inability to escape through the slit -like openings of the 
venous sinusoids; this is supported by the work of Bjorkman 
(1947) who found that animal spleens selectively retain 
particles ranging from 3 -4 µ, in diameter. Crosby and 
Conrad (19GO) reported observations, however, which make it 
unlikely that it is the shape of the red cell of congenital 
spherocytosis which is implicated. They removed blood by 
venesection from two healthy patients with congenital 
spherocytosis and compensated haemolytic disease until they 
developed iron deficiency and their red celisbecame hypo - 
chromic; in consequence the red cells became smaller and 
thinner, the resistance of the cells in tests of osmotic 
and mechanical fragility improved and autohaemolysis during 
incubation was greatly diminished. Modification of the red 
cell characteristics, relating to size, shape and iron 
content, was not, however, reflected in improved red cell 
survival. 
Griggs, Weisman and Harris (19GO) made an important 
contribution by studying the behaviour of an identifiable 
group of spherocytic red cells using in vivo labelling with 
radioactive iron (59Fo). It is well established that iron 
administered/ 
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administered in this way is incorporated only into newly 
formed red cells and not into older erythrocytes. These 
investigators found that the osmotic fragility of newly 
formed red cells was similar to the fragility of the main 
body of red bells in the peripheral blood; none of the new 
59Fe labelled erythrocytes were found in the tail of the 
osmotic curve, but then there was progressive increase in 
osmotic and mechanical fragility and it took at least ten 
days for "conditioning" to reach a maximum. It was 
impossible to say from the nature of the study whether the 
labelled erythrocytes were trapped in the spleen for the 
full period of "conditioning" or whether this change was 
achieved on multiple circuits. Then Griggs and his 
colleagues studied the survival of erythrocytes taken from 
the splenic pulp at the time of elective splenectomy in the 
patient's circulation. They found that the erythrocytes 
obtained from the spleen showing the most marked fragility 
had an extremely short survival and disappeared from the 
circulation in forty -eight hours. Motulsky, Casserd, 
Giblett, Broun and Finch (1958) performed a complementary 
experiment to the foregoing by transfusing 59Fe labelled 
spherocytes from a patient, who had had a splenectomy, into 
his brother, who also had congenital spherocytosis but had 
not yet proceeded to operation. Approximately six days 
were required for these transfused cells to show the same 
marked increase in osmotic fragility as was present in the 
recipient's/ 
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recipient's own cell population. 
Studies supporting the conditioning role of the spleen. 
Additional studies have been undertaken in the present 
series of patients. First, in two subjects (Cases 52 and 
72) serial measurements of red cell survival have been made 
using chromium -51, before splenectomy, in the immediate 
post- operative period (within 48 - 72 hours), and at a later 
interval of 80 and 60 days respectively. The data are 
presented in Fig.3E. 
The shortened survival time before operation is seen in 
each patient, as is the return to a normal survival time of 
the patient's cells by the time of the third measurement 
two to three months after splenectomy. The form of the 
survival curve in the immediate post- operative period 
indicates, however, that at this stage red cell survival is 
not yet corrected and that there still remains in the 
circulation a proportion of cells that are abnormally sensi- 
tive to destruction, and that these have to be cleared 
before the haemolytic process is completely arrested. 
Dacie (1960) has also shown in one patient that the rate of 
haemolysis remained unchanged for three days after splene- 
ctomy before becoming approximately normal. 
Secondly, in eight of the patients body surface 
measurements of radioactivity during red cell survival 
estimates with chromium -51 were undertaken as in the patients 






Mr. J.C. 21 yrs CASE 52 
5 10 
DAYS 
151Cr labelled patient's red cells 
15 
Mr. N.S. 16 yrs. CASE 72 
- Before splenectomy. 
o o qB hrs. (Case 52) and 72 hrs. (Case 72) after splenectomy. 
x -x 2 -3 months after splenectomy. 
Fig. 31 
Serial measurements of red cell survival in two patients 
with congenital spherocytosis. The haemolytic process is 
not immediately corrected by splenectomy, presumably due 
to persistence of a proportion of excessively fragile cells 
in the circulation for a few days after operation. 
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anaemia. The data are presented in Table ( and are 
illustrated for seven of the patients in Fig.32.. 
It is seen that the spleen sequestration index ranges 
from 40 to 265, mean 153, and the spleen /liver ratio at 
TiCr from 1.7 .to 3.3, mean 2.42. The Spleen Number which 
has been used as the most sensitive indicator of splenic 
sequestration ranges from 82 to 585, mean 371. 
These values and visual inspection of Fig.3]- show 
that, while in most patients there is a significant accumula 
tion of radioactive chromium in the spleen, this is not 
always so, and in any case it never reaches the very high 
levels of spleen radioactivity (p.loo,ts2) encountered in 
patients with the other haemolytic diseases. For example, 
the Spleen Numbers of Cases 10 and 14, with idiopathic 
autoimmune haemolytic anaemia, were 734 and 753 respectively 
and for Cases 27, 32 and 35, with symptomatic non - immune 
haemolytic anaemia, 920, 960 and 1056 respectively. 
Study of the results of Jandl, Greenberg, Yonemoto and 
Castle (1956) and of Hughes -Jones and Szur (1957) also 
suggests that the uptake of radioactive chromium in 
congenital spherocytosis may not be as high as in cases of 
acquired haemolytic anaemia. 
These óbservations are in good accord with experimental 
work recently reported by Belcher and Hughes -Jones (1960). 
These investigators made quantitative estimates of radio- 












































































































































































































































































































































































































































































IO 15 20 
DAYS 
Data regarding red cell survival and uptake of radioactivity 
from 51Cr labelled red cells in 7 patients with congenital 
spherocytosis. The main feature is the relatively low 
uptake of radioactivity in the spleen in some patients 
compared with that seen in a proportion of the patients 
with acquired disease. 
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after 51Cr labelled cells had been injected for the purpose 
of red cell survival measurement. They took account of the 
rate of random destruction and the potential life span of 
the red cells and made assumptions relating to the rate of 
elution of 51Cr from red cells in the circulation and the 
rate of elution of 51Cr from the spleen once it had been 
deposited there. In one patient with acquired haemolytic 
anaemia the injected 51Cr appeared to be almost entirely 
deposited in the spleen and haemolysis ceased after 
splenectomy; in another with acquired haemolytic anaemia 
the result indicated that the spleen was only partially 
responsible for the destruction of labelled cells, and this 
was consistent with body surface radioactivity measurements 
which had earlier shown an uptake of radioactivity by both 
the liver and the spleen. In each of two patients with 
congenital spherocytosis studied, the spleen content of 
radioactivity was relatively lower than the first patient 
with acquired haemolytic anaemia, and it was therefore 
believed that the spleen was only partially responsible for 
the destruction of labelled cells in this disease. 
When all these data are considered together, particular- 
ly the correction of osmotic fragility after splenectomy, 
the delay in correction of the haemolytic process after 
plenectomy and the relative splenic sequestration of 51Cr 
Labelled red cells in patients with congenital spherocytosis, 
ompared with that seen in some patients with acquired 
aemolytic/ 
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haemolytic disease, it is concluded that the main role of 
the spleen in congenital spherocytosis is to trap the 
spherocytes and critically increase their spheroidicity and 
fragility rather than to destroy them; while some red cell 
destruction takes place in the spleen, it seems likely that 
the "conditioned" erythrocytes are removed from the circula- 
tion in different parts of the body. 
5. 7. Hypocholesterolaemia in congenital spherocytosis 
An incidental finding 
During the course of study of this series of patients 
incidental observations have been made of low levels of 
plasma cholesterol in some patients with untreated congenital 
spherocytosis. The first of these was made in Case 71 
(M.S., 36 years); this patient had a plasma cholesterol of 
133 mg. per 100 ml. (the normal range is 125 -300 mg. /100 ml.) 
The next was in Case 76 (W.W., 29 years); his plasma 
cholesterol was 51 mg. per 100 ml. (mean of two readings, 
62 and 40 mg. /100 ml.). After splenectomy the respective 
values of plasma cholesterol for these patients were 275 and 
235 mg. per 100 ml. 
The data regarding plasma cholesterol that are avail- 
able are summarised in Table I. Most but not all of the 
nine untreated subjects are shown to have a low value, while 
the eight splenectomised patients all have levels well 
within the normal range. The mean value before splenectomy 
is 156 mg. /100 ml. and after splenectomy 242 mg. /100 ml. 
This/ 
TABLE Iß 
PLASMA CHOLESTEROL LEVELS IN PATIENTS WITH 
CONGENITAL SPHEROCYTOSIS BEFORE AND AFTER SPLENECTOMY 
Before Splenectomy 
Plasma 
Case No. Cholesterol 
mg. /100 ml. 
After Splenectomy 
Plasma 
Case No. Cholesterol 
mg. /100 ml. 
51 118 53 192 
52 119 57 285 
58 170 60 237 
59 264 63 207 
64 173 67 258 
71 133 71 275 
72 100 75 250 
74 276 76 234 
76 51 
Mean 156 242 
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This is a subject for further study, and as far as is 
known the observation has not previously been reported in 
the literature. The suggestion is advanced that cholesterol 
is lost from the circulation with the bile which is excreted 
in excess, consequent on the haemolytic process, and this 
is corrected when excessive red cell destruction is arrested 
by splenectomy. In this regard it is notable that the 
four patients with the highest figures for plasma cholestero_ 
before splenectomy (above 150 mg. /100 ml.) are the four who 
have such mild well compensated haemolytic disease that 
operation has not so far been considered justifiable. 
5. 8. The inheritance of congenital spherocytosis 
Reference was made earlier (p.166) to the inheritance 
of congenital spherocytosis and to the evidence indicating 
transmission of the abnormal gene as a Mendelian dominant 
with varying penetrance. The possibility of gene mutation 
as an explanation for "sporadic" examples of the condition 
was also stated but this had been considered unlikely by 
Race (1942) and Dacie (1960). 
A number of observations relating to the different 
modes of inheritance have been made in the present series of 
patients. 
In eighteen patients there was evidence of a dominant 
type of inheritance in living siblings and descendants. 
In twelve, disease was also found in a parent but in the 
other/ 
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other six this was not so either because the parents were 
dead and the history was negative (four cases), or because 
the examination of the parent and his or her blood, includ- 
ing incubation osmotic fragility (p. 3(o ), was negative 
(two cases).. 
In eight patients in the series no evidence of disease 
elsewhere in the family could be obtained. Three require 
special mention. Case 72 was an adopted child whose 
relations were not known. The parents of Case 60 were dead 
(but gave no history of illness), she was an only child and 
had had no descendants because of three miscarriages. The 
parents of Case 57 were examined with negative results; 
she was also an only child who had no descendants because of 
three miscarriages. Of the remainder, Case 68 was an only 
child and none had children. All available parents and 
siblings were examined for splenomegaly, anaemia, reticulo- 
cytosis and spherocytosis (by blood film scrutiny, standard 
osmotic fragility test and incubation fragility test) with 
negative results. 
Three complete family trees serve to illustrate the 
main findings. Fig.33 relates to Case 61 (G.I., 20 years). 
All four siblings were healthy as were the parents. All 
four grandparents were dead but had lived to ages exceeding 
sixty -five years and were never suspected of having any 
haematological disease. Fig. 3y- relates to Case 63 (R .M., 
12 years); there was no disease in her siblings or in her 
parents/ 
Died 89yrs. Died 72yrs. r F (Died 72yrs. 














- - - Not examined 
The family tree of Case 61. No evidence of congenital 
spherocytosis was obtained in siblings or in two 
generations of antecedents. 
i Died 62 yrs i ̀Accident' ' 
i 
Died 70 +yrs 
' ?Cause i 
Died of'pernicious ,' j1 anaemia'30yrs ago 
age 60 yrs. 
46 050 
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Male O Female 
- -- -Not examined / / / / /Possible carrier 
The family tree of Case 63. No evidence of congenital 
spherocytosis was obtained in siblings or in two 
generations of antecedents. The maternal grandfather 
who died aged 60 years of "pernicious anaemia" may have 
been a carrier of the disease and the family may illustrate 
poor penetrance and expression of the abnormal gene. 
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parents; however, the maternal grandmother died at the age 
of sixty years of "pernicious anaemia ". This death occurr 
thirty years ago and the diagnosis may well have been 
correct, but suspicion is raised that this individual was a 
"carrier of congenital spherocytosis, illustrating the 
suggestion of Race (1942) and Young (1955) that expression 
of the abnormal gene in some families may be extremely 
feeble. 
Fig.3S illustrates the behaviour of a gene with very 
full expression and includes Cases 53, 54, 55, 56, 69, 70, 
71 and 73. In the first generation there is little doubt 
that grandfather was affected as was one of his sisters, but 
both were dead before study could be undertaken. Grand- 
father had had recurrent attacks of jaundice throughout his 
life. He was examined in the Royal Infirmary, Edinburgh, 
in 1926 because of such an attack; the spleen was enlarged 
at the time and the diagnosis was considered to be biliary 
cirrhosis. The patient eventually died of a cerebro- 
vascular accident at the age of seventy -three. Three of 
his children were affected, one presenting with chronic 
dyspepsia and jaundice, one with a splenic infarction and 
one with acute anaemia associated with megaloblastic ery- 
thropoiesis. Five of the third generation show the 
disorder; brother and sister of one family developed a 
haemolytic crisis together and the three children in the 
other family (one of whom is a Mongol), because of anaemia 
and/ 
Died of cerobrovascular 
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A family with congenital spherocytosis in which the 
abnormal gene has behaved as a Mendelian dominant with 
full penetrance and expression. There is also evidence 
of advancing severity of the disease in succeeding 
generations. 
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and failure to thrive, have also required splenectomy. 
Not only does this family show the vagaries of the disease 
but it also illustrates advancement of the severity of the 
condition in succeeding generations. Although this 
phenomenon is well known in some inherited disorders, e.g. 
dystrophia myotonica, no reference has been found to its 
occurrence in congenital spherocytosis. 
5. 9. Main conclusions from studies in congenital 
spherocytosis. 
(i) Congenital spherocytosis has been studied in an 
unselected group of twenty -six patients. As in other serie 
neither sex predominated, there being fourteen males and 
twelve females, and there was a wide range of age at the 
time of presentation, from eighteen months to sixty -two 
years. 
(ii) Many modes of presentation were encountered; 
chronic relapsing anaemia, acute crisis of anaemia (in one 
instance occurring simultaneously in two members of a family 
megaloblastic anaemia, splenomegaly, splenic infarction, 
jaundice, gall stones, cholangitis following cholecystectomy 
and anaemia in pregnancy. 
(iii) There was a varying degree of anaemia, sphero- 
cytosis, reticulocytosis and acholuric jaundice at the time 
of diagnosis, and all but'two patients had palpable splenic 
enlargement. Of the miscellaneous features, two were 
mentally backward (one was a mongol), one had a hare lip, 
two/ 
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two had childless marriages, each having three miscarriages, 
and two had a chronic dermatosis affecting the legs above 
the malleoli. 
(iv) Three subjects showed megaloblastic erythropoiesi 
In two of these it was possible to reverse the thrombocyto- 
penia and reticulocytopenia which accompanied the marrow 
changes by the giving of folic acid. Data are given 
suggesting that megaloblastic erythropoiesis may result from 
folic acid deficiency or vitamin B12 deficiency or both. 
(v) All but four patients (who had little or no 
anaemia and well compensated haemolysis) proceeded to 
splenectomy. One patient died in the immediate post- 
operative period; in the others clinical cure has been 
achieved. Six of the patients were children and splenectomy- 
was advised because of a severe haemolytic crisis or because 
of chronic anaemia and failure to thrive. In follow -up 
periods ranging from four to eighteen months, there has been 
so far no incidence of serious infection. 
(vi) In view of the lack of information regarding the 
red cell survival time after splenectomy for congenital 
spherocytosis, this measurement has been undertaken in 
eight patients. In all the TZCr was restored to normal, in 
the range 24 to 32 days. 
(vii) Evidence is advanced to suggest that the role of 
the spleen in congenital spherocytosis is to "condition" the 
cells and to critically increase their spheroidicity and 
fragility/ 
209. 
fragility, rather than to destroy them. This is based on 
the improvement in osmotic fragility that succeeds splene- 
ctomy, the delay in arrest of the haemolytic process after 
splenectomy and' on the measurements of splenic sequestration 
of 51Cr labelled red cells. The last indicate that the 
uptake of radioactivity in congenital spherocytosis is never 
as high as is encountered in some patients with acquired 
haemolytic disease, and is in accord with absolute estimates 
of splenic sequestration made by others at the time of 
splenectomy. 
(viii) Hypocholesterolaemia not previously reported, has 
been an incidental finding in untreated patients with 
congenital spherocytosis. The plasma cholesterol level was 
51 mg. /100 ml. in one patient and less than 140 mg. /100 ml. 
in four others. The four patients with higher values than 
this had such mild haemolytic disease that splenectomy has 
not so far been found to be indicated. In measurements 
made after splenectomy, the plasma cholesterol level was 
normal and the suggestion has been advanced that this 
finding may be due to loss of cholesterol with the excessive 
amounts of bile that are excreted in haemolytic disease, 
correction being achieved by arrest of the haemolytic proces 
(ix) Finally, studies of the mode of inheritance of 
the disease confirm the findings of others. In one family 
the gene behaved in a classical Mendelian dominant manner 
and showed increase in the severity of expression in 
succeeding/ 
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succeeding generations. In eight patients no evidence of 
the disorder was found elsewhere in the family, but the 
influence of miscarriages and possible "carrier" states on 
this finding is discussed. 
211. 
S U M M A R Y 
1. The thesis has considered the investigation of haemo- 
lytic disease and has discussed observations on seventy -six 
patients regarding the pathogenesis, natural history and 
management of excessive red cell destruction in the three 
conditions that are most commonly encountered in Great 
Britain, namely autoimmune haemolytic anaemia, symptomatic 
non - immune haemolytic anaemia and congenital spherocytosis. 
2. The clinical features and the diagnostic value of 
routine examination of the peripheral blood, bone marrow and 
urine for signs of anaemia, reticulocytosis and acholuric 
jaundice, the classical indicators of haemolysis, are 
described in each group. Where applicable, study has been 
made of the role of serological investigation and of tests 
of red cell fragility. 
Since measurements of red cell survival using chromium - 
51 as an erythrocyte label have formed a major interest, 
they have been considered in detail. The technique has 
been examined for reproducibility, studied in normal subject 
and various chronic and haematological diseases and compared 
simultaneously with the Ashby method. It was decided to 
use the TIC/. (the time in days when 50 per cent of the 
injected 51Cr has been cleared from the circulation) as the 
basis for comparison between data. 
The/ 
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The procedure for estimating the role of the spleen in 
a haemolytic process by measuring its uptake of radio- 
activity, due to sequestration of 51Cr labelled red cells, 
has been widely applied. The spleen sequestration index 
(the percentage increment in radioactivity over the surface 
of the spleen between the start of the test and T2Cr) and 
the spleen /liver ratio at TzCr have been used, but neither 
adequately describes the implication of the spleen; the 
former ignores any liver uptake of radioactivity and the 
latter does not take account of high blood flow through the 
spleen. Accordingly a new measurement, the Spleen Number, 
a multiple of the spleen sequestration index and the spleen/ 
liver ratio at TiCr has been proposed. 
3. In the group of patients with autoimmune haemolytic 
anaemia, apart from two subjects with the cold haemagglutin 
syndrome, the nature of the red cell antibody has not 
clearly influenced the course of disease or its response to 
treatment. Blood transfusion has been used freely without 
incident; one patient required more than 40 litres in six 
weeks for survival. All patients received steroid therapy 
at some stage of their management; the dilemma that arises 
when response is poor or when the steroid preparation cannot 
be withdrawn to an acceptable maintenance level has been 
well illustrated; approximately one third of the patients 
had major complications from steroid therapy. Splenectomy 
was recommended in nine of the twenty -three patients; only 
one/ 
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one of these had a good result from operation while three 
others had a partial remission. From the data that are 
available a high Spleen Number (exceeding 300) appears to 
offer prospect of remission from splenectomy; it is also 
of interest that high Spleen Numbers were seen in those who 
had the best remissions from steroid therapy. 
The course of autoimmune haemolytic anaemia followed 
three paths; self limiting disease, chronic relapsing 
disease and fulminating, potentially fatal, disease. Three 
unique patients were considered in detail. The first died 
in infancy of a peculiar haemophagocytic reticulosis that 
had earlier killed two of his three siblings. The second 
was observed for several years; she was a good example of 
the chronic relapsing variety of illness and required sterol 
therapy only during exacerbations of anaemia; the haemolyti 
process was constantly active and during this time she had 
two normal pregnancies, in the second of which she was given 
large doses of prednisone in the first trimester without 
ill effects; she had two crises of anaemia, one while 
receiving folic acid supplements and one which was believed 
to be due to folic acid deficiency. The third patient 
developed a violent haemolytic process while being treated 
with prednisone for idiopathic thrombocytopenia, previously 
cured by splenectomy. Some influence on the condition was 
achieved by irradiation of the thymus; haemolysis was 
eventually arrested and the thrombocytopenia corrected by 
the/ 
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the combined use of the new antineoplastic agents, 
Actinomycin -C and BW 57 -322 (Imuran). 
4. Studies on symptomatic non - immune haemolytic anaemia 
have been confined to patients with leukaemia, reticulosis 
and myeloid metaplasia. The usual signs of overt haemo- 
lysis, reticulocytosis and acholuric jaundice, were found in 
only one patient, despite markedly reduced red cell survival 
in many in the group. Neither splenomegaly nor its degree 
correlated with severity of red cell destruction or with 
the splenic uptake of 51Cr labelled red cells; all grades 
of splenic sequestration were found, the Spleen Numbers 
ranging from 26 to 1056. Irradiation of the spleen caused 
a valuable reduction in haemolysis in some patients, but 
this effect was not related to the Spleen Number; the role 
of this form of treatment has been discussed. 
Two patients in this group were subjected to autopsy 
shortly after red cell survival measurement with chromium -51 
and it was possible to estimate the content of radioactivity 
in most body tissues. There was good agreement between 
the spleen /liver ratio at autopsy and that obtained earlier 
in vivo at T2Cr. The data from one of the patients suggest 
that the marrow may be a much more important site of ery- 
throclasis than is generally realised. 
5. Congenital spherocytosis was encountered over a wide 
range of age from the first months of life to sixty -two 
years./ 
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years. There were all grades of severity and many differen 
modes of presentation; there was a small incidence of menta 
defect, developmental anomaly, miscarriages and chronic 
dermatosis of the legs and this has been described. Only 
five patients (23 %) had gall stones. One simple point 
emerged that might be useful in the early steps towards 
diagnosis; the E.S.R. tends to be low in this condition and 
very high in autoimmune haemolytic anaemia, the only other 
haemolytic disorder which is commonly accompanied by sphero- 
cytosis. 
Splenectomy has been undertaken in all but four patient 
who have mild well compensated disease. Removal of the 
spleen appears to have arrested haemolysis in all but one 
patient who died in the post -operative period; red cell 
survival has returned to normal in the eight patients in 
whom this has been measured. Observations have been made 
which support the view that the role of the spleen in con- 
genital spherocytosis is to "condition" the red cells and 
critically increase their spheroidicity and fragility rather 
than to destroy them; these show improvement in the osmotic 
fragility of red cells after splenectomy, some delay in the 
correction of red cell survival after operation and lower 
Spleen Numbers than have been encountered in some of the 
patients with acquired disease. 
Hypocholesterolaemia in untreated patients with con- 
genital spherocytosis has been an incidental finding. The 
values/ 
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values for plasma cholesterol after the haemolytic process 
has been arrested by splenectomy are normal. 
6. Megaloblastic erythropoiesis has been observed in seven 
patients, four with autoimmune haemolytic anaemia (one in 
early pregnancy and one with a previous history of gastro- 
enterostomy) and three with congenital spherocytosis. 
While the available data suggest that conditioned deficiency 
of folic acid is most usually implicated and that the giving 
of folic acid supplements will correct leucopenia, reticulo- 
cytopenia and thrombocytopenia, if these be present, three 
of the patients (including the patient with previous gastro- 
enterostomy) had low levels of vitamin B12 in the serum. 
217. 
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